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Abstract 
 
Severe outcome following influenza infection has been linked to the over induction 
of the host innate immune response resulting in a “cytokine storm.” In certain patient 
populations, a therapeutic approach to help control the innate immune response may be of 
benefit. However concerns have been expressed that suppression of the host immune 
response might also lead to an increase in virus replication and directly enhance viral 
induced pathology. Using cultures of primary well-differentiated human airway epithelium 
(HAEs), the ability of a small molecule, narrow spectrum kinase inhibitor, developed by 
RespiVert (RV1088) to inhibit the extent of influenza virus induced expression of an array of 
human cytokines including IL6, IL8, IP10, and RANTES was investigated. The virus-induced 
response following infection with influenza virus was found to be diminished at the mRNA 
and protein level in the presence of the drug. Importantly, drug treatment did not adversely 
increase viral replication. In contrast, treatment with a steroid did not suppress the 
cytokine/chemokine response and resulted in increased viral titres.  RV1088 inhibited the 
viral induction of transcription from the interferon promoter acting at or below the level of 
MAVS, preventing nuclear translocation of both IRF-3 and NFkB.  Used alone, RV1088 
inhibited cytokine production by all currently circulating subtypes and lineages of influenza 
A and B virus.  Used in combination with currently licenced antivirals, the virus titre released 
from HAE cells was suppressed even further than for either drug alone, suggesting a 
synergistic antiviral effect. Finally, a novel murine model of influenza infection using 
nebulized virus to infect the mouse airways was developed. Drug also administered through 
the nebulised route suppressed the interferon response in the mouse lung and did not 
result in increased viral lung titre or weight loss. Administered intranasally with or without 
Relenza to mice infected with pH1N1 2009 virus, RV1088 suppressed interferon levels in 
mouse lung and reduced weight loss and mortality. This, or similar molecules, may 
represent a new generation of compounds suitable for the treatment of respiratory virus 
infections. 
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Chapter 1 
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Chapter 1. Introduction 
 
1.1 The influenza virus 
 
 The Orthomyxoviruses, which include influenza A, B, and C viruses, are 
responsible for annual human respiratory infections. Current epidemiological data 
suggests that each flu season affects 10-15% of the UK population, and can be 
associated with 12,000 deaths (Donaldson, 2005). While a number of factors 
contribute to the general cost burden of the disease, the economic impact to society 
is primarily associated with the large number of lost work hours and overall 
productivity by infected individuals. In a review of published studies examining 
absenteeism due to influenza, Keech & Beardsworth (2008) found that the mean 
number of days lost per episode of illness in laboratory confirmed cases was 3-5 
days. In Europe, it has been estimated that influenza accounts for around 10% of 
sickness absence from work, with the cost of lost productivity in France and 
Germany alone estimated at around €6.84bn and €10.37bn annually (OECD, 2011). 
In terms of a pandemic, the economic burden of disease as well as the cost with 
respect to “Years of Life Lost” can be significant. Vibound et al., (2010) examined the 
effects of the first wave of the 2009 H1N1 pandemic (May-December, 2009) and 
reported that in the United States alone between 334,000 and 1,973,000 years of life 
were lost. This high estimate results from the majority of pandemic deaths occurring 
in children and young adults (85% of laboratory-confirmed H1N1 deaths occurred in 
individuals under the age of 60 with 37 being the mean age of death). A proportion 
of fatal cases have been linked to an aberrant, over-induction of the hosts’ innate 
immune response. As such, it has been suggested that suppressing this over-
induction could prove beneficial to the host in the case of such infections.  
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1.2 The influenza virus structure and components  
 
 The three genera (types) of influenza (A, B, and C) are classified based on the 
antigenic differences exhibited by two internal structural proteins, the matrix (M) 
and the nucleocapsid protein (NP). Influenza A infects humans, pigs, horses and birds 
and through antigenic shift, has the potential to cause major epidemics and even 
pandemics (Matrosovich et al., 2004; Nobusawa et al., 2006). As influenza types B 
and C primarily infect humans (with minor reports of type B infecting seals and type 
C in pigs), antigenic shift does not occur (Jackson et al., 2011; Osterhaus et al., 2000; 
Kimura et al., 1997).  
The negative sense single-strand (ss)RNA genomes of influenza A and B 
viruses occur as eight separate segments; influenza C viruses contain seven 
segments of RNA, lacking a neuraminidase gene (Racaniello and Palese, 1979). 
Members within any of the three influenza types can readily exchange genetic 
material via reassortment; however, the exchange of genetic material among the 
three genera has not been demonstrated to date, probably due to incompatibility of 
the different polymerase complexes as a result of evolutionary divergence (Iwatsuki-
Horimoto, et al., 2008).  
 The high error rate associated with RNA viral replication combined with 
ecological, population and immune selective pressures continuously drive the 
selection for evolutionary advantageous changes to the genetic make-up of the 
influenza virus. Ongoing antigenic changes in the haemagglutinin (HA) and the 
neuraminidase (NA) surface glycoprotein antigens of the influenza virus is a process 
referred to as antigenic drift. The RNA polymerases encoded by the influenza virus 
lacks proofreading capability and thus, gives rise to a high rate of mutation that, in 
part, is responsible for the antigenic drift associated with this group of viruses.   
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1.2.1 The virion 
 
The influenza A virion is highly pleomorphic and consists of a protein capsid 
containing the viral ribonucleoprotein complex (RNP), which is encapsulated by a 
lipid membrane derived from the host cell. This membrane harbours the 
glycoproteins haemagglutinin (HA) and neuraminidase (NA) which protrude from the 
envelope surface by ~10-14nm and are responsible respectively for viral attachment 
and viral release (Chu, 1949). Also projecting from the membrane is the ion channel 
matrix protein (M2). The function of the M2 is to modulate the pH across the 
membrane and allowing protons to enter the core where acidification leads to the 
core’s disassembly so that viral replication can commence. The influenza virion has 
been further characterised with the aid of electron microscopy as existing primarily 
as a sphere with a diameter of ~100nm, although clinical isolates can often be found 
to be filamentous with a length of ~300nm (Calder et al., 2010; Choppin et al., 1960; 
Chu, 1949). 
The eight RNA genetic segments contained within the core are each folded 
into a rod-shaped, double-helical RNP (Arranz et al., 2012; Moeller at al., 2012; Ye et 
al., 2012). Each RNP complex contains a viral RNA, a heterotrimeric viral polymerase 
(consisting of PB1, PB2 and PA) and numerous copies of the viral-encoded 
nucleoprotein (NP) which associated directly with the viral RNA in a stoichiometric 
manner (Zheng et al., 2013).  
Each viral segment has non-coding regions at the 3’- and 5’-ends that are 
partly complementary to each other and form the viral promoter (Desselberger et 
al., 1980). In total, the eight gene segments encode for a minumum of 12 viral 
proteins, namely PB1, PB2, PA, NP, HA, NA, M1, M2, NS1, NEP/NS2 and PB1-F2 with 
recently reported PA-X and M42 further increasing the proposed number of virally-
encoded protiens up to 14 (Wise et al., 2012; Jagger et al., 2012; Palese & Shaw, 
2007).  
 
  
 
19 
Table 1. The viral segments and associated proteins of the three different influenza 
viruses A, B & C. All segments are discussed further below.  
 
 
1.2.2 The haemagglutinin (HA) glycoprotien 
 
First described in 1941 by George Hirst, this protein’s name was derived from 
the observation that it posesses the ability to agglutinate erythrocytes by binding to 
specific sialic acid structural motifs (Hirst, 1941). Currently, 16 different 
hemagglutinin subtypes (H1-H16) have been identified in type A influenza strains 
circulating in wild waterfowl (Galloway et al., 2013; Fouchier et al., 2005) with two 
novel subtypes, H17 and H18, reportedly found in bats (Tong et al., 2012). Thus far, 
however, only viruses with either the H1, H2 or H3 HA subtype have been sustained 
in humans (Galloway et al., 2013).  
Structurally speaking, the HA protein forms a rod-shaped trimeric complex. 
The precursor protein HA0 is cleaved by a trypsin-like serine protease, found either 
on the plasma membrane or in the extracellular spaces of the respiratory tract, into 
HA1 and HA2 subunits that remain linked by disulphide bonds (Galloway et al., 2013; 
Kido, et al., 2012). The HA1 subunit forms a globular domain which is responsible for 
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binding to sialic acids of glycosylated cell surface proteins or lipids (discussed further 
in section 1.3.1). Following attachment, the virus is internalized via pH-dependent 
endocytosis (Stegmann et al., 1985). The acidification of the host cell endosomes 
initiates a dramatic conformational change in the HA1/HA2 structure which exposes 
a hydrophobic fusion peptide in the HA2 subunit (Skehel & Wiley, 2000). The fusion 
peptide promotes fusion of the viral membrane with the endosomal membrane 
(Figure 1) permitting the release of the vRNP into the cytoplasm (Steinhauer, 1999; 
Taubenberger, 1998). 
In addition to its role in receptor-binding and endosomal fusion, the HA 
protein represents a major antigen for the stimulation of an adaptive immune 
response (Brandenburg et al., 2013; Fouchier et al., 2005). The resulting selection 
pressure created by neutralizing antibodies can drive changes in the antigenic nature 
of the HA1 domain giving rise to the generation of escape mutants (Martinez et al., 
2009; Hensley et al., 2009). This gradual and step-wise accumulation of changes in 
the antigenic structure of HA1 in viruses as they circulate in humans is referred to as 
antigenic drift. The consequences of this process is that it allows closely related 
viruses of the same subtype to re-infect individuals, necessitating the annual 
production of new vaccines to match the new antigenic character of circulating 
strains. 
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Figure 1. Structural changes that occur to the HA in a low pH environment. The 
trimeric HA molecule is shown as a ribbon diagram with the HA1 subunit coloured in 
blue, the HA2 subunit in red, and residues corresponding to the fusion peptide in 
yellow (Diagram from: Galloway et al., 2013).  
 
1.2.3. The neuraminidase (NA) glycoprotein  
 
Encoded by the 6th RNA segment, the NA protein was named for its ability to 
catalyze the cleavage of glycosidic linkages between terminal sialic acids of 
glycoproteins and glycolipids on the surface of target host cells (Gamblin & Skehel, 
2010). Currently, there are nine described NA subtypes (N1-N9) identified for type A 
in wildwater fowls (Gamblin & Skehel, 2010) with a novel subtype, N10, reportedly 
found in bats (Tong et al., 2012). The NA protein forms a homo-tetrameric complex 
that has a globular domain on top of a short stem region (Shtyrya et al., 2009).   
The cleavage of sialic acid from the cell surface by the NA protein allows for 
efficient release of mature, newly-synthesized virions. This function is vital as viruses 
lacking a functional NA protein would be unable to spread from a host cell and 
would simply be bound to the same cell from which the virions were attempting to 
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egress (Shtyrya et al., 2009). Thus, a balance between the functionality of HA and NA 
is necessary for efficient influenza virus replication (Mitnaul et al., 2000). 
The ability of newly-synthesized virus particles to escape from the host cell is 
a crucial step in viral propagation, making the NA a tempting target for therapeutic 
intervention (von Itzstein et al., 1993). The structure of the NA active site is highly 
conserved across all subtypes, (von Itzstein et al., 1993) and indeed the only class of 
directly acting antiviral drugs against influenza at present are neuraminidase 
inhibitors that bind into the enzyme active site (see section 1.8.1). Like the HA 
protein, the NA protein can also generate an immune response that results in the 
production of non-neutralizing antibodies by the adaptive arm of the host’s immune 
response (Marcelin et al., 2011).  Although less potent than HA antibodies, NA 
antibodies restrict viral spread to a certain degree, potentially allowing the host time 
to moderate the viral infection (Marcelin et al., 2011). 
 
1.2.4 The small transmembrane proteins M2/BM2 and NB 
1.2.4.1 The M2 protein 
 
The M2 protein forms a tetrameric complex that is embedded in the lipid 
bilayer of the virion and functions as an ion channel; being activated at low pH (Pinto 
et al., 1992; Sugrue & Hay, 1991). It has been implicated in having both an early and 
late role in the viral life cycle (Helenius, 1992). 
In the early stages of infection, the M2 protein channel allows the flow of 
protons from the acidified endosome into the virion resulting in a lowering of the pH 
within the capsid (Ivanovic et al., 2012). This weakens the binding of the M1 protein 
to the vRNPs; allowing their release into the cytosol after fusion of viral and 
endosomal membranes (Ivanovic et al., 2012; Martin & Helenius, 1991). The late-
infection-stage role of the M2 is associated with regulating the pH in the trans-Golgi 
network (Henkel et al., 2000). By allowing the flow of protons out of the Golgi 
network, the M2 channel raises the intra-vesicular pH thus preventing a premature 
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conformational change of the HA1/HA2 protein which is transported to the budding 
site (Henkel et al., 2000). This activity of M2 is thought to be of more importance for 
viruses with HA0 that is cleaved intracellulary such as the highly pathogenic avian 
influenza viruses of H5 or H7 subtypes.   
A histidine (His) at position 37 in the M2 protein, serves as a pH sensor (Wang 
et al., 1995) while a tryptophan (Trp) at position 41 acts as the “gate-keeper” 
occluding the C-terminal end of the closed channel (Tang et al., 2002). The side 
chains of both these residues converge to form the narrowest point in the channel, 
through which no molecules can pass (Shuck et al., 2000; Pinto et al., 1997).   
The protonation of His37 in the low pH environment on the endosome 
initiates an important cascade of events that ultimately leads to the opening of the 
M2 channel (Wang et al., 1995). This process occurs by means of electrostatic 
repulsion between the positively charged imidazole rings of His37 leading to the 
destabilization of the helix-helix packing and resulting in widening of the channel 
(Wang et al., 1995). It is theorized that once the channel is open, the pH gradient 
drives the protons from the low pH side to the high pH side by simple diffusion 
(Leiding et al., 2010). The necessity for a replicating virus to possess functional M2 
proteins makes the M2 yet another attractive target for antivirals (Discussed further 
in section 1.8.2).  
  
 
Figure 2. 3d stick model of M2 influenza A protein. Viewed from (a) above and (b) 
sideways complexed with the M2-inhibitor, rimantadine (balls) (Figure from: Schnell 
et al., 2008) 
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1.2.4.2 The BM2 protein 
The BM2 protein is encoded on the 7th segment of the type B viruses and is 
produced via a stop-start strategy reading the bicistronic mRNA transcript which also 
encodes for the M1 protein of the type B viruses (Hiebert et al., 1986; Briedis et al., 
1982). The presence of BM2 in all type B strains and the highly conserved nature of 
BM2s amino acid sequence suggests that this protein plays a crucial role in the life 
cycle of the virus (Imai et al., 2004).  Studies have demonstrated that BM2 is an 
oligomeric integral membrane protein that associates with the viral envelope via the 
trans-Golgi network (Paterson et al., 2003; Watanabe et al., 2003). Further studies 
conducted by Mould et al., (2003) have indicated that BM2 has an ion channel 
activity, similar to that seen with the M2 protein of type A viruses through which 
protons are allowed to enter the virions during the uncoating of particles in the 
endosomes facilitating the release of vRNPs. 
 
1.2.4.3 The NB protein 
 
The NB protein is encoded within the neuraminidase (NA) gene (sixth vRNA 
segment) of influenza B viruses (Brassard et al., 1996; Betakova et al., 1996).  
Influenza A viruses do not encode an NB homologue and the function of NB is 
currently not known. 
Sequencing of the sixth vRNA segment indicated the presence of two 
overlapping open reading frames with the two AUG initiation codons separated by 
only four nucleotides (Shaw et al. 1982). Williams & Lamb, 1989 demonstrated that 
in influenza B infected cells, NB and NA accumulate in roughly equimolar amounts 
(NB:NA = 0.6:1.0). This observation suggests that the ribosome pre-initiation 
complex bypasses the first AUG initiation codon more often than expected and that 
~60% of the ribosome pre-initiation complexes on the sixth vRNA segment bypass 
the first AUG codon and use the second AUG codon four nucleotides downstream of 
the first.  
  
 
25 
It was for many years believed that NB was the functional analogue of the 
influenza A virus M2 protein. This belief was based on several factors including: a) 
the similarity in size (100 and 97 amino acids for NB and M2 respectively), b) both are 
integral membrane protein expressed on the surface of influenza-infected cells, c) 
both M2 and NB are synthesized in virus-infected cells in amounts comparable to 
those of other viral membrane proteins but are incorporated into the viron 
membrane in relatively small, yet similar, amounts and, d) both proteins possess 
potential ion channel activity.   
However, important differences between the two proteins also exist. Firstly, 
NB is glycosylated whereas the M2 is not. Secondly, NB and M2 do not share any 
primary sequence homology (Zebedee et al., 1985). In addition, the characterization 
of the influenza B viral BM2 protein has shown it to be far closer in structure and 
function to the influenza A M2 protein and like the M2 protein, is vital for viral 
replication (Hatta et al., 2004; Jackson et al., 2004; Imai et al., 2004).   
In order to determine whether the NB protein has any role in the replication 
of influenza B virus, NB deleted viruses were constructed via a reverse genetics 
system. The resultant viruses growth characteristics and other properties was then 
examined in cell culture and animal models. Interestingly, NB was shown not to be 
essential for replication of the influenza B virus in vitro but was required for efficient 
viral replication in animal models (Hatta & Kawaoka, 2003). These results strongly 
suggest that the NB protein has been highly conserved because its existence and 
possible function(s) are somehow advantageous to the virus even though not 
essential for viral replication. 
 
1.2.5 The matrix protein (M1) 
 
Along with the NP protein, the M1 protein is the most abundant viral protein 
found in an infected cell. In the virion, the M1 protein is associated with the lipid 
membrane and although the protein lacks a trans-membrane domain, it has been 
  
 
26 
suggested that this association with the lipid membrane is mediated by M1s 
interaction with the cytosolic domains of the surface transmembrane proteins NA, 
HA and M2 (Veit & Thaa, 2011).  In addition to its interactions with the lipid 
membrane, an interaction of M1 with the NP protein of packaged RNPs has been 
described (Elton et al., 2001; Martin & Helenius, 1991). Specifically, in the infected 
cell, M1 is necessary for the export of RNPs out of the nucleus (Elton et al., 2001). 
This is achieved by the M1/RNP-complex binding, via M1 and the NEP/NS2 protein to 
Crm1 (Chase et al., 2011; Elton et al., 2001).  As a cellular export receptor, Crm1 is a 
vital component involved in directing the export of the M1/RNP/NEP-complex into 
the cellular cytosol (Chase et al., 2011; Elton et al., 2001; Watanabe et al., 2001) 
(Figure 3). 
 
 
Figure 3. Diagram of the proposed mechanism of influenza viral RNP nuclear 
export. The nuclear export of newly synthesized viral RNP complexes is mediated by 
the viral NEP. It interacts with the cellular export factor Crm1 and with the viral RNPs 
via the M1 protein. The interaction with the cellular export machinery facilitates the 
transport of the viral genome through the nuclear pore into the cytoplasm (Adapted 
from Paterson & Fodor, 2012). 
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1.2.6 The Nucleoprotien (NP) 
   
One of the most abundant viral proteins found within an infected cell, NP is 
involved in a variety of viral processes including intracellular trafficking of the viral 
genome, vRNA replication, viral genome packaging, and virus assembly. A highly 
conserved protein, an alignment of the predicted amino acid sequences of the NP 
genes of the three influenza virus types (A, B and C) reveals significant similarity 
among the three proteins, with the NPs of type A and B showing the highest degree 
of conservation (Shu et al., 1993). Importantly, NP has demonstrated an ability to 
interact with a variety of factors, of both viral and cellular origins (Portela & Digard, 
2002). The NP protein is a major component of the RNP complex, binding genomic 
vRNA segments and forming helical, rod-like RNP structures (Figure 4) (Resa-Infante 
et al., 2011; Noda et al., 2006).  In addition to binding ssRNA, NP is able to form large 
oligomeric complexes via self-association (Turrell et al., 2013; Elton et al., 1999). 
Furthermore, NP has been shown to bind to the polymerase subunits PB1 and PB2 
and M1 (Gabriel et al., 2008; Biswas et al., 1998). With respect to host factors, NP 
has demonstrated to interact with at least four cellular polypeptide families: nuclear 
import receptors of the importin α class, filamentous actin, the nuclear export 
receptor Crm1 and the DEAD-box helicase BAT1/UAP56 (Gabriel et al., 2008; Elton et 
al., 2001; Palese et al., 1997; Avalos et al., 1997). It seems logical to reason that NPs 
multifunctional nature stems from its ability to bind vRNA, associate with numerous 
viral factors and interact with many host cell factors. 
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Figure 4. The influenza ribonucleoprotein complex. A) diagram of the structure of a 
helical vRNP, including the negative-polarity template RNA (red) associated to NP 
monomers (orange circles). The polymerase subunits are coloured in blue (PB1), 
green (PB2) and yellow (PA). The promoter is depicted in its corkscrew structure. B) 
Cryo-EM 3D structure of an influenza mini-RNP complex with a perspective view and 
two side views and (C), a top view of the same structure with the atomic structure of 
the NP docked into each monomer (Adapted from: Resa-Infante et al., 2011).  
 
 
 
 
  
 
29 
1.2.7 The polymerase proteins: PA, PB1 and PB2  
 
The viral RNA polymerase complex is composed of three subunits, the PB1, 
PB2 and PA proteins. The majority of transcription and replication of the viral RNA 
takes place in the infected cell’s nucleus. Once the incoming viral RNAs undergo 
nuclear translocation, they are transcribed into mRNAs which, in turn, are capped 
and polyadenylated (Dias et al., 2009; Poon et al., 1999). The cap is derived from 
host cell pre-mRNAs by a process colloquially referred to as “cap-snatching” and the 
poly-A-tail is generated by the viral polymerase via a stuttering mechanism (Dias et 
al., 2009; Poon et al., 1999). Subsequent rounds of infection require newly 
synthesized polymerase proteins that must be imported into the nucleus to 
encounter their RNA templates. PB1 and PA form a dimer before entering the 
nucleus (Fodor & Smith, 2004) and once inside the nucleus, they form a complex 
with PB2, which is imported independently (Mukaigawa & Nayak, 1991). 
The replication of the viral genome can be divided into two processes. The 
negative-sense vRNA is copied into positive-sense complementary cRNA (1st step of 
replication) which itself serves as a template to generate more vRNA (2nd step of 
replication) (Figure 5).  
Within the replication complex, PB1 catalyzes the sequential addition of 
nucleotides to RNA transcripts and initiates replication and transcription by binding 
to both ends of vRNA or cRNA (Biswas & Nayak, 1994). The PB2 protein binds to the 
caps of host pre-mRNAs and delivers them to the PA subunit that subsequently 
cleaves the pre-mRNAs at a position 9-17 nucleotides downstream of the cap 
(Fechter et al., 2003). The PB2 protein has been identified as being an important 
determinant of mammalian adaptation and virulence (Subbarao et al., 1993). 
Specifically, the residue 627 is typically a glutamine in avian viruses and a lysine in 
human isolates. A/H5N1 viruses possessing a glutamine at position 627 are 
considered to be less pathogenic in humans; however, isolates that contain a lysine 
instead of a glutamine have been found to be highly pathogenic (Hatta et al., 2001). 
Other mutations, for example T271A and D701N, have been implicated in enhancing 
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avian polymerase activity in human cells (Bussey et al., 2010; De Jong et al., 2006) 
The PA protein is a component of the polymerase complex that is required for 
replication and transcription. The N-terminal domain of PA has also been 
demonstrated to have cap-dependent endonuclease activity with a highly conserved 
active site (Dias et al., 2009; Yuan et al., 2009; Fodor & Smith, 2004). 
Of significant importance to the evolution of the virus is that the viral 
polymerase does not possess proof-reading capability (Shu et al., 1993; Fitch et al., 
1991). The polymerase is thus error-prone and it has been estimated that a 
mismatch occurs one in every 10,000 nucleotides that is generated (Lauring & 
Andino, 2010). This implies that in every newly synthesized viral genome, there 
exists at least one mutation (Lauring & Andino, 2010). This relatively high mutation 
rate leads to a high number of defective viral particles but also enables the virus to 
easily escape the pressures exerted on it by the host’s immune response or by 
treatment with antiviral drugs (Fitch et al., 1991). 
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Figure 5. Influenza virus replication. The incoming negative sense vRNA(-) is copied 
in complementary form to cRNA(+) in the first step of replication. This cRNA(+) is 
subsequently copied back into vRNA(-) during the second step of replication. The 
vRNA(-) is then transcribed into protein encoding mRNA(+) (Adapted from: Fields 
Virology, 5th Edition, Chapter of Orthomyxoviridae, Palese and Shaw).   
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1.2.8 The non-structural protein (NS1) and nuclear export protein (NEP) 
 
Viral segment 8 encodes for both the NS1 and the NEP/NS2 proteins (Robb et 
al., 2010). NS1 is translated from unspliced mRNA transcripts derived from the full-
length vRNA segment, whereas the NEP/NS2 is derived from spliced mRNA 
transcripts (Chua et al., 2013; Robb et al., 2010). The ratio of unspliced NS1 mRNA 
and spliced mRNA remains constant during the course of viral infection with 
NEP/NS2 mRNA being approximately 17% of the total NS mRNA (Robb et al., 2010).  
Soon after its synthesis, unspliced NS1 mRNA, is rapidly exported out of the cell 
nucleus in order to minimize the likelihood of the mRNA being spliced (O’Neil, 1998; 
Alonso-Caplen et al., 1992). The rapidity of this process ensures that the NS1 protein 
is present at the early stages of the virus replication cycle and is able to counteract 
the host’s antiviral response (Hale et al., 2008). In addition, this mechanism has the 
added benefit of preventing early expression of the NEP/NS2 protein, and thus 
preventing the premature export of vRNPs from the nucleus (Chua et al., 2013; 
Hutchinson & Fodor, 2013). 
 
1.2.8.1 NS1 – the interferon antagonist 
The NS1 protein forms a dimeric complex that prevents recognition of viral 
RNA by the RNA helicase retinoic acid-inducible gene I (RIG-I) in complex with 
TRIM25, and by protein kinase R (PKR) by directly binding to dsRNA (Hale et al., 
2008; Pichlmair et al., 2006). RIG-I is a cytoplasmic pattern recognition receptor that 
senses the 5’-triphosphates of viral RNAs and triggers the activation of a signaling 
cascade which includes both interferon regulatory factor 3 (IRF3) and the nuclear 
factor-kappa B (NFkB), ultimately leading to the transcription of type I interferon 
(IFN) (Rückle et al., 2012; Hiscott et al., 2003). The formation of an NS1-RIG-I/TRIM25 
complex leads to the inhibition of IRF-3 activation, thus preventing the transcription 
and secretion of IFN-β (Kuo et al., 2010).  In the absence of NS1, secretion of IFN-β 
stimulates the IFN α/β receptors in an autocrine and paracrine fashion leading to the 
up-regulation of interferon stimulated genes (ISGs) including protein kinase R (PKR) 
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(Dauber & Wolff, 2009). PKR phosphorylates the α-subunit of eukaryotic translation 
initiation factor 2 (eIF-2α) which results in the suppression of protein translation and 
thus, viral replication (Bergmann et al., 2000). Importantly, the NS1 protein 
counteracts the activity of PKR by directly binding to the kinase as well as averting its 
activation by sequestering dsRNA (Hale et al., 2008; Bergmann et al., 2000). The 
importance of the NS1 protein to the virus has been demonstrated in studies where 
genetically engineered viruses lacking the NS1 protein were found to be highly 
attenuated in cells or hosts with intact interferon systems (Hale et al., 2008; 
Quinlivan et al., 2005). Although interferon antagonism is the major role for NS1, it a 
multifunctional protein and interacts with many different cellular partners (de 
Chassey et al. 2013).  
 
1.2.8.2 NEP/NS2 – the nuclear export protein 
The NEP/NS2 protein functions as an adaptor protein for the nuclear receptor 
Crm1 and the viral M1 protein (Hutchinson & Fodor, 2013; Iwatsuki-Horimoto et al., 
2004; O’Neill et al., 1998). It directs the nuclear export of newly synthesized RNPs 
that are complexed to M1 (Figure 3). The M1-binding site of NEP/NS2 masks a 
nuclear localization signal in M1 and that may prevent the re-entry of vRNPs into the 
nucleus (Akarsu et al., 2011). NEP also regulates the viral polymerase and this may 
play some role in overcoming the host range restriction (Mänz et al., 2012). The NEP 
interactome is also reported to be extensive and therefore may have numerous 
additional roles as yet undescribed (de Chassey et al. 2013). 
 
1.2.9 The PB1-F2 protein 
The accessory protein PB1-F2 is expressed from an alternative +1 open 
reading frame found in segment 2 of some influenza type A virus strains (Chen et al., 
2001). PB1-F2 has been shown to be a pathogenicity factor in the pandemic 
influenza strain of 1918 and in highly virulent strains of A/H5N1 (Conenello et al., 
2007; McAuley et al., 2007; Zamarin et al., 2005). It has been proposed that PB1-F2 
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acts as a virulence factor by modulating the immune response and enhancing the 
establishment of secondary bacterial infections, a significant cause of increased 
morbidity and mortality in influenza patients (Conenello et al., 2007; McAuley et al., 
2007). Several in vitro studies have demonstrated that upon expression, PB1-F2 
localizes to the mitochondria and induces apoptosis by oligomerizing and forming 
pores in mitochondrial membranes leading to disruption of the membrane potential 
and the subsequent release of cytochrome C (Zamarin et al., 2005; Gibbs et al., 2003; 
Chen et al., 2001).  
1.3 Influenza virus replication  
 
The replication of the influenza virus is a complex, intricate and elegant 
process requiring a precise sequence and timing of events (Figure 6). That being said, 
the entire life cycle of the virus can be simply summarised as a singular drive to 
infect, replicate and spread. While these processes are taking place, the virus is 
constantly having to battle and evade the host’s formidable physical and innate 
immune defences. By better understanding how the virus operates, it has been 
possible to devise antiviral chemotherapeutic interventions which act by thwarting 
key steps in this complex and robust life cycle.  
 
1.3.1 Attachment and entry 
 
The initial step in the replication cycle of a viable influenza particle is the 
attachment to the new host cell. Attachment occurs when HA glycoprotein’s binding 
site makes contact to the appropriate sialic-acid (primarily, D2,6 – or D2,3-SA) 
binding receptor (Matrosovich et al., 1997). The cleaving of the HA into its subunit 
constituents (HA1 and HA2) by a host cell protease enables a low-pH dependent 
process to expose the fusion peptide region of the HA2 N-terminus which in turn, 
permits joining of the viral envelope and the cell membrane leading to cell-mediated 
endocytosis (Skehel & Wiley, 2000; Steinhauer, 1999; Taubenberger, 1998).  Once 
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internalised, the M2 (or BM2 for type B viruses) protein channels permit the inward 
flow of protons from the endosome to the virion acidifying the core (Ivanovic et al., 
2012; Mould et al., 2003).  This lowering of the core pH facilitates the disassociation 
of the vRNPs from the Matrix (M1) proteins and allows the vRNPs to enter the 
cellular cytosol (Ivanovic et al., 2012; Martin & Helenius, 1991).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. A schematic diagram of the life cycle of the influenza virus. Virus particles 
enter the host cell via receptor-mediated endocytosis. After acidification of the 
virion, the vRNP complex is released into the cytoplasm. Subsequently, the vRNP is 
transported to the nucleus, where replication and transcription take place, with 
mRNAs being exported to the cytoplasm for translation. Early viral proteins, are 
transported back to the nucleus to aid in the transcription and replication process. 
Late viral proteins (M1 and NS2) facilitate the nuclear export of newly synthesized 
vRNPs. The assembly and budding of progeny virions occurs at the plasma 
membrane at lipid raft microdomains where the glycoproteins HA and NA are in 
abundance (Adapted from: Neumann et al., 1997).  
 
 
  
 
36 
1.3.2 Nuclear import, transcription and replication of vRNPs 
 
Once the vRNPs have become disassociated from the virion, they localise to 
the cell’s nucleus due to a nuclear localisation signal (NLS) present on the NP protein 
(Neumann et al., 1997). This NLS interacts with cellular proteins involved in nuclear 
import importin D, p10 and Ran (Nieto et al., 1992; Mukaigawa & Nayak, 1991; Nath 
& Nayak, 1990).  The nuclear translocation of the vRNP complexes occurs via nuclear 
pores in an ATP-dependent manner (Kemler et al., 1994).  The virus’ own RNA-
dependent RNA polymerase (a component of the vRNP complex) is responsible for 
both transcription and replication (Hay et al., 1977). The switch from transcription to 
replication is not completely understood and may depend on the accumulation of 
viral proteins such as NP, the viral polymerases or NEP. Thus, the first step in the 
replication process is mRNA transcription to produce the required proteins (Portela 
& Digard, 2002). Once mRNA transcription has occurred, the mRNAs are transported 
into the cytosol where the translation step takes place and is mediated by the 
cellular protein GRSF-1. The proteins of the polymerase complex  (PB1, PB2, PA and 
NP) are translated in the early stages of infection so that the replication process can 
be further augmented (Garfinkel & Katze, 1993; Katze & Krug, 1990).  In addition to 
the polymerase subunits, NS1 (a potent innate immune antagonist) is also translated 
early (Hale et al., 2008).  The remaining five proteins (HA, NA, NEP, M1 and 
M2/BM2) are translated later in infection as they are only required during the 
assembly process of new virions (Garfinkel & Katze, 1993; Katze & Krug, 1990).  It is 
imprtant to note, however, that the evidence for such strict temporal regulation is 
not robust.     
During the transcription process, a critical point is reached and a switch from 
mRNA transcription to vRNA replication (via a cRNA intermediate) occurs (Figure 5).  
The de novo vRNA is then encapsulated by NP in a helical manner and associates 
with the polymerase complex to form new vRNPs which are subsequently 
transported out of the nucleus via a Crm1-NEP-M1 interaction (Chase et al., 2011; 
Elton et al., 2001).  Once located out of the nucleus, the vRNPs are further 
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transported on to the cell’s plasma membrane and packaged into newly forming 
virions (Martin & Helenius, 1991).  
 
1.3.3 Virion assembly and release of viral particles 
 
Virion assembly occurs at the apical surface of the cell where new viral 
particles bud through the plasma membrane at lipid-raft microdomains (Simons & 
Ikonen, 1997; Naim & Roth, 1993). Why the virus chooses these microdomains as a 
point for budding is still under examination but it seems likely that the high 
concentration of viral glycoproteins at these same sites might play a role along with 
cellular-based factors (Barman et al., 2007; Barman et al., 2004; Barman et al., 2003; 
Zhang et al., 2000). It is at these lipid-raft locations that the glycoproteins HA and NA 
accumulate through a transport process involving the addition of N-glycans and the 
sequence motifs of their trans-membrane domains which potentiate an association 
with sphingolipid-cholesterol rafts (Simons & Ikonen, 1997; Scheiffele et al., 1995). 
Under the plasma membrane, a sheet consisting of multiple M1 proteins forms and 
is thought to interact with the cytoplasmic tails of the HA/NA proteins, aid in 
genome packaging and shape the morphology of the developing virus particle (Veit 
& Thaa, 2011).  The newly formed vRNPs are then incorporated into the virion via 
cis-acting signals located with in the vRNA gene segments (Liang et al., 2005; Fujii et 
al., 2003). Finally, the new virion buds through the plasma membrane while in the 
process encapsulates itself with part of the membrane (Nayak et al., 2009) (Figure 
7). M2, which accumulates at the edge of the rafts, mediates scission of the viral 
membrane from the host cell (Rossman et al., 2010). The viral NA acts to cleave the 
terminal sialic acids on surrounding receptors to prevent aggregation on the cell 
surface of newly released viral particles (Shtyrya et al., 2009). The free-floating 
virions are thus able to be transmitted to another host or initiate infection in 
neighbouring cells. 
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Figure 7. The budding of influenza virions from a host cell membrane. A) Side view 
of rod-like structure demonstrating the inclusion of vRNA segments into the budding 
particle. B) ET microscopy of WSN budding from the surface of MDCK cells. C) 
Scanning EM of spheroid viral buds covering the surface of an influenza-infected cell. 
(Images adapted from: Nayak et al., 2009; Noda et al., 2006). 
 
1.4 Sialic acid binding and Tropism 
 
The generic term sialic acid (SA) refers to a family composed of nine carbon 
amino acid sugars (5-amino-3,5-dideoxy-D-glycero-D-galacto-nonulosonic acid). SA is 
typically located at the capping position of glycans which are linked to the 
glycoproteins and glycolipids that extend from a cell surface (Nicholls et al., 2008; 
Meng et al., 2010). The hydroxyl groups can be substituted by methyl, sulphate, 
phosphate, lactoyl, or acetyl residues while the amino group is always substituted 
with either an N-acetyl or N-glycolyl group producing N-acetylneuraminic (NeuAc) or 
N-glycolylneuraminic (NeuGc) acid respectively (Suzuki et al., 2000) (Figure 8).   
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Figure 8. The chemical structure of N-acetylneuraminic and 
N-glycolylneuraminic acid. (Adapted from: Angata & Varki, 2002). 
 
When an SA is added to the hydroxyl group of galactose, it can either be 
added to the hydroxyl located at the carbon-3 position or the carbon-6 position 
creating an α2-3 or α2-6 glycosidic linkage respectively (Nicholls et al., 2008). The SA 
residues are attached to glycolipids or the terminal sugar of a glycoprotein via the 
sialyltransferase enzymes that are expressed in a species- and cell- specific manner 
(Angata & Varki, 2002).  
Many viral pathogens utilise SA to help them gain entry into host cells 
(Kumlin et al., 2008). It was Gottschalk in the 1950s who first demonstrated that 
influenza viruses recognise SA moieties (Schauer, 2000). Since then, a considerable 
amount of effort has been put into further elucidating and characterising the 
relationship that exists between SA and the biology of influenza viruses, although 
the majority of the work concerns the preferences of influenza A virus subtypes 
while influenza B viruses are poorly characterized in this respect.    
Haemagglutinins from various influenza viruses differ in their ability to 
recognize sialyloligosaccharide structures. The receptor preference of the virus is 
vital in determining host range, the site of infection (i.e. upper or lower respiratory 
tract) and general virulence. One of the most conspicuous examples of 
haemagglutinin receptor specificity lies in the difference between avian and human 
influenza A virus, described below. 
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The study of viral tropism made considerable progress after the refinement 
of staining techniques employing lectin-based fluorescence histochemistry. Lectins 
are proteins derived from plants, animals or microbial life forms which recognize and 
bind to specific carbohydrate structures (Sharon, 2007; Loris, 2002). With respect to 
influenza studies, the plant lectins Maackia amurensis agglutinin (MAA) and 
Sambucus nigra agglutinin (SNA) are used in in vitro studies to identify SAα2,3Gal 
and SAα2,6Gal moieties respectively (Baum & Paulson, 1990).  It is important to 
note, however, that lectin-based assays, while useful in determining the distribution 
of various SAs in tissue samples, can only act as an indirect measure of virus 
attachment to such tissues and do not take into account other factors which may 
influence viral binding (van Riel et al., 2007; Ibricevic et al., 2006). 
With respect to human strains, the influenza virus preferentially targets and 
binds to SA attached to the sugar chain by an α2-6 glycosidic link (Matrosovich et al., 
1997; Couceiro et al., 1993). In cultured cells from the human respiratory tract, the 
SAα2,6Gal link is primarily found at the apical surface of the ciliated epithelium 
whereas basal cells exhibit SAα2,3Gal (Ibricevic et al., 2006). It has been reported 
that mucus-secreting goblet cells possess both the SAα2,3Gal and SAα2,6Gal linkage 
with a sufficient density to facilitate viral entry and replication of both human and 
‘avian-type’ viruses (Baum & Paulson, 1990). More recently however, Matrosovich et 
al., (2004) and Thompson 2006; Shelton et al., (2011) have demonstrated that the 
predominant SA expressed on nonciliated cells is of the α2,6 form. 
These receptor types can be found in different regions of the respiratory 
tract or within the same region but on different cells; the overall picture is that in the 
human respiratort tract SAα2,6 predominates (Kogure et al., 2006; Shinya et al., 
2006; Matrosovich et al., 2004; Thompson et al., 2006; Nicholls et al., 2007; 
Dobrovolny et al., 2010) (Table 2).   
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Table 2. Distribution of SAα2,3 or SAα2,6 within the human respiratory tract.  
(Adapted from Kumlin et al., 2008).  
Tissue   Glycan   
M cells in nasopharyngeal 
lymphoid tissue 
 
SAα2,6 
 Nasal mucosa 
 
SAα2,6 & SAα2,3** 
 Paranasal sinuses  
 
SAα2,6 
 Nasopharynx 
 
SAα2,6 & SAα2,3 
 Pharynx 
 
SAα2,6 
 Larynx 
 
SAα2,6 
 Trachea 
 
SAα2,6 & SAα2,3 
 Trachea/Bronchi junction 
 
SAα2,6 
 Bronchi 
 
SAα2,6** & SAα2,3 
 Bronchioles 
 
SAα2,6 
 Goblet cells 
 
SAα2,6 & SAα2,3 
 Alveoli 
 
SAα2,3 
     ** Reported to be in low concentrations 
    
Avian influenza viruses, on the other hand, preferentially bind to SAα2,3Gal, 
the main receptor type found in the alimentary and respiratory tracts of birds 
(Hinshaw et al., 1979; Gambaryan et al., 2002; Matrosovich et al., 1997). The widely 
held view is that for these viruses to adapt for transmission into humans, it is 
necessary for them to alter their HA binding pattern towards a preference for 
SAα2,6Gal, the predominant receptor type found in the human respiratory tract 
(Connor et al., 1994; Matrosovich et al., 2004). 
It is important to note that many early studies (pre-mid 1990s) did not 
routinely employ antigen retrieval techniques (via enzymes or heating) to unmask 
antigenic sites that may have become cross-linked during the formalin fixation 
process.  Nicholls et al., (2009) have reported that when antigen retrieval techniques 
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were used, there was a greater detection of SAα2,3Gal in respiratory epithelium 
then previously reported. Nevertheless, SAα2,6Gal still predominated. 
Primary cultures of human airway epithelium have been generated in the 
labortaory and can contain a mixture of ciliated and non-ciliated cells, the latter able 
to produce and secrete mucus. Lectin staining of these cultures has shown a 
predominance of SAα2,6Gal found at the apical surface of both ciliated and 
noncilated cells but that the SAα2,3Gal is exclusively present on ciliated cells 
(Thompson et al., 2006; Matrosovich et al., 2004).  
Matrosovich et al., (2004), and later Thompson et al. (2006) reported that 
followng infection, human adapted influenza viruses spread laterally from cell-to-cell 
in human tracheobronchial epithelial (HTBE) cultures – infecting both ciliated and 
non-ciliated cells using the abundant a2,6SA expressed on both cell types. In 
contrast, avian viruses under the same conditions did not form continuous foci of 
infection and were found to infect primarily ciliated cells due to their preference for 
α2-3 linked SA.    
Studies have shown that with only a few amino acid substitutions in the gene 
encoding the viral HA, it is possible to alter the binding specificity of the HA.  These 
amino acid substitutions have been well characterized for H3 HA (for example HA 
from the H3N2 virus A/Udorn/307/72) and a substitution at position 226 (leucine to 
glutamine or methionine) of the HA1 protein has been reported to alter the receptor 
preference from SAα2,6Gal to SAα2,3Gal (Rogers et al., 1983; Ito et al., 2000). In 
addition, a mutation at position 228 (serine to glycine) in Udorn HA was found to 
alter the virus’ ability to recognize the SA molecular species Neu5Ac and Neu5Gc. 
Prior to this mutation, the virus preferentially recognized NeuAcα2,6Gal while after 
the serine to glycine substitution, the virus was able to recognize both Neu5Ac and 
Neu5Gc equally well (Ito et al., 2000).    
Ito and colleagues (1998) found that pig trachea contains both avian and 
human influenza virus receptors and, as such, could constitute a theoretical “mixing 
vessel” for the generation of human-avian influenza A virus with pandemic potential. 
Furthermore, they noticed that with extended replication in pigs, avian viruses 
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would undergo a total shift in receptor specificity to the SAα2,6Gal form. It was 
proposed that this receptor switch could arise via two, not mutually exclusive, 
routes. Firstly, a pig could be infected with both human and avian influenza viruses 
and that classical reassortment could take place and/or, secondly, an infection with 
an avian virus alone could take place and through a stepwise fashion the virus could 
increase its recognition of human cell surface receptors. Either of these routes could 
potentially yield a virus that readily transmits to humans but for which we are 
antigenically naive. 
While traditional views tend to suggest that influenza virus HAs would only 
recognize and attach to one specific form of SA, recent studies have demonstrated 
that receptor preference is not absolute; rather, there exists a degree of plasticity 
and a range of receptor binding affinity (Meng et al., 2010). In fact, studies have 
shown that receptor preference can be overcome by employing high concentrations 
of virus (Nicholls et al., 2008; Meng et al., 2010).    
The submucosal glands of the human respiratory tract play two important, 
albeit conflicting, roles with regard to influenza infection. The mucus produced by 
these glands has been demonstrated to contain a high concentration of SA – 
predominantly in the α2,3 form (van Riel et al., 2007). It has been proposed that SAs 
present in the mucus can act as potential inhibitors of infection by binding the 
viruses before they are able to reach the cells of the respiratory tract (Gentry et al., 
1988). The fact that human respiratory mucin is particularly rich in the α2,3SA would 
suggest that it would be particularly adept at inhibiting avian influenza viruses and 
may help to explain the low transmissibility of influenza from avian hosts to humans. 
In addition, the negative charge held by SAs causes them to repel each other and, 
when attached to filamentous glycoproteins, help to give mucus its high viscosity 
(Schauer, 2000).  If however, a virus is able to successfully navigate through the 
mucus layer and establish an infection within the glandular cells, the resultant 
infection can easily spread to neighbouring cells.  
The viral protein neuraminidase, in addition to its role in aiding the 
detachment of new virions from the SA on the surface of infected cells, also uses the 
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same enzymatic property to help the virus navigate through the SA-rich mucus. As 
Wagner et al., (2002) explain, it is important that a functional balance is maintained 
between haemagglutinin and neuraminidase activity. As such, viruses must be 
allowed to recognize and attach to the SA present on cell surfaces but their 
attraction must not be so strong as to inhibit viral release or unduly attach them to 
decoy receptors in mucus.  
 
1.5 Circulating Strains & Reassortment 
The reassortment of viral gene segments has been implicated in the 
emergence of viruses with novel antigenic properties leading to the pandemics of 
1918 (A/H1N1), 1957 (A/H2N2), 1968 (A/H3N2) and recently 2009 (A/H1N1). The 
pandemic viruses of 1957 and 1968 were found to be reassortants of human and 
avian viruses (Reid et al., 2004; Schafer et al., 1993; Kawaoka et al., 1989) whereas 
the 2009 pandemic was a triple reassortant containing the genetic material of 
human, avian and swine viruses (Trifonov et al., 2009). 
After the emergence of the Spanish influenza pandemic virus in 1918, 
A/H1N1 viruses circulated until they were displaced by an A/H2N2 virus in 1957 
which gave rise to the Asian influenza pandemic. The A/H2N2 viruses continued to 
circulate until 1968 before they, in turn, were replaced by an A/H3N2 virus that 
caused the Hong Kong influenza pandemic (Figure 9) (Kawaoka et al., 1989; 
Scholtissek et al., 1978).  Since then, A/H3N2 viruses have circulated causing 
seasonal epidemics. In 1977 A/H1N1 viruses reemerged and have been found co-
circulating with A/H3N2 viruses since. These viruses were then displaced by the 
emergence of the A(H1N1)pdm09 triple reassortment strain. During the 2013-2014 
influenza season in the UK, the predominant circulating type A strains continues to 
be the A(H1N1)pdm09 as well as the A/H3N2 strain (Public Health England, 2014). 
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Figure 9. Circulating types and strains of influenza from 1900-2000.  
 
1.5.1 Influenza B virus circulation 
 Antigenically speaking, it is possible to separate Type B viruses into two distinct 
groups (Figure 9). One set resembling B/Yam/88 circulated in the United States while 
the other set resembled B/Vic/97 and was found in Asia (Rota et al., 1990). It is from 
these two proteotypic lineage strains that all subsequent antigenic classification is 
based. The circulation of genetically similar, yet antigenically distinct lineages with 
little to no cross reactivity has profound vaccination implications (discussed further 
in section 1.7).  
 Multiple strains of the influenza B virus belonging to either lineage frequently 
arise and, at any one time, variants belonging to the different lineages co-circulate in 
the human population (Matsuzaki et al., 2004; Rota et al., 1992; Rota et al., 1990; 
Oxford et al., 1984; Lu et al., 1983). This is hardly surprising as studies have shown 
that multiple co-circulating Type A viruses belonging to different evolutionary 
lineages have existed and co-circulated (Cox et al., 1989; Lindstrom et al., 1999 and 
Xu et al., 1996). This co-circulation last for only short periods of time until a 
  
 
46 
dominant strain emerges as a result of antigenic selection pressures. The co-
circulation of multiple lineages or subtypes of influenza viruses provides an 
opportunity for genetic reassortment to occur during a mixed infection of a single 
individual with two viruses belonging to different subtypes in the case of Type A or 
two lineages for Type B. Importantly, it should be noted that due to incompatibility 
of their polymerase genes, there has been no documented reports of reassortment 
between Type A and B occurring in a host (human or otherwise).  
 
1.6 Immune response:  
 
In terms of pathology and clinical presentation, influenza infections are 
generally associated with a disease of predominantly the upper, but in some cases 
lower, respiratory tract ranging from asymptomatic to fatal. Influenza-related 
disease is often most severe in patients/hosts that are either immunocompromised 
or have a predisposing co-morbidity including, but not limited to, asthma, chronic 
obstructive pulmonary disease (COPD) and neuromuscular disorders (Peiris et al., 
2009; Keren et al., 2005). 
As Fukuyama and Kawaoka (2011) re-iterate, the broad spectrum of clinical 
presentations described for influenza A and B viruses are quite similar. Over the past 
seventy years, influenza B has been responsible for 16 seasonal epidemics and has 
been the predominant circulating type every 3-4 years (Thompson et al., 2003). 
Influenza B infections have been reported to induce clinical signs and symptoms 
similar, if not indistinguishable from, infections caused by influenza type A strains 
resulting in morbidity and mortality worldwide (Kim et al., 2009; Wright & Webster, 
2001). It has been noted that some influenza-related symptoms occur more 
commonly in children after influenza B infection and include leukopenia, myalgia and 
myositis, the latter occurring more in males than females (Peltola et al., 2003; Hu et 
al., 2004). Typically, the burden of influenza B infections falls mostly on young adults 
and children, although in some epidemics, it is the elderly population that is more 
adversely affected (Olson et al., 2007; Li et al., 2008; Glezen et al., 1980). On the 
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other hand, there is a body of opinion in the literature that influenza B viruses cause 
milder pathogenesis and weaker inflammatory response than influenza A viruses, 
leading to a much milder clinical presentation (Kim et al., 2009; Kim et al., 1979). 
Most of these conclusions rely on data derived from animal models (ferrets) or 
clinical studies conducted from the late 1950’s to the mid 1970’s. It should be noted 
that these clinical studies took place before the divergence of type B lineages (mid-
1980’s, see below) and no recent large-scale clinical-based influenza B study has 
been conducted examining pathogenesis or immune response. However, serious 
influenza type B infections are observed in children (Dr. Susan Chiu and Prof. Malik 
Peiris, personal communications 2011).  
Ferret experiments conducted by Kim et al., 2009 demonstrated reduced 
viral replication and lower induction of inflammatory cytokines in lung tissues in 
animals infected with influenza B (B/Malaysia/2506/04 and B/Shanghai/361/2002) 
when compared to those infected with influenza A (A/New Caledonia/20/99 and 
A/Puerto Rico/8/34). In addition, those ferrets infected with the flu B strains 
exhibited a reduced level or viral replication and an overall lower induction of 
inflammatory cytokines. While the viruses selected in this study were representative 
of the two B lineages, they were not temporally matched with their flu A 
counterparts. Furthermore, the viruses were amplified in eggs prior to infection and 
such amplification has been shown to alter the receptor specificity of influenza 
viruses (Robertson et al., 1985). Furthermore, these studies may simply prove that 
the influenza B virus, being an exclusively human adapted virus, does not replicate 
well in the ferret. 
The current belief is that much of influenza virus pathogenesis is influenced 
by the host’s immune response to the virus infection. The vast majority of work in 
this area is centred around influenza type A viruses. The adaptive immune system 
plays a vital role in actively protecting a host during an infection and aids in the 
prevention of repeat infections while the innate immune response serves as a non-
specific form providing front line defence against microbial assault. If however, this 
response is unregulated, it can cause damage to the very organs that the immune 
system is trying to protect.  
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During the early stages of infection, the ssRNA of the virus is recognized by 
toll-like receptor seven (TLR7) in dendritic cells and retinoic acid-inducible gene-I 
(RIG-I) in epithelial cells (Diebold et al., 2004; Pichlmair et al., 2006). Both of these 
“ssRNA sensors” independently activate signalling pathways that induce the 
production of type 1 IFNs and acute antiviral host responses. TLR7 and RIG-I are also 
responsible for inducing the production of inflammatory proteins (IL-1β, IL-6, IL-8, 
MCP-1, MTP-1α, TNF-α, IP-10 and RANTES) which is mediated via NFkB activation 
(Kawai & Akira, 2008). Importantly, the viral protein NS1 can interfere with the RIG-I 
signalling pathway and the expression of induced mRNAs and thus hinders the host’s 
ability to mount an effective innate immune response (Hale et al., 2008; Jiao et al., 
2007). 
Studies have shown that two broad patterns exist related to the kinetics of 
cytokine gene transcription – an early and late phase. We are primarily interested in 
the early phase of cytokine gene transcription because this sets up the outcome of 
infection. To investigate the cell’s early, primary response to the virus, Cheung and 
colleagues (2002) infected human peripheral-blood monocytes with influenza A 
(H5N1) strains using a high multiplicity of infection (moi = 2) in order to ensure 
infection of the vast majority of cells during a single round of viral replication. What 
they ascertained was that from one hour p.i. onwards, IFN-α, IFN-β, IL-1β and TNF-α 
were progressively up-regulated (with TNF-α levels peaking at 12-24hrs p.i.) and that 
at six hours p.i. MCP-1, RANTES and IL-12 were induced.  After this period, many of 
the subsequent responses are the product of feedback loops resulting from this early 
induction pattern (Mok et al., 2009).  
It is currently believed that the most severe presentations of influenza-
related hospitalizations result from an unregulated response of pro-inflammatory 
cytokines and chemokines induced by the TLR signalling cascade, creating a so-called 
“cytokine storm” (Chung et al., 2002; Fukuyama & Kawaoka, 2011; Osterholm, 
2005). The severe pathology and mortality rates associated with 1918 Spanish flu, 
and in about half the people infected with HPAI H5N1 infection, are believed to be 
linked to this dysregulation of the immune response (To et al., 2001; Seo et al., 2002; 
Abdel-Ghafar et al., 2008). Ex vivo studies employing primary human alveolar and 
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bronchial epithelial cells infected with H5N1 found that cytokine induction was 
dependent on active viral replication as inactivated viruses did not induce any 
detectable cytokine up-regulation (Chan et al., 2005). Furthermore, these studies 
demonstrated that, although high replicating viruses did induce high cytokine levels, 
the differences in cytokine up-regulation observed between the various strains 
tested was not only due to differences in replication kinetics (Peiris et al., 2007). 
Several genotypic variations in influenza A virus have been associated with a highly 
virulent pheontype. Some of these are listed in Table 3. For influenza B viruses this 
type of detailed study on the way genetic variation might affect virus virulence has 
not been undertaken.   
Although generally a rare complication, pneumonia can follow an influenza 
infection and can vary from mild to fatal in consequence.  If however, they occur 
together in the form of a heterologous or secondary infection, the resultant 
infectious disease is associated with significant morbidity and mortality (Small et al., 
2010; Hussell & Williams, 2010). The pneumonia can be primary viral pneumonia or 
more commonly, be secondary to bacterial infection (Peiris et al., 2009). It has been 
postulated that the “cytokine storm” associated with certain viruses may create an 
environment conducible for pneumonia to set in (Small et al., 2010; Madhi et al., 
2008; Seki et al., 2007). Interestingly, primary viral pneumonia has been frequently 
reported as a common manifestation of H5N1 infections in humans (Abdel-Ghafar et 
al., 2008). In addition, the major findings from autopsy performed on fatal cases of 
the disease were in line with the pathology observed in Acute Respiratory Distress 
Syndrome (ARDS) and included diffuse alveolar damage with hyaline membrane 
formation, patchy interstitial infiltrates (primarily composed of neutrophils, 
macrophages and activated lymphocytes) and pulmonary congestion with associated 
haemorrhage (Headley et al., 1997; To et al., 2001; Cheung et al., 2002).    
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Table 3. Mutations in viral proteins that influence viral pathogenicity. (Adapted from Kumlin et al., 2008). 
 
                
Protein   Virus   Mutation   Pathogenic effect     
HA 
 
H7N7 
 
A143T 
 
Increased attachment to bronchial epithelial cells and alveolar macrophages in humans 
HA 
 
H1N1 (1918)     D190E, D225G 
 
          Switch of receptor specificity (alpha2,6 to alpha2,3) 
HA 
 
H3N2 
 
L226Q 
 
Switch of receptor specificity (alpha2,6 to alpha2,3) 
HA 
 
H1N1 (2009)     D222G 
 
          Switch of receptor specificity (alpha2,6 to alpha2,3) 
NA 
 
H3N2 
 
R292K, E119V, N294S Oseltamivir-resistant (R292K, loss of ability to readily transmit) 
NA 
 
H5N1 
 
H274Y 
 
Oseltamivir-resistant 
  PB1-F2 
 
H1N1 (1918)    N66S 
 
 Delay of innate immune response and increased cytokine production 
PB2 
 
H5N1 
 
T271A 
 
Increased polymerase activity in mammalian cells 
PB2 
 
H5N1, H7N7 
 
E627K 
 
Increased replication activity in mammalian respiratory tract 
PB2 
 
H5N1 
 
D701N 
 
Increased replication activity 
PA 
 
H5N2 
 
T97I 
 
Adaptation In mice 
  NS1 
 
H5N1 
 
P42S 
 
Increase in IFN antagonism 
NS1 
 
H5N1 
 
85-94 inclusive deletion Impaired inhibition of IFN production 
NS1 
 
H5N1 
 
D92E 
 
Decreased sensitivity to IFN and TNF-α 
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A large part of the clinical presentation and morbidity associated with influenza-
related disease is induced not only by viral factors but also by the host immune response. 
Mall and colleagues (2011), documented an outbreak in Germany of benign acute myositis 
in children. During the outbreak, a seasonal influenza B strain (B/Florida/4/06-like) was 
found to be the causative agent by qRT-PCR in 93% of cases (n=216). As there was no 
evidence of systemic spread of the virus, the systemic manifestations could be attributed to 
the actions of cytokines and other inflammatory mediators (To et al., 2001; Hayden et al., 
1998; Peiris et al., 2009). 
Studies have demonstrated that differences in numerous viral factors including HA 
antigenicity, expression of virally encoded proteins and RNA (Diebold et al., 2004) 
contribute to differences observed between type A and B in terms of both the type of 
cytokines expressed and their relative level of expression by NKT cells and dendritic cells 
(Minami et al., 2005; Sato et al., 2009; Divanovic & Lai, 2004), but these are not well 
characterized at the molecular level.  
In the late 1980s researchers noticed the emergence of several strains of influenza B 
that possessed different antigenic properties than the standard reference strains (Rota et 
al., 1990).  It was later determined that a divergence had taken place with two distinct 
lineages emerging; B/Victoria and B/Yamagata (the former possessing the novel antigenic 
properties) (Rota et al., 1990; McCullers et al., 2004). Currently, both of these lineages freely 
circulate within the human population (Li et al., 2008; Belshe, 2010). This has led to 
speculation that representatives from both lineages should be included in the seasonal 
vaccine, making it quadrivalent rather than trivalent if full coverage is to be achieved. 
During the 2010-2011 influenza season, influenza B virus infections were common 
and a relatively high number of influenza B cases were hospitalized. Strikingly, there were a 
number of influenza B cases involving young adults (both male and female) that did not 
have any underlying comorbidities or risk factors A similar scenario was also reported for 
influenza A infections and autopsy results of fatal cases found a large accumulation of 
complement (specifically C4d) cells around the bronchi indicating an abnormal immune 
response may have contributed to the pathogenesis of these strains (Fukuyama & Kawaoka, 
2011).  
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1.7 Vaccines 
 
The most effective defence we have against insult from the influenza virus is a well-
matched vaccine that induces an antigenic response strong enough to protect the individual 
from the circulating viral strains. Our antiviral arsenal, while generally effective, has limited 
to no ability to protect an individual against an infection and are only effective at symptom 
alleviation. 
In the UK, influenza vaccines are offered to “at-risk” individuals, influenza 
researchers, healthcare workers and other frontline occupations deemed a priority by 
national health and security organisations.  The “at-risk” group is typically comprised of 
anyone over the age of 65, pregnant women, children/adults with underlying conditions 
(particularly long standing heart or respiratory disease) and children/adults with weakened 
immune systems.  As of the 2013-2014 influenza season, healthy children aged two and 
three years have the option of receiving the nasal spray flu vaccine (“FluMist”) 
(http://www.nhs.uk/Conditions/vaccinations/Pages/flu-influenza-vaccine.aspx). 
Antibodies raised against one influenza virus type or subtype confer limited, to no 
protection, against a different type or subtype. Due to the constant antigenic drift and, for 
type A occasional shift, associated with influenza viruses, influenza vaccines have to be 
updated annually to account for the new antigenic properties of the predominant 
circulating stains. The efficacy of a vaccine relies on Th cell regulated development of high 
affinity B cell memory and the consolidation of the response through antigen re-challenge 
(Wee, 2009). 
For example, the influenza vaccine does not induce protective immunity in a large 
proportion of the elderly population due to what researchers have described as 
“immunosenescence” (Goronzy & Weyand, 2013). The diminished response in the elderly to 
a vaccine is believed to be due, at least in part, to a defective T cell memory response. 
Responses to the vaccine against the influenza virus in the adult rely strongly on somatic 
mutation of the memory repertoire rather than recruitment of new antibody sequences (Li, 
2012; Wrammert, 2011). It is the inability of the T cell memory repertoire to adapt to the 
new HA/NA present in the vaccine that prevents the induction of the desired immune 
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response when the individual is challenged by the circulating virus. Numerous attempts to 
improve vaccine uptake in the elderly have included the use of adjuvant, higher vaccine 
doses or booster vaccination; however, all have been of limited success (Couch, 2007; 
Brown, 2010).  
A systematic review of reviews concluded that vaccination against the influenza virus 
provides substantial protection to both healthy and at-risk individuals, children as well as 
adults. The efficacy of vaccines against laboratory confirmed cases ranges from 26-87% 
depending on the vaccine match and the age of the recipient individual (Nichol, 2008).  
Lower protection can be expected in years where there is a suboptimal match between the 
vaccine strain and the circulating strains. This however, does not mean that a “miss-match” 
vaccine does not afford the individual any protection since the vaccine generally will reduce 
disease symptoms even though it may not protect against the primary infection (Nichol, 
2007; Herrera, 2007). A more thorough understanding of the concept of vaccine cross-
protection could have numerous implications in terms of improving planning for both 
seasonal and pandemics vaccines. 
There are several licensed manufacturers of vaccines around the world, all of which 
grow their vaccine stocks in eggs, either formulated as a trivalent inactivated virus for 
intramuscular injection or as a live attenuated virus vaccine for intranasal administration.  
Studies comparing the protection offered by these two vaccine types have indicated that 
the live attenuated influenza vaccine offers a significantly better protection than its 
inactivated counterpart against both well matched strains and strains which have 
undergone antigenic drift (Belshe, 2007). 
Standard trivalent vaccines cover two type A stains and one type B strain. However, 
since the emergence of two antigenically distinct influenza type B lineages in the 1980’s, 
one lineage would typically displace the other lineage in circulation for several years only to 
be almost fully replaced by the other lineage at a later date. However, since 2001 both Type 
B lineages have been co-circulating with year-to-year variation in the predominant lineage 
(Glezen, 2013).  
As vaccine strains have to be chosen at least 6 to 8 months prior to vaccine 
distribution, the possibility of a mismatch between the selected vaccine strains and the 
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predominant circulating strains is a real possibility and has, in fact, occurred numerous 
times (Schaffner, 2006; Tosh, 2010). From the 2001/02 to the 2010/11 influenza seasons, 
the Type B component of the vaccine has only matched the predominant circulating strain 
5/10 times (Belshe, 2010a). When vaccine mismatch occurs, it can be a serious problem. If 
the new circulating strains are significantly different, cross-protection afforded through the 
vaccine may diminish or be absent altogether. Xu et al., (2004) have found that there is only 
a low level of antigenic cross-reactivity between the hemagglutinins (HAs) of viruses from 
the two lineages. This lack of cross-reactivity holds serious consequences for seasonal 
vaccine planning and administration. Indeed, during the 2000-2001 and 2004-2005 seasons 
in the USA, significant mismatch occurred and there was a higher than normal reported 
incidence of severe illness (Schaffner, 2006).   
Currently, both of these type B lineages freely circulate within the human population 
(Li, 2008; Belshe, 2010a).  This has led to calls for representatives from both lineages to be 
included in the seasonal vaccine, thus replacing our current trivalent vaccine with a more 
protective quadrivalent vaccine (Reed, 2012; Belshe, 2010a; Belshe, 2010b). The first FDA 
licensed quadrivalent vaccine (Sanofi Pasteur’s Fluzone® Quadrivalent) suitable for patients 
as young as 6 months of age is expected to be commercially available for the 2013/2014 
influenza season (http://www.sanofipasteur.com).   
There are efforts underway to design a rapid pandemic vaccine production system 
employing the reverse genetics approach where 6 plasmids would carry attenuating internal 
genes originated from a stable master donor virus and two additional plasmids encoding for 
the haemagglutinin and neuraminidase from the potential pandemic strain (Chen & 
Subbarao, 2009; Hoffmann, 2002). If effective, this system could dramatically cut down 
vaccine production time and thus offer a much more acute response to an emerging 
pandemic. Initial vaccine trials employing this approach had yielded disappointing results 
with the vaccine inducing limited immunogenicity. However, with the development of novel 
adjuvant strategies that can be used in combination with the reverse genetic vaccines, a 
more desirable protection level has been achieved (Leroux-Roels, 2007).  
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1.8 Antivirals 
 
Currently, there are two classes of anti-influenza drugs licensed for the prophylaxis 
and treatment of influenza infection: 1) neuraminidase inhibitors and 2) M2 channel 
inhibitors. 
National Institute for Health and Care Excellence (NICE) guidelines currently 
recommend the use of antiviral treatments for influenza only if the patient is deemed to be 
at-risk. The at-risk group includes individuals aged 65 years and older, those aged 6 months 
and over with comorbidities which put them at-risk for influenza-related complication, 
which include diabetes, chronic respiratory, cardiac, renal, neurological and liver disorders 
and immunosuppression (NICE, 2009).  
The licensing of antiviral drugs such as the neuraminidase inhibitors (NAIs) zanamivir 
and oseltamivir has been largely based on clinical trials in which otherwise healthy adults 
experiencing seasonal influenza were recruited rather than in the at-risk groups.  Here NAIs 
have been shown to reduce the duration of symptomology resulting from influenza 
infection, by between half a day and one day (Cayley, 2012). The NICE treatment guidelines 
do not take the societal perspective into account when evaluating interventions. If, 
however, a wider view was taken which considered the number of lost working days and the 
socio-economic impact of influenza infections in a working healthy adult population, more 
emphasis might be given to treating influenza infections in those not classified as “at-risk.” It 
should be noted, that if antiviral drugs were made more available and injudiciously used, 
resistance could spiral out of control.  
 
1.8.1 Neuraminidase inhibitors 
 
The viral neuraminidase facilitates the spread of influenza progeny virions after 
successful replication by the cleaving of N-acetylneuraminic acid from the cell surface 
glycoprotein. By inhibiting this cleavage, the release of the newly formed viruses is 
prevented (Moscona, 2005a). Due to the highly conserved enzyme site of the neuraminidase 
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glycoprotein and its requirement for successful viral replication, it poses a tempting target 
for antiviral intervention. The neuraminidase active site is comprised of eight catalytic 
residues that make direct contact with the sialic acid substrate. A further 11 framework 
residues stabilize the shape of the active site (Colman, 1983). The modelling of the 
interactions that occur between these highly conserved residues and the sialic acid 
eventually led to the development of the first neuraminidase-inhibitor (NAI), the zanamivir, 
the structure of which is analogous to a sialic acid but also allows for additional interactions 
that lock this substrate analogue into the active site rendering the neuraminidase inactive  
(von Itzstein, 1993). Zanamavir has poor bioavailability and is administered as an inhaled 
formulation. A similar approach was used to design oseltamivir, an oral prodrug formulation 
(Laver, 1999). Both NAIs have been licensed for use in many countries around the world 
since 2000 with oseltamivir being the more widely used due to its ease of oral 
administration (Ikematsu, 2012; Cooper, 2003). 
The neuraminidase inhibitors (oseltamivir and zanamivir) have been shown to be 
effective at reducing the duration of illness from seasonal influenza by approximately one 
day if the drug is administered within 48 hours after the appearance of symptoms but when 
used as prophylactics role, when compared to placebo, neuraminidase inhibitors were 
found to have no effect against influenza-like disease (Jefferson, 2006). This original report 
was latter re-assessed and augmented in subsequent Cochrane reviews (2007, 2010, 2011, 
and 2012) where in the clinical efficacy of the neuraminidase inhibitor class of antivirals has 
been called into question. This new assessment has arisen over a dispute around the 
Cochrane researchers ability to gain full access to clinical trial data, including non-published 
results, from studies conducted by the pharmaceutical companies (in this instance, namely 
GlaxoSmithKline and Roche) (Jefferson & Doshi, 2013). In addition, concerns over study 
flaws and inappropriate extrapolations from published data by these same companies have 
become an issue (Kmietowicz, 2013). Despite all these discrepancies, a major meta-analysis 
conducted by Muthuri et al., (2014) examined the effectiveness of neuraminidase inhibitors 
in 29,234 hospitalised patients infected with A/H1N1pdm09 from 78 studies conducted 
between Jan 2, 2009 till March 14, 2011. The results of their analysis indicate that treating 
A/H1N1pdm09-infected patients at any stage of illness with neuraminidase inhibitors 
compared to non-treatment patients was associated with a reduction in the risk of 
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mortality. Additionally, this association in reduced risk of mortality increased the sooner 
after the onset of symptoms that treatment with a neuraminidase inhibitor was 
commenced. Furthermore, they reported that their findings were consistent for adults, 
pregnant women and adults requiring critical care however, the authors were unable to 
demonstrate any similar associations in paediatric populations. 
 
1.8.1.1 Oseltamivir (Tamiflu) 
 
Oseltamivir ((3R, 4R, 5S)-4-acetylamino-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-
1-carboxylic acid ethyl ester) is  an orally available and widely-used neuraminidase 
inhibitors. A prodrug, oseltamivir is metabolised to its active form upon first-pass through 
the liver (Davies, 2010). 
Treanor and colleagues (2000) reported on a 60-center trial where 627 otherwise 
healthy patients aged 18 to 65 presenting with influenza-like illness of less than 36hrs in 
duration were randomly assigned to oseltamivir (75 or 150mg, twice daily) or placebo for 5 
days. Sixty percent of patients later were determined to have laboratory confirmed 
influenza infections. Their results indicated that both doses of oseltamivir led to a 
statistically significant reduction in symptom duration by approximately one day. 
Furthermore, oseltamivir was found to reduce severity scores and the incidence of 
secondary complications. 
Another study conducted by Nicholson et al., (2000) found comparable results. Their 
trial consisted of 51-centers with 719 healthy adult patients treated with either oseltamivir 
or placebo either within 24hrs or 24 to 36hrs post the onset of symptoms. Among the 66% 
of patients who were found to have laboratory confirmed influenza A infections, oseltamivir 
significantly reduced the duration of illness by approximately 1.5 to 2 days for the within 
24hrs treatment group and 1 day for the 24 to 36hrs treatment group. Muthuri et al., (2014) 
conducted a meta-analysis in which data from 29,234 patients (across 78 studies) admitted 
to hospital worldwide with laboratory confirmed or clinically diagnosed pandemic influenza 
(A/H1N1pdm09) virus infection and assessed the association between NAI treatment and 
mortality. They found that compared with no treatment, neuraminidase inhibitor treatment 
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(irrespective of timing of intervention) was associated with a reduction in mortality risk. 
However, the association of reduced mortality risk associated with NAI treatment was not 
significant in children.  
Within at risk groups, the influenza-related disease processes can be far more severe 
and antiviral intervention (and the timing of said intervention) is often critical to patient 
outcome. Indeed, during the 2009 influenza pandemic, the severity of illness was found to 
increase with increasing interval from onset of symptoms to the start of antiviral therapy 
(Zarychanski et al., 2010). 
In order to exert its effect, oseltamivir requires a re-arrangement in the 
neuraminidase active site. Thus, a mutation which prevents this re-arrangement of the 
active site would render the drug inactive. A single nucleotide change can confer resistance 
such as that encoding the NA amino acid substitution H274Y. The tyrosine causes 
displacement of glutamine at position 276 and subsequent disruption of the hydrophobic 
pocket that would otherwise accommodate the pentyloxy section of the Oseltamivir 
molecule (Figure 10) (Collins, 2008). Several influenza strains have already acquired 
resistance against oseltamivir including several isolated cases of A/H5N1 (Horimoto & 
Kawaoka, 2005; Beigel, 2005; Le, 2005 & de Jong, 2005). 
A significant rise in the frequency of viruses with mutations conferring oseltamivir 
resistance became apparent in circulating seasonal influenza A/H1N1 strains in the winter of 
2007-2008. The majority of the mutations were characterized by the H274Y switch (Sheu, 
2008). The spread of the oseltamivir-resistant virus reached such proportions that by the 
2008-2009 influenza season, almost 100% of all tested seasonal A/H1N1 strains in the 
United States and numerous counties worldwide were found to be oseltamivir-resistant 
(CDC, 2009; WHO, 2008). Thankfully this seasonal H1N1 virus was displaced by the incoming 
A(H1N1)pdm09 virus, in 2009.  Despite the widespread prophylactic and therapeutic use of 
oseltamivir during the early waves of the pandemic, oseltamivir-resistant mutations have 
not thus far become predominant in this strain as it continues to circulate world-wide.  
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Figure 10. Effect of H274Y mutation on the electrostatic surface potential and hydrogen-
bond network of the binding pocket of A/H1N1 neuraminidase.  The addition of the H274Y 
into the NA of A/H1N1, provoked a displacement of the glutamine at position 274 which 
subsequently results in a disruption of the hydrophobic pocket adversely effecting the 
ability of Tamiflu (Oseltamivir, yellow structure) to bind to the NA active site. (Adapted 
from: Vergara-Jaque et al., 2012).  
 
With respect to A/H5N1, the efficacy of oral oseltamivir is limited. In a situation 
where the overall mortality is reported to be ~60%, the case fatality ratio among patients 
receiving oseltamivir is approximately 50% compared to nearly 90% of those not receiving 
oseltamivir therapy (Zhou, 2010; Beigel, 2005). However, the emergence of NAI-resistant 
strains have been reported in patients treated with oseltamivir (de Jong, 2005). In a case-
series study of 8 patients from Vietnam, where a standard course of oseltamivir therapy was 
initiated a median of 6 days post onset of symptoms, two of the patients had treatment-
emergent oseltamivir-resistant viral variants. The mutation in questions was the commonly 
observed histidine-to-tyrosine at position 274 (de Jong, 2005). This mutation results in 
oseltamivir having a >400-fold reduction in efficacy against the N1 NA; susceptibility to 
zanamivir remained unchanged (Ozawa, 2011; McAuley, 2010).  
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1.8.1.2 Zanamivir (Relenza) 
 
In contrast to oseltamivir, zanamivir (5-acetamido-4-guanidino-6-(1, 2, 3-
trihydroxypropyl)-5, 6-dihydro-4H-pyran-2-carboxylic acid) acts on neuraminidase without 
requiring a conformational change in the glycoprotein’s active site (Moscona, 2005a&b). 
However, zanamivir is administered via inhalation using a specialized devise and has a poor 
bioavailability profile (Min, 2007; Cooper, 2003). In special circumstances zanamivir has 
been given as an iv formulation. 
 
1.8.1.3 NAI resistance 
 
As mutations referring reduced sensitivity and resistance continue to arise and 
spread, it is essential that detailed surveillance programs track these changes. To date, the 
inhibitory activity of NAIs against all 9 of the neuraminidase subtypes found in avian viruses 
predict that NAIs will likely be active against any emergent pandemic strain originating from 
an avian host whether it be A/H5N1 or employing any other of the 9 neuraminidase 
(Hayden, 2009).  Indeed oseltamivir has been used to treat patients infected with the 
emegring A/H7N9 virus in China, although in some cases resistance in the N9 NA conferred 
by R292K mutation has been selected (Sleeman et al., 2013). Alarmingly, recent 
experimental studies in guinea pigs indicates little fitness cost or reduction in 
transmissibility resulting from this mutation (Hai et al., 2013). 
Usually mutations that confer resistance to one of the two licensed NAIs dose not 
confer resistance to the other. However cross-resistance can occur, depending on the 
neuraminidase type and sub-type, and the particular neuraminidase mutation Abed et al., 
2006; McKimm-Breschkin et al., 2003). I223R NA mutation is an example of cross-resistance, 
selected during treatment of a child infected with pH1N109 virus (LeGoff et al., 2012). 
While the frequency of resistance-conferring mutations for NAIs is considered to be 
less than that for M2-inhibitors, it is still not insignificant. This is especially true in paediatric 
populations where one study conducted in Japan found resistant-variants in nearly 1 in 5 
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paediatric patients (Thompson, 2004). While many NAI-resistant viruses usually 
demonstrate a reduced infectivity and virulence in animal models this is not always the 
case, for example the seasonal H1N1 viruses of 2007-08 (McAuley, 2007; Zamarin, 2006). As 
such, the rise and spread of NAI-resistant variants should be considered a key observational 
target for any surveillance program. 
 
1.8.2 Adamantanes 
 
Amantadine and rimantadine are both members of the adamantanes family. This 
class of drug exerts its effect by blocking the interior channel within the tetrameric helical 
bundle of the viral Matrix 2 (M2) protein, thus inhibiting the influx of H+ ions which are 
crucial for triggering the un-coating stage of the viruses replication cycle (Horimoto & 
Kawaoka, 2005; Sansom & Kerr, 1993). There is some considerable debate about whether 
the drug blocks by binding within the channel or on the periphery. 
The Cochrane team have analysed the clinical data regarding efficacy of these 
compounds, and they find little evidence to support their therapeutic use. This is surprising 
because in vitro these compounds are very good at supressing influenza replication, and in 
preclinical animal models they are also effective. In terms of prophylaxis, amantadine was 
found to prevent 61% of confirmed influenza A infections and 25% of cases of influenza-like 
illness in prevention trials involving human test subjects; both of these results were deemed 
to be statistically significant (Jefferson, 2006). In contrast rimantidine, a preferred 
prophylactic due to fewer side effects, was not effective in preventing infection. As a 
therapeutic treatment, both amantadine and rimantidine significantly shortened the 
duration of fever when compared to placebo; however, no significant effect was seen in 
terms of nasal viral shedding or persistence of the virus in the upper airway after 5 days of 
oral or inhaled treatment (Jefferson, 2006). 
The side effect profile of amantadine includes gastrointestinal symptoms (mainly 
nausea), insomnia and hallucinations. CNS adverse effects and side effects requiring 
withdrawal from trials were significantly more frequent in subjects receiving amantadine 
than those given rimantadine (Jefferson, 2006). 
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Rimantadine was found not to be an effective prophylaxis against either confirmed 
cases of influenza or influenza-like illness (Jefferson, 2006). In a treatment role for influenza 
infection, rimantadine was found to significantly shorten the duration of fever when 
compared to placebo however, no significant effect was seen in terms of nasal viral 
shedding or persistence of the virus in the upper airway after 5 days of treatment (Jefferson, 
2006). However, no statistical difference in efficacy between amantadine and rimantadine 
was found and both were determined to have mainly symptomatic effect on influenza A, 
since they do not prevent infection and do not affect viral shedding (Jefferson, 2006). 
The clinical usefulness of the adamantanes as a monotherapy has been practically 
obliterated due to the near complete displacement of A/H3N2 adamantane-sensitive strains 
by resistant strains since 2005 (Deyde, 2007). Early surveillance studies reported that 
primary resistance typically occurred at low frequencies among circulating seasonal strains 
that had a frequency of resistance between 1-3% (Hayden, 2009). However, during the 
2003-2004 influenza season, an increasing frequency in M2-inhibitor resistance to A/H3N2 
was noted in isolates from China and Hong Kong (Figure 11). This resistance continued to 
spread and by the 2005-2006 season, had reached global distribution with >90% of isolates 
in Asia and the United States and ~50% of European isolates being resistant to M2-inhibitors 
(Hayden, 2009).   
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Figure 11. The rise of adamantane-resistant A/H3N2 viruses, 1994–2005. Adapted from: 
Bright et al., 2005.  
 
The M2-inhibitor resistance in recent isolates of A/H3N2 and A(H1N1)pdm09 was 
identified as being caused by a serine-to-asparagine substitution at position 31 in the M2 
protein (Saito, 2003; Holsinger, 1994). As a result of this natural resistance-conferring 
mutation, in order to work with this virus in the lab, it is necessary to engineer in a N31S 
backmutation. Unfortunately, resistance to either of the adamantanes confers resistance 
against both drugs. In laboratory and epidemiology studies, the mutation does not confer a 
loss of biological activity or fitness and resistant virus is able to spread from human-to-
human without any additional hindrance (Hayden, 2009).  
Alarmingly, M2-inhibitor resistance has also been described in some A/H5N1 viruses 
(Tumpey, 2005). The same mutation seen in some A/H3N2 (a serine-to-asparagine 
substitution at position 31) has been found in clade 1 viruses circulating in Vietnam, 
Thailand and Cambodia (Cox, 2007). A relatively high frequency of resistance has also been 
noted in the clade 2.1 viruses circulating in Indonesia due to either a substitution at position 
31 or position 27 (WHO, 2005). However, over 90% of clade 2.3 viruses, which circulate 
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across Eurasia to Europe and Africa, have maintained their sensitivity to the M2-inhibitors 
(WHO, 2012). 
 
1.8.3 Peramivir 
 
Peramivir, a next generation cyclopentane derivative of a neuraminidase inhibitor, 
has been shown to demonstrate an equal, if not greater, inhibitory effect against influenza 
when compared to the first two neuraminidase inhibitors both in vitro and in vivo models 
(Bantia, 2006; Chand, 2005; Bantia, 2001). Of great interest is that in comparative studies, 
strains resistant to zanamivir and oseltamivir were susceptible to peramivir (Mishin, 2005). 
Despite these promising results, the in vivo protection of peramivir is dependent on the 
route of administration due to low oral bioavailability and is thus more effective if 
administered as an IV preparation (Barroso, 2005). 
 
1.8.4 Laninamivir 
 
Already approved for clinical use in Japan, laninamivir, is designed to have long 
retention time in tissues, such that a single inhaled dose (of either 20mg or 40mg) remains 
present in target tissues and effective for ~5 days (Hayden, 2012; Yamashita, 2010). In 
contrast, conventional NAIs must be taken twice daily for 5 days to achieve and maintain 
effective dose levels. Laninamivir, has a similar antiviral spectrum to zanamivir and suitable 
for use in paediatric patients infected with seasonal oseltamivir-resistant, A/H1N1 (Sugaya & 
Ohashi, 2010; Yamashita, 2009). 
 
1.8.5 Ribavirin 
 
Well recognised as a broad spectrum antiviral, ribavirin (1-β-D-ribofuranosyl-1, 2, 4-
triazole-3-carboxamide), is a guanosine analogue that has shown activity against RSV, 
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hepatitis, herpes and influenza (Eggleston, 1987).  Its mode of action is to target a key 
enzyme required for viral replication, inosine 5’-monophosphate dehydrogenase, which is 
associated with viral RNA synthesis. This drug has been shown to be highly effective against 
influenza both in vitro and in vivo models and, to date, there have been no reports of 
influenza-associated resistance. This lack of resistance may be due to the fact that ribavirin 
is rarely used in a clinical setting as it performed poorly in clinical trials and has been 
implicated as having potential teratogenic properties and the ability to cause haemolytic 
anaemia (Rodriguez, 1994; Smith, 1980; Cohen, 1976). Nonetheless, it has been 
administered to patients with severe influenza (A(H1N1)pdm09) and infection with avian 
influenza viruses (A/H5N1). In terms of sever A/H1N1, there are reports of ribavirin being 
given to ventilated patients as part of combination therapy. However, the results seem to 
indicate that triple therapy employing ribavirin was no more successful than simply using 
oseltamivir monotherapy (Kim et al., 2011).  These results are further supported by work 
conducted by Ilyushina et al., (2008) where the effectiveness of employing Oseltamivir-
ribavirin combination therapy in mice infected with two different strains of A/H5N1 was 
evaluated. They found that combination therapy including ribavirin demonstrated a greater 
or lesser antiviral effect than monotherapy with Oseltamivir, and that the effectiveness 
depended on the A/H5N1 virus and the concentrations used. 
 
1.8.6 Taribavirin 
 
A carboxamidine analog of ribavirin, taribavirin, has been shown by Sidwell et al., 
(2005) to have significant antiviral effects on influenza A and B infections both in vitro and in 
vivo. In Phase IIb testing as a drug candidate against hepatitis C viral infections, it 
demonstrated equitable activity as ribavirin but with much improved toxicity and 
bioavailability profiles (Sidwell, 2005). Although there are not currently any clinical trials 
involving taribavirin and influenza, the improved toxicity and bioavailability profiles could 
make taribavirin an attractive candidate for further anti-influenza examination.  
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1.8.7 DAS181 (Fludase) 
 
A recombinant fusion protein, DAS181 incorporates the sialidase from Actinomyces 
viscosus and acts by targeting and cleaving sialic residues on host cells (Belser, 2007; 
Malakhov, 2006). It has been shown to cleave both α(2,3)- and α(2,6)-linked sialic acids 
(Triana-Baltzer et al., 2010). In the mouse model, DAS181 was found to be protective 
against a lethal challenge of A/H5N1 (Belser, 2007). As this drug targets the host and not the 
virus, it is likely that it will be effective against all influenza strains and that resistance is 
unlikely to arise.  Moss et al.,  (2012) recently published a phase II clinical study showing 
that DAS181 was effective at lowering both viral load and duration of viral shedding. 
Moreover, despite targeting a host function the drug was reasonably well tolerated. DAS181 
is also being used to treat parainfluenza virus infection and in severe cases has been found 
to improve symptom scores, as well as oxygenation levels and pulmonary function tests. In 
addition, nasopharyngeal samples have demonstrated that DAS181 in capable of reducing 
patient viral load (Chen et al., 2011). 
 
1.8.8 T-705 (Favipiravir) 
 
A pyrazinecarboxamide derivative, T-705, has demonstrated broad spectrum 
antiviral activity against a number of RNA viruses including arenavirus, West Nile virus, 
Yellow Fever and all three types of influenza (Yuan, 2013; Furuta, 2009). T-705 undergoes 
ribosylation and then phosphorylation to a nucleoside and thus acts as an RNA polymerase 
inhibitor (Furuta, 2009). With respect to influenza, T-705 has shown effectiveness against a 
wide array of different influenza strains both in vitro and in vivo. Sidwell et al., (2007) noted 
that while T-705’s efficacy was less than that exerted by oseltamivir or zanamivir, it still 
offered markedly better protection than ribavirin. Furthermore, they found that in mice, 
even a single dose treatment of T-705, could offer protection up to 60hrs post inoculation 
with a lethal challenge.  Attempts to generate resistance to T-705 in the laboratory showed 
a high barrier, and led to the suggestion that at least part of the antiviral activity was based 
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on induction of a higher rate of mutations, perhaps due to base mispairing, adding to error 
catastrophe (Baranovich et al., 2013). 
 
1.8.9 Nitazoxanide 
 
Already a well-accepted anti-parasitic agent, nitrazoxanide (and its active metabolite 
tizoxanide) have recently received attention for its potential ant-influenza properties. A 
member of the thiazolide family, nitrazoxanide is thought to effect viral replication of 
seasonal A/H1N1 (PR8) by targeting the viral haemagglutinin at the post-transcriptional level 
(Rossignol et al., 2009). It is believed that this occurs by blocking a stage preceding 
resistance to endoglycosidase H digestion and therefore inhibiting intracellular trafficking of 
the glycoprotein to the cell membrane however, the exact mechanism remains unclear. In 
vitro experiments have demonstrated that nitrazoxanide possesses potent antiviral activity 
against both human and avian influenza viruses, including Oseltamivir-resistant and 
amantadine-resistant strains. In addition, nitrazoxanide is synergistic in combination with 
the neuraminidase inhibitors Oseltamivir and zanamivir (Belardo et al., 2011). A Phase 2B-3 
clinical trial conducted in the United States looked at treating acute uncomplicated influenza 
with nitrazoxanide. Approximately half of the influenza-infected patients enrolled in the trial 
were infected with influenza A/H1N1 with approximately 30% being infected with influenza 
B and 20% with A/ H3N2. There results indicated that influenza-infected patients treated 
with NT-300 (nitrazoxanide) administered 600mg twice daily for five days experienced 
statistically significant reduction in time from beginning treatment to alleviation of flu 
symptoms when compared to placebo (P=0.008) (Rossignol et al., 2011). 
 
1.8.10 RNA inhibition 
 
In recent years, there have been a growing number of interesting preclinical reports 
regarding the use of siRNAs and antisense strategies for the treating of influenza and other 
respiratory viral infections (Devincenzo, 2012; Zhou, 2007). AVI-7100 is a phosphodiamidate 
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morpholino oligomer which contains three modified linkages and has been designed to 
interfere with the translation of both the M1 and M2 mRNAs has been highlighted as 
holding possible clinical application (Hayden, 2012).  This oligomer targets the translation 
initiation start site which, is shared by both the M1 and M2 mRNAs. This molecule has been 
shown to be effective against oseltamivir-resistant A(H1N1)pdm09 virus infection in the 
ferret model. Specifically, when administered intranasally or intraperitoneally, AVI-7100 was 
found to reduce both BAL and nasal virus loads and reduce symptomology (Iversen, 2011). 
 
1.9 Immunomodulation 
 
Directly acting antiviral described above have been used in the clinic but the 
controversy surrounding their efficacy as measured by reduction of symptoms has led to the 
idea of controlling the immunopathology associated with influenza infection as a 
therapeutic strategy. However, this in itself is also controversial for if an over suppression of 
the immune response was to occur, unchecked viral replication might take place and 
overwhelm the host. Thus, targeting specific components of the innate immune response 
linked has been proposed as a possible novel therapeutic route for severe influenza. 
 
1.9.1 Steroids 
 
The transrepression effect of corticosteroids occurs within a few hours after 
administration, when nuclear transcription factors such as NFkB and AP-1 are sequestered 
in the cytosol by monomeric glucocorticoid-glucocorticoid receptor alpha (GGRa) complexes 
(Annane, 2011; Auphan et al., 1995). This in turn, prevents the downstream transcription of 
genes encoding for the majority, if not all, proinflammatory mediators (Annane, 2011; 
Ehrchen et al., 2007).   In contrast to their transrepressive effects, the transactivation effect 
of corticosteroids requires several days post administration (Annane, 2011). This process 
involves the GGRa complex to enter the nucleus where, via glucocorticoid-responsive 
elements, it up-regulates genes encoding for regulators that are responsible for the 
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termination of inflammation (Annane, 2011). Following this, other anti-inflammatory 
processes, including chemokinesis, phagocytosis and antioxidative processes, become 
activated (Annane, 2011). Thus, one might envision that corticosteroids do not strictly 
inhibit cellular processes; rather, they divert them to alternative functions that, go against 
the demands placed on immune cells at that time. Furthermore, corticosteroids induce the 
migration of anti-inflammatory monocyte subtypes to inflamed tissues and enhance the 
survival of these same cells by triggering an anti-apoptotic effect via the A3 adenosine 
receptor (Barczyk, 2010). 
Glucocorticoids, a subgroup of corticosteroids, have been demonstrated in clinical 
trials, using prolonged low-to-moderate doses, to enhance the anti-glucocorticoid-activated 
GC receptor (Pawliczak, 2005). This receptor acts as a major regulator of inflammation in 
ALI/ARDS, a prominent feature of severe influenza (Meduri, 2009). In support of the clinical 
trial observations, glucocorticoids have been demonstrated to supress cytokine expression 
and inhibit COX-2 expression, an IFN-induced pro-inflammatory gene, in ex-vivo human 
bronchial epithelial cell cultures (Pawliczak, 2005; Almawi; 1996). 
The efficacy of employing systemic corticosteroids for the treatment of ARDS has 
been the subject of considerable debate and study. Thus far, their therapeutic value remains 
unclear with several meta-analysis and reviews offering conflicting evidence and opinions 
(Agarwal, 2007; Tang, 2009; Steinberg, 2006). Endogenous glucocorticoids play an important 
part in supressing local inflammatory responses and low-level systemic inflammation but 
may not be effective in suppressing the “cytokine storm” driven by unregulated 
inflammation, even though cortisol levels have been positively correlated with illness 
severity and mortality (Annane, 2000). With the rise in acceptance of the critical-illness-
related-corticosteroid insufficiency (CIRCI) concept and the results of clinical trials 
demonstrating respiratory immune and hemodynamic benefits of such an approach, 
corticosteroid therapy has re-emerged as a promising adjunct for the treatment of severe 
sepsis (Marik, 2008). 
Animal studies from the 1950s employing mice infected with influenza A virus and 
treated with either cortisone and hydrocortisone during the first 4 days of influenza 
infection lowered the median lethal dose (LD50) of the viral inoculum and increased the viral 
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titer in the lung (Kass, 1954). More recent studies involving A/H5N1 and glucocorticoid 
therapy in mice have also found results along similar lines (Salomon, 2007; Xu, 2009). This is 
further supported by a study conducted by Lee et al., (2009) where patients hospitalized 
with seasonal A/H1N1 pneumonia and treated with glucocorticoids showed higher viral 
titers and prolonged viral shedding when compared to non-glucocorticoid-treated patients. 
This finding was reiterated in recent cases of H7N9 and the higher viral loads may also have 
allowed development of oseltamivir resistance in these individuals (Hu et al., 2013). 
There exists considerable debate regarding the effectiveness and safety of using 
steroids in patients with severe influenza infections due to the lack of controlled clinical 
trials. Most of the treatment guidelines for corticosteroid use in influenza patients has been 
extrapolated from experiences reports relating to the 2002-2003 severe acute respiratory 
syndrome coronavirus (SARS-CoV) outbreak (Cameron et al., 2008).  
Pandemic influenza variant-A/H1N1 was first isolated and described in Mexico in 
April 2009. Less than 3 months latter on the 11th of June, the World Health Organisation 
(WHO) declared the first pandemic of the 21st century with mortality rates as high as 38% 
being reported (Rello, 2009). As of March 2010, more than 214 countries and territories had 
reported laboratory-confirmed cases of A(H1N1)pdm09 resulting in 17,919 deaths (WHO 
update 98, 2011).The pulmonary presentation of A(H1N1)pdm09 in infected patients was 
commonly characterised as a rapidly progressing viral pneumonia with bilateral alveolar 
infiltrates, visible on chest radiograph, and ARDS (Webb, 2009). Interestingly, Bermejo-
Martin et al., (2009) noticed that patients who tended to have a severe presentation 
(ALI/ARDS with severe refractory hypoxemia) were also found to have an abnormal innate 
immune response and an exaggerated trafficking of neutrophils and macrophages. 
Postmortem examination of patients who had succumbed to A(H1N1)pdm09 revealed three 
distinct abnormalities: classic exudative diffuse alveolar damage, severe necrotizing 
bronchiolitis with extensive neutrophilic inflammation of bronchiolar walls and diffuse 
alveolar damage with alveolar heamorrhage often present (Nin et al., 2012).  This damage is 
believed to induce the release of large quantities of pro-inflammatory cytokines, 
superoxides and reactive oxygen & nitrogen species from the lung parenchyma which go on 
to induce further “cytokine-mediated” damage (Vlahos, 2011; Kobasa, 2007). 
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In addition to traditional supportive measures and antiviral therapy, many clinicians 
administered corticosteroids to patients who developed ALI/ARDS secondary to 
A(H1N1)pdm09 infection. Two sizable studies of severe respiratory failure associated with 
A(H1N1)pdm09 reported that between 59 and 69% of patients were given corticosteroids, 
primarily as an adjuvant – a pharmacological or immunological agent that modifies the 
effect of another agent(s) (Kumar, 2009; Dominguez-Cherit, 2009). Their rationale was that 
if the corticosteroids could reduce lung inflammation, clinical outcome could be improved. 
However, investigators later concluded that corticosteroid administration may actually have 
deleterious effects in cases of severe influenza pneumonia.  
Martin-Loeches et al., (2011) reported the analysis of a large cohort prospective 
multicenter study which found that, early use of corticosteroids in critically ill patients 
admitted to the ICU due to influenza A(H1N1)pdm09 virus infection did not result in a 
reduction of mortality. However, they found that treatment with a corticosteroid was 
associated with an increased risk of bacterial or fungal super-infection. The authors 
however, failed to exclude patients with confounding conditions including age, asthma, 
COPD and chronic use of steroids. Furthermore, the non-influenza ARDS control group 
contained a substantial number of patients receiving low-to-moderate doses of 
glucocorticoids (levels associated with reduced mortality in ARDS patients) thus potentially 
skewing the mortality results. 
This work was additionally supported by a cohort study conducted by Brun-Buisson 
et al., (2011) in which it was reported that corticosteroid therapy administered within 2 days 
of ARDS presenting was not associated with an improved outcome. Conversely, it was found 
that commencing treatment with a corticosteroid within the first three days of developing 
ARDS was actually associated with a significantly poorer outcome. Taken together, their 
findings suggest that very early administration of corticosteroid therapy might actually be 
detrimental in cases of severe influenza pneumonia by limiting the host defenses to such a 
degree that persistent viral replication is allowed to take place (Giannella, 2011). 
In a retrospective cohort study conducted by Han et al., (2011), the early use of 
parenteral corticosteroids for the treatment of fever and pneumonia prevention associated 
with influenza A(H1N1)pdm09 infection led to an increased risk of developing subsequent 
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critical illness or death. Alarmingly, this finding was specific to the effects of the 
glucocorticoids rather than to any other treatment or underlying condition and 
demonstrated a dose-response effect. 
Kim et al., (2011) concluded that the addition of adjuvant corticosteroid therapy 
among 245 critically ill patients (136 of which met the criteria for ARDS) admitted to ICU or 
requiring mechanical ventilation with influenza A(H1N1)pdm09 infection was associated 
with an increased 90-day mortality rate (58% versus 27%, P < 0.001) and an increased risk of 
developing secondary bacterial pneumonia or invasive fungal infection. The short-term 
mortality rates of the steroid treatment group were similar to the non-treatment group, 
while the long-term mortality rates were higher for the steroid-treatment group indicating 
the possible effect of the superinfections.  If however, one examines only the subgroup of 
136 patients with ARDS, the association between increased risk of death and steroid use is 
no longer statistically significant, likely due to an issue of power. Furthermore, it is 
important to point out that, although small in number, this study did not distinguish 
between patients who received steroids for underlying conditions from those who received 
steroids for severe A(H1N1)pdm09 infection and refractory shock. 
While there is a large body of compelling evidence against the use of steroids in 
cases of influenza-induced ALI/ARDS due to detrimental outcomes, other investigators have 
presented positive evidence which leaves the story open to further debate. For instance, a 
small (n = 13) 2010 prospective study of A(H1N1)pdm09 infection in patients demonstrated 
that low-to-moderate dose corticosteroid treatment was well tolerated and associated with 
a significant reductions in lung injury, multiple organ dysfunction scores, and hospital 
mortality (Quispe-Laime, 2010).  
A Finnish prospective observational study examined ICU admissions between 11 
October and 31 December 2009 across the country during the pandemic. In total, 132 ICU 
patients tested PCR positive for A(H1N1)pdm09, with 58 patients progressing to ARDS. 
Oseltamivir was given to 96% of all patients while corticosteroids were given to 55% of all 
patients and 79% of ARDS patients. Patients who received steroids were significantly more 
severely ill at presentation than those not given corticosteroids. Both crude hospital 
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mortality and SAPS II-adjusted mortality indicated that there was no significant difference 
between patients treated with corticosteroids and those who did not receive this treatment.     
A study conducted by Kil et al., (2011) examined the effects of corticosteroid 
treatment in two paediatric populations in South Korea (n = 32, age range = 4-18, median 
age = 6). Patients presented on admission, or shortly thereafter, with pneumonia and 
exhibited respiratory distress with hypoxemia. The therapy regime consisted of oseltamivir 
in conjunction with a rapid, high-dose of methylprednisolone, 10 mg/kg/day and tapered off 
within a week. The short duration of the course avoided any complications that normally 
arise with long-term corticosteroid use and was effective at halting clinical and radiographic 
exacerbation as well as preventing progression to ARDS. While the study is based on a small 
patient population, it does raise some interesting points in terms of corticosteroid therapy 
in a paediatric population.  
In a prospective, observational, Spanish multicentre study performed in 148 ICU 
(covering approximately a third of ICUs in Spain) and involving 372 patients with viral 
pneumonia, Diaz et al., (2012) found that corticosteroid therapy, when adjusted for case 
severity and potential confounding factors, was not significantly associated with mortality. 
Furthermore, it should be noted that there may be other influenza associated 
complications, such as influenza-associated encephalopathy, where the benefit of 
corticosteroids may outweigh the risk (Ito, 2011).  
Throughout the 2009 pandemic, the World Health Organization did not recommend 
the use of systemic high-dose corticosteroids for influenza-associated pneumonia. They 
concluded that prolonged use of systemic high-dose corticosteroids could result in serious 
adverse events in influenza virus-infected patients, including opportunistic infection and 
prolonged viral replication. However, physiological replacement doses could be indicated in 
adrenocortical deficiency states and septic shock when hypotension is poorly responsive to 
fluid and vasopressor therapy (Dellinger et al., 2013). Despite the WHO guidelines, there 
was great deal of variability in terms of national and regional protocols for using 
corticosteroids in patients with severe A(H1N1)pdm09 infections. 
It is possible that clinicians were more inclined to give steroids to patients they 
deemed to be “sicker,” thus biasing the results against the possibility that a steroid therapy 
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would be beneficial. Furthermore, the timing and doses of steroids were not controlled in 
the majority of studies; despite some researchers attempting to address this issue by 
adopting more rigorous inclusion criteria for patients or analyzing mortalities in treatment 
groups based on the timing of steroid administration. It is important to note that given the 
acute nature of the A(H1N1)pdm09 influenza pandemic, it was simply not feasible to 
conduct a prospectively designed, randomized clinical trial to address all these 
shortcomings. There are numerous examples (dopamine, epinephrine, albumin and 
synthetic colloids) of treatment regimens that were found to be harmful in cohort studies 
but not subsequently in randomized trials.  
 
1.9.2 Cyclooxygenase Inhibitors: 
 
In the context of viral infections, the production of exogenous pyrogens (PAMP) 
stimulates leukocytes resulting in NFkB activation and the up-regulation in the synthesis and 
release of a variety of endogenous pyrogens (IL-1β, IL-6 and TNF-α). These endogenous 
pyrogens stimulate the central production of the inducible enzyme cycolooxygenase (COX) 
and subsequently the production of prostaglandins. These prostaglandins are then able to 
cross over leaky areas in the blood brain barrier via the circumventricular vascular organs 
(the oranum vasculosum of the lamina terminalis) and activate the thermoregulatory 
neurons of the anterior hypothalamic area to elevate body temperature (Watkins et al., 
1995). The COX enzyme has been found to exists in two isoforms – COX-1 and COX-2 with 
both of these isoforms being involved in numerous physiological processes. COX-1 is 
constitutively expressed and has been implicated in maintaining normal renal function, 
regulating the gastrointestinal tract’s mucosal protection as well as numerous additional 
functions (Vane & Blotting, 1998; Rao & Knaus, 2008).  COX-2 on the other hand, is believed 
to play a role in mediating pain, inflammation and fever and the expression of which, been 
shown to be induced by cytokines and numerous inflammatory mediators (Vane, 2000; 
Vane & Botting, 1998). 
Carey and colleagues (2005), sought to elucidate the impact of inhibiting individual 
isoforms of the COX enzyme. C57BL/6J x 129/O1a mice that had either their COX-1 or COX-2 
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genes “knocked out” were infected with A/Hong Kong/8/68 (H3N2) and their response to 
viral infection was compared to wild type controls. COX-1 (-/-) mice showed enhanced 
inflammation and up regulation in the production of pro-inflammatory cytokines while the 
levels of PGE2 in the airways was reduced. In the COX-2 (-/-) there was observed a marked 
blunting of IFN-y expression which was linked to milder clinical signs but also markedly 
elevated viral lung titers and attenuation in the recruitment of inflammatory cells. 
Interestingly, in a follow-up study by the same group, mice with a C57BL/6J x 129/O1a (COX 
intact) genetic background were given equivalent doses of a type 1 and type 2 COX inhibitor 
for two weeks prior to infection with A/Hong Kong/8/68 (H3N2). Lungs were harvested on 
day 1 and 4 post-infection and the viral titers were examined. While there was no statistical 
significant difference between the groups – although there is a trend where the COX-2 
inhibitor led to higher viral titers in the lung (Carey et al., 2010). 
Antipyretic agents, such as NSAIDs, work by lowering the elevated thermal set-point 
by inhibiting the COX enzyme and by which, inhibit the transformation of arachidonic acid to 
prostaglandins. The introduction of COX-2-selective agents lead to improved specificity and 
decreased side-effects for users (most notably improved gastrointestinal safety) and 
ultimately contributed to a general increase in the use of NSAIDs. Chronic use of NSAIDs has 
been shown to increase with age and it has been estimated that 10-40% of adults over the 
age of 65 use a prescribed or over-the-counter NSAID daily (Hawkey et al., 2000; Lanas & 
Ferrandez, 2007). 
The use of antipyrectics during a fever attributed to an influenza infection has been a 
widely debated topic and to date, no clear consensus nor guidance dealing with this issue 
exists. Shimazu (2009) suggests that the virulence of the 1918 pandemic was enhanced by 
the use of aspirin and during the early stages of the last pandemic (H1N1) and subsequently, 
Hama (2009) had suggested that an urgent and critical review be undertaken to assess the 
use of NSAIDs in Mexico during the start of the most resent pandemic. With conflicting 
advice originating from numerous organisations and governmental bodies (including the 
WHO and the HPA), the need for a comprehensive review and evaluation of current data is 
imperative.  
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1.9.3 Macrolides 
 
A class of bacteriostatic protein synthesis inhibitors, which includes clarithromycin, 
azithromycin and erythromycin, that have been shown to have a wide range of anti-
inflammatory activity. They have been demonstrated to inhibit the production of a large 
number of cytokines from monocytes and lung epithelia including IL-1, IL-8, TNF-α, eotaxin 
and RANTES (Culic, 2001). Possibly contributing further to their anti-inflammatory action, 
these drugs also are inhibitors of oxidative burst, NO production, degranulation, leucocyte 
chemotaxis and expression of antigen receptors (Culic, 2001; Schultz et al., 2000). 
Azithromycin and clarithromycin are notable for accumulation in the cells fluids of the lung 
of patients – suggesting that they will have strong action in these areas (Hoffman et al., 
2003). 
It has been suggested that macrolides could prove beneficial in cases of influenza 
infection by interfering with the viral replication cycle mainly by inhibiting intracellular 
haemagglutinin HA0 proteolysis (Min & Jang, 2012). Sato et al., (1998) demonstrated that 
when mice were challenged with a lethal dose of A/H3N2 (A/Kumamoto/Y5/67), 
erythromycin strongly inhibited inflammatory cellular responses and resulted in a dose-
dependent decrease in the level of nitric oxide (NO) in the serum and a reduction of NO-
synthase (NOS) in the lungs of the mice. As a result, the administration of erythromycin 
significantly improved the survival rate of influenza-infected mice.  In addition, 
clarithromycin has been shown to inhibit the activation of NFkB, the migration of 
neutrophils, and the production of pro-inflammatory cytokines by interfering with 
extracellular signal-regulated kinases (Min & Jang, 2012; Aoki & Kao, 1999; Labro, 1998). 
 
1.9.4 Sphingosine-1-phosphate receptor agonists 
 
Sphingosine-1-phosphate (S1P) is a blood borne signalling sphingolipid with 
numerous cardiovascular and circulatory functions (Rosen & Goetl, 2005).  In addition to 
these effects, S1P has been linked to an increase in mast-cell-derived pro-inflammatory 
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mediators (Rosen & Goetl, 2005). Thus, suppression of S1P could impede this inflammatory 
activation and prove beneficial in cases of severe influenza infection. Marsolais et al., (2008) 
published a proof-of-concept paper indicating that modulation of lung S1P receptors during 
an active influenza infection alters dendritic cell (DC) activation, resulting in blunted T-cell 
response resulting in a decrease in characteristic immunopathological features of such an 
infection. This same group have also demonstrated that the S1P4 receptor is an activator of 
the ERK, MAPK, and PLC cytokine/chemokine signaling pathways and may help explain the 
anti-inflammatory effect of S1P receptor agonists (discussed further in Section 1.9.7) 
(Toman & Spiegel, 2002). 
Walsh et al., (2011) examined the effects of blocking S1P with a sphingosine analog 
in mice infected with the influenza virus (A/California.04/2009, A/H1N1). They found that 
blocking S1P pprovided significant protection from mortality (82%) over that of Oseltamivir 
alone (50%). Intriguingly, a combination of the sphingosine analogue along with Oseltamivir 
provided maximum protection against a lethal challenge of influenza virus (96%). 
Importantly, the sphingosine analogue inhibited cellular and cytokine/chemokine responses 
thus limiting immunopathology while at the same time maintaining host control over virus 
replication. Complementing these results is the work by Teijaro et al., (2014) where S1P 
receptor agonists were found to be effective at blunting clinical signs and histopathology in 
ferrets infected with A/H1N1 (A/California.04/2009). Unfortunately, due to the 
unavailability of reagents, an examination of cytokines/chemokine levels was not possible. 
However, of great importance, was the observation that (as in the mouse model), inhibition 
of the inflammatory process did not result in increased viral replication. 
 
1.9.5 HMG-CoA reductase inhibitors 
 
HMG-CoA reductase inhibitors (commonly known as statins) are a widely used class 
of cholesterol lowering drugs. They exert their anti-cholesterol effect by inhibiting the 
function of liver HMG-CoA reductase, an enzyme crucial to the synthesis of cholesterol, and 
by up-regulating low density lipoprotein (LDL) receptors (Ma et al., 1986). These 
subsequently bind circulating cholesterol facilitating cellular reabsorption (Ma et al., 1986). 
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In addition to this class of drugs anti-cholesterol activity, statins have also been 
demonstrated to reduce inflammation (Lahera et al., 2007). Simvastatin, a member of the 
statin drug family, has been shown to dramatically reduce the induction of proinflammatory 
cytokines by C-reactive protein in a human umbilical vein endothelial cell inflammatory 
model and in the mouse model, was found to induced pronounced endothelial barrier 
protection in times of acute lung injury (Jacobson et al., 2005). 
Due to the anti-inflammatory and immunomodulatory effects which could be 
beneficial in circumstances of acute lung injury, Fedson (2006) has suggested that statins 
might prove to be beneficial in the treatment influenza infections. This view is echoed by 
Terblanche et al. (2006) who also suggests that statins might be useful against infectious 
diseases that are characterized by hyperinflammatory responses, such as influenza. It has 
been postulated that the anti-inflammatory response elicited by statins occurs via the 
blocking of influenza -mediated activation of RhoAGTPase protein although the exact 
mechanism of action is yet to be elucidated (Haidari et al., 2007). 
Supporting the potential benefit of statins during an active influenza infection are 
the results from several retrospective cohort and case-control studies (Kwong et al., 2009; 
Frost et al., 2007). One such study conducted by Vandermeer et al., (2012) found that when 
adjusted for age, race, cardiovascular disease, chronic lung disease, renal disease, influenza 
vaccine receipt, and initiation of antivirals within 48 hours of admission, statins were 
associated with a decrease in odds of dying among cases hospitalized with laboratory-
confirmed cases of influenza. While these results appear quite promising, other studies have 
reported that statins did not correlate with positive respiratory infection outcomes and as 
such, there is still considerable debate in this area (Fleming et al., 2010; Smeeth et al., 
2009). 
 
1.9.6 Peroxisome proliferator-activated receptor agonists 
 
Another class of immunomodulators are the peroxisome proliferator-activated 
receptor (PPAR) agonists. Composed of two classes (PPAR-alpha agonists and PPAR-gamma 
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agonists) these drugs are indicated for alleviating the symptoms associated with various 
metabolic syndromes (Fievet et al., 2006).  Recently, PPARs have been evaluated for their 
anti-inflammatory abilities in the context of influenza infections. Gemfibrozil, a PPAR-α 
agonist with a long history of clinical use for lipid reduction, has been noted to exert 
pleiotropic effects including the reduction of TNF-α and Interferon-γ in serum (Madej et al., 
1998). In vivo mice studies have demonstrated a significant mortality reduction from H2N2 
challenge virus when animals received gemfibrozil when administered as late as four days 
post-infection (Budd et al., 2007). While no direct antiviral mechanism has been described 
for this class of drugs, the in vivo results indicate that the anti-inflammatory effects of PPAR 
agonists enhance survival in cases of influenza infection. 
Taken together, these results providing a proof of principle indicating that 
immunomodulation might provide a beneficial and complementary arm in the treatment of 
severe influenza infections. The “silver bullet” would be a treatment regime that enabled 
one to suppress deleterious over-induction of the innate immune response but did not 
facilitate an unregulated and un-checked increase in the level of viral replication.  
 
1.9.7 Kinase inhibitors: a brief overview 
 
Protein kinases are a class of enzymes that catalyse the transfer of the gamma 
phosphate (the phosphate furthest from the ribose and purine ring) of a purine nucleotide 
triphosphate (ATP or GTP) to the hydroxyl groups of their protein substrates.  There are a 
reported 518 kinases in the human genome that can be divided into eight groups (Kontzias 
et al., 2012). 
While the idea of targeting host kinases is appealing from many aspects, early work 
was fraught with toxicity, specificity and efficacy complications (Kontzias et al., 2012).  
Compounding the situation was the fact that all protein kinases bind ATP and that the 
majority of enzymes use ATP as a substrate; therefore, achieving a limited and targeted 
effect posed a daunting task as one has to be careful to not effect more than the desired 
target through structural similarity of the inhibitor to ATP. However, significant progress was 
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achieved when the differences between subsets of kinases began to be elucidated allowing 
for a more targeted approach. For example, a significant subset of protein kinases (including 
Src, p38 MAPKs) were found to possess a threonine residue at a “gate-keeper” site creating 
a hydrophobic pocket close to the ATP binding site. The addition of a bulky hydrophobic 
residue on to the end of a kinase inhibitor helps to create specificity for this subset of 
kinases, leaving the majority of other kinases unaffected, reducing undesirable side-effects 
while increasing efficacy (Bain et al., 2007). 
The original development of kinase inhibitors for application in the treatment of 
human disease focused on malignancies. One of the first kinase inhibitors developed for 
clinical application was Imatinib (Kontzias et al., 2012). Imatinib was developed to target the 
Abl tyrosine kinase in chronic myeloid leukemia (CML). The translocation between 
chromosome 9 and 22 (specifically designated t(9;22)(q34;q11) commonly know as 
Philadelphia chromosome) associated with CML results in the generation of an oncogenic 
BCR-Abl fusion protein (Sawyers, 1999).  The application of Imatinib in the clinical setting 
has revolutionised the treatment of CML by limiting the growth of tumour clones and 
decreasing the risk of the onset of the final phase of CML the much dreaded “blast crisis” 
(Gambacorti-Passerini et al., 2011). More recently, the use of kinase inhibitors has expanded 
beyond malignancies to autoimmune diseases with favourable safety profiles being 
reported (Kontzias et al., 2012). 
With the majority of the major classes of receptors responsible for triggering 
immune cell activation signalling via protein phosphorylation, the targeting of host 
regulatory kinases presents an attractive target for drug intervention. Numerous receptors 
of immune cells (including T cell, NK, B cell and Fc receptors) have been demonstrated to be 
phosphorylated by, and to physically associate with, kinases with the first step of their 
respective activations involving the phosphorylation of receptor subunits on tyrosine 
residues (Janeway et al., 2001).  Importantly, cytokine receptors (especially Type I&II) signal 
directly by activating kinases causing the activation of down stream signalling cascades 
(Alberts et al., 2002).    
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1.9.7.1 Kinase-driven signalling cascades and Influenza 
 
The initiation of gene transcription in response to external stimuli occurs as a result 
of an intricate signalling cascade controlled through phosphorylation and de-
phosphorylation of key regulatory subunits by kinases and phosphatases respectively. These 
signalling systems are key in facilitating an appropriate immune response from cells facing 
pathogenic insult. In these circumstances, the initiating stimuli often can include cytokines, 
chemokines, antigen-antibody complexes, reactive oxygen species, and pathogen associated 
molecules patterns (PAMPs) (Jeffrey et al., 2007). 
With respect to infection, the family of mitogen-activated (MAP) kinases mediate a 
wide variety of cellular functions in response to extracellular stimuli (including viral 
infection) by acting as focal points in discrete signalling cascades. In mammalian cells, there 
are four major groups of MAPKs -the ERKs (Extracellular signal-Regulated Kinases, the JNKs 
(c-Jun NH2-terminal Kinases), the ERK5 (Extracellular signal-Regulated Kinase-5) and the 
p38MAPKs (Risco & Cuenda, 2012). These MAPKs are activated by dual phosphorylation at 
the tripeptide motif Thr-Xaa-Tyr, whose sequence is different in each group of MAPKs: ERK 
(Thr-Glu-Tyr); p38 (Thr-Gly-Tyr); and JNK (Thr-Pro-Tyr) (Roux & Blenis, 2004). Each MAPK 
pathway contains a three-tiered kinase cascade comprising a MAP3K (MAP Kinase Kinase 
Kinase), a MAP2K (MAP Kinase Kinase) and the MAPK. This three-tier module mediates 
ultrasensitive switch-like responses to stimuli (Risco & Cuenda, 2012; Roux & Blenis, 2004). 
This makes members of the MAPK family and components of their respective cascades 
attractive targets for novel therapeutic agents that seek to prevent over-induction of the 
host immune response or “cytokine storm” which has been demonstrated to occur with 
certain influenza strains (Fukuyama & Kawaoka, 2011; Osterholm, 2005; Chung et al., 2002).  
Extensive and ground-breaking work has been conducted by Ludwig & Planz, 
wherein the potential of supressing part of the MAPK cascade as a treatment for influenza 
has been evaluated. Specifically, they have examined the potential of targeting the 
Raf/MEK/ERK pathways – a pathway which has been implicated to contribute to cytokine 
production and airway inflammation in response to influenza infection, as a novel 
therapeutic approach (Mizumura et al., 2003). In addition, there is evidence that this 
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pathway is involved in the efficient replication of the virus itself, suggesting that inhibition 
could lead to a dual effect of controlling virus as well as controlling immunopathology. The 
kinase pathway appears to be involved in the process of nuclear release of vRNP complexes 
for the nucleus in the latter stages of viral replication (Ludwig et al., 2009; Pleschka et al., 
2008). Where the pathway is over-stimulated the viral titers recovered from MDCK cell 
culture are increased compared to the baseline pathway-expression groups (Marjuki et al., 
2007; Olschlager et al., 2004; Ludwig et al., 2004). If however, this pathway is blocked by 
employing specific inhibitors, there is a striking impairment of viral growth for both type A 
and B viruses (Olschlager et al., 2004; Ludwig et al., 2004; Pleschka et al., 2001). While the 
exact mechanism is still under investigation, it has been hypothesised the this anti-viral 
effect may be due in part in the ability of the kinase inhibitors to prevent the 
phosphorylation of the viral proteins NEP and NP two of the viral proteins in the viral 
phosphoson (Planz, 2013; Hutchinson et al. 2012). 
Another strand of research from the Ludwig and Planz groups has focused on the 
evaluation and development of nuclear factor-kappa B (NFkB) inhibitors against influenza 
virus infection. A transcription factor that controls the expression of numerous genes 
involved in an array of physiological responses to viral attack  (including acute phase 
inflammatory responses, cell adhesion, oxidative stress response, apoptosis and generation 
of antiviral states), NFkB makes a tempting target for therapeutic intervention (Ludwig & 
Planz, 2008; Pahl, 1999). A member of the Rel family and composed of five homo- and 
heterodimer subunits, the NFkB transcription complex bind (as dimers) to DNA regulatory 
sites referred to as kappaB sites (Gilmore, 2006). The different NFkB transcription complex 
dimer subunits can act either as transcription activators (RelA, RelB or c-Rel) or suppressors  
(p50 and p52) (Gilmore, 2006). Although ubiquitously expressed, NFkB complex subunits 
target specific genes based on the cellular environment and the presence of signalling 
stimuli where they are located. In their inactive form, NFkB dimers are found in the cytosol 
bound to the inhibitor-of-kappa-B (IkB). After a stimulation signal is received via the cascade 
pathway, IkB is phosphorylated by the IkB kinase (IKKD/E), ubiquinated and degraded by the 
proteasome resulting in the release of the NFkB dimers (Scheidereit, 2006; Hoffmann et al., 
2006; Bonizzi & Karin, 2004; Karin & Ben-Neriah, 2000). The unbound, activated NFkB is 
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then free to translocate to the nucleus to activate and suppress the transcription of specific 
response genes (Bonizzi & Karin, 2004; Karin & Ben-Neriah, 2000). 
Studies conducted in MDCKs, Vero and A549 cell lines have demonstrated that when 
NFkB signalling is blocked, the production of progeny viruses is impaired (Wurzer et al., 
2004; Nimmerjahn et al., 2004). To explain these results, it has been postulated that NFkB 
must be associated with viral-supportive functions. Namely, the generation of pro-apoptotic 
factors which help to facilitate the escape of vRNPs from the nucleus, suppression of IFN-
induced gene (ISG) expression via cytokine signalling-3 (SOCS-3) and through the regulation 
of vRNA synthesis have all been proposed (Ruckle et al., 2012; Kumar et al., 2008; Pauli et 
al., 2008; Mazur et al., 2007; Wei et al., 2006).  
Numerous groups have thus conducted screens to see which, if any, compounds 
known to act as kinase inhibitors found in pharmaceutical collections have anti-influenza 
activity. Martinez-Gil et al., (2013) report finding that compound ON108110 (a kinase 
inhibitor) is capable to inhibiting viral replication of not just the influenza A virus but also 
vesicula stomatitis virus (VSV) and Newcastle disease virus (NDV). The presence of 
ON108110 in cell cultures reduced expression of a transfected NP-firefly luciferace reporter 
by the viral polymerase complex in a dose dependent manner. While the levels of the 
Renilla transfection control were also affected, the fact that the levels of virus-specific 
transcript were reduced to a much higher degree suggests that ON108110 preferentially 
inhibits vRNA replication as opposed to a simple nonspecific or cytotoxic effect.  As kinase 
have been shown to be involved in both the induction of the innate immune response and 
the viral replication process, they represent a tempting target for pharmacological 
intervention. 
 
1.9.7.2 The kinase inhibitor RV1088   
 
RV1088 is novel narrow spectrum kinase inhibitor that has been developed by the 
Imperial start-up company RespiVert for the treatment of respiratory disorders linked with a 
strong inflammatory response (i.e. asthma and COPD). It has been reported that this 
compound has been able to inhibit human rhinovirus (HRV) -induced IL-8 release and viral 
Chapter 1 │ Introduction 
 
 
- 84 - 
replication in primary airway epithelial cells (Ito et al., 2011; Vuppusetty et al., 2011) and 
resulted in increased interferon beta and lambda in the presence of virus (Contoli et al., 
2011). Personal communication from RespiVert colleagues revealed that RV1088 targets 3 
host kinases involved in signaling networks linked to the innate immune response (p38 
alpha/p38gamma, c-SRC and Syk). Further information about these kinase targets is 
discussed below. Unfortunately, due to proprietary restraints, we are unable to provide any 
further specific information of the detailed structure of this compound or its precise mode 
of action. 
 
1.9.7.2.1 p38  
 
Discovered in 1994 and originally referred to as cytokine-suppressive anti-
inflammatory drug binding protein (CSBP), p38 is a member of the MAPK superfamily (Lee et 
al., 1994). p38 plays  important roles in the signal transduction of a wide array of biological 
processes including cell maintenance and survival, apoptosis and the regulation of 
inflammatory cytokine biosynthesis (Lee et al., 1994). Thus far, four splice variants of p38 (D, 
E, J, G) have been described (Chung, 2011). Of these, p38D has been characterised to the 
furthest extent and is considered to be the most relevant in the inflammatory response 
(Kumar et al., 2003). 
Several studies have linked p38-related cytokine/chemokine expression to the down 
stream activation and nuclear translocation of IRF3 and NFkB and subsequent IFN-b 
expression (Hui et al., 2009; Saccani et al., 2002; Uddin et al., 1999). The activation of NFkB 
via an anti-viral signalling cascade leads to the up-regulation of a variety of antiviral genes 
(Hiscott et al., 2001). However, a number of studies indicate that the influenza virus have 
acquired the ability to manipulate and use this pathway to their own advantage; exploiting 
NFkB for efficient replication (Nimmerjahn et al., 2004; Wurzer et al., 2004). In further 
support of this observation, Mazur et al., (2007), demonstrated that blocking the activation 
of NFkB with acetylsalicylic acid (ASA), a known suppressor at sub-toxic doses, resulted in 
blocking influenza virus replication by several orders of magnitude. It is thought that by 
blocking NFkB, ASA exerts antiviral effects by decreasing the expression of FasL and TRAIL, 
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reducing caspase activity and causing the retention of vRNPs in the nucleus as well as 
suppressing the inflammatory response (Mazur et al., 2007).  
Furthermore, p38 MAPK has been shown to phosphorylate a variety of transcription, 
including some responsible for transcription of genes encoding for inflammatory cytokines 
(Kumar et al., 2003). In this regard, the p38 kinase has been demonstrated to be essential in 
the production of virally-induced IL-6, IL-8 and several other cytokines/chemokines (Griego 
et al., 2000; Hashimoto et al., 1999; Matsumoto et al., 1998). Lee et al., (2007) have 
reported the co-existence of hyper-activated p38 kinases in the presence of increased 
cytokine expression in the plasma of patients infected with severe influenza; suggesting a 
direct link between the level of p38 activity and plasma cytokine levels.  
Lee et al., (2005) compared the activation of MAPK signalling pathways and the 
transcription factor NFkB in A/H5N1- and A/H1N1-infected PBMCs. Their results 
demonstrated that both of these viruses activate NFkB to comparable levels but that 1hr p.i. 
A/H5N1 hyperinduces p38 MAPK phosphorylation to a far greater extent then levels 
observed for A/H1N1. Börgeling et al., (2014) then examined the role of p38 signalling in the 
context of an A/H5N1 virus infection. They report that in the context of in vitro infection 
studies employing highly pathogenic avian influenza viruses (HPAIV), p38 controls 
interferon-stimulated gene expression via co-regulation of STAT1 which is achieved through 
phosphorylation at serine 727. Interestingly, through a global mRNA profile, they 
determined that the vast majority of HPAIV-induced genes were either partial (23%) or fully 
(71%) dependent on the p38 pathway.  
Marchant et al., (2010) have demonstrated that prior to host cell entry, PRR 
recognition of the virus (i.e. recognition of sugars residues on the surface of the virion by 
TLRs and other such non-receptor host cell proteins) is required to stimulate MyD88 which, 
in turn, activates p38 and subsequently host cellular internalization machinery. The levels of 
activation of p38 during the first 10min of infection were found to be approximately 10-fold 
higher than for other respiratory viruses (RSV and HPIV3, for example) and may represent 
an effective adaptation mechanism to augment viral uptake by the host cell. Blocking p38 
however, did not completely ablate influenza virus entry suggesting that there are also 
ancillary pathways which facilitate virus entry.   
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In addition to activating host cell virus internalisation machinery, p38 has been 
linked to other important stages of the influenza virus life-cycle. The export of vRNPs from 
nucleus to cytoplasm is a key event in influenza virus life-cycle. The NP protein, one of the 
component of the vRNP complex, is a phosphoprotein, the phosphorylation status of which, 
changes during the virus replication cycle and has been reported to affect export of vRNPs 
from the nucleus. It has been demonstrated that specific intracellular pathways are 
responsible for phosphorylation of NP (Ludwig, S et al, 2006; Palamara, AT et al, 2005). In 
particular, Nencioni et al., (2009) have demonstrated the involvement of p38 MAPK in this 
event. Furthermore, it has been demonstrated that p38 can mediate both apoptosis and cell 
survival through a variety of mechanisms. 
One such mechanism involves the p38-mediated regulation of the apoptosis-
controller B-cell lymphoma 2 (Bcl-2) protein. Bcl-2 is widely recognized as a cellular 
protective mechanism against virally-induced apoptosis and the interaction of p38 with Bcl-
2 has been shown to disrupt the protective role of this protein and is accomplished via 
phosphorylation of Thr-56 and Ser-87 residues of Bcl-2 (De Chiara et al., 2006; Reed, 1994; 
Hinshaw et al., 1994). Some viruses, such as Herpes simples virus type-1, have developed 
ways of preventing the phosphorylation of Bcl-2 and thus suppressing virally-induced 
apoptosis thus freeing p38 to augment viral replication in the nucleus (Zachos et al., 2001). 
The quantity of active p38 in the nucleus has been shown to be inversely related to 
the quantity of Bcl-2 substrate present in the cytosol. This is supported by the observation 
that in Bcl-2neg cells, the p38-mediated apoptosis is markedly diminished and that this kinase 
is found almost exclusively in the nucleus where it’s phosphorylation of key targets aids in 
the efficient export of vRNPs for the nucleus. The expression of Bcl-2 varies between cell 
types and of great importance is the finding that Bcl-2 is absent in normal, well-
differentiated epithelial cells of the respiratory tract thus freeing-up p38 to act in the 
nucleus and augment influenza viral replication (Tesfaigzi et al., 1998). 
Implicated in numerous signalling cascades linked to the over induction of the innate 
immune response as well as demonstrating pro-viral actions, p38 MAPK represents a unique 
and tempting target for therapeutic intervention.  
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1.9.7.2.2 c-Src  
 
The Src family of protein tyrosine kinases (SFK) consists of eight members: Lyn, Hck, 
Lck, Blk, Fyn, Yes, Fgr and c-Src. These members have all been demonstrated to exert their 
effect via similar modes of action and are implicated in controlling and regulating a diverse 
array of signalling networks linked to regulating cellular metabolism, proliferation, viability, 
differentiation and migration of numerous cell lineages (Frame, 2006; Levin, 2004; Brown & 
Cooper, 1996). The substrate targeting and activity of the SFK members is highly regulated 
through intra-molecular interactions of the SH3 and SH2 domains of the kinase and by its 
association with ancillary molecules including substrates, activators and inhibitors (Sicheri et 
al., 1997; Xu et al., 1997). Based on biochemical and structural details, the active and 
inactive configurations of the SFKs have been elucidated as have their common modes of 
regulation including differential phosphorylation, domain interaction and competitive 
domain displacement (Xu et al., 1997). SFKs are controlled by receptor protein-tyrosine 
kinases, antigen- and Fc-coupled receptors, cytokine receptors, steroid hormone receptors 
and integrin receptors (Thomas & Brugge, 1997). 
Proto-oncogene tyrosine-protein kinase Src (c-Src) is a non-receptor protein tyrosine 
kinase which acts by phosphorylating specific tyrosine residues on other proteins. It has 
been demonstrated that when TLR3 binds viral dsRNA it, acting via TICAM-1, it activates the 
transcription factors NFkB, IRF3, and AP-1 leading to cytokine, chemokine and type I IFN 
(Lowell, 2011; Oshiumi et al., 2003). Intriguingly, TLR3 has also been shown to associate with 
c-Src on endosomes in response to dsRNA and inhibit the activation of IRF-3; although the 
exact details of these pathways and their impact on innate immune signalling has yet to be 
fully elucidated (Lowell, 2011; Kim et al., 2009; Sarker et al., 2004). Thus if over expressed, c-
Src could lead to inflammation with out concurrent IFN production. As such, inhibiting c-Src 
could help prevent this and restore a beneficial balance where IFN is induced but cytokine 
over induction is prevented. Chu & Yang (2007) reported that when multiple dengue 
infected cell cultures were treated with dasatinib (a known and specific c-Src inhibitor), this 
resulted in a dose-dependent inhibition of viral titers. This suggests that Src and its down 
stream effects may be beneficial for viral replication and that blocking those pathways may 
prove beneficial in supressing viral replication. 
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1.9.7.2.3 Syk 
 
In contrast to the SFK, the Syk family (composed of Syk and ZAP-70) are 
characterised by the presence of two-tandemly arranged Src homology 2 (SH2) domains 
(Yanagi et al., 1995; Taniguchi et al., 1991). Activation of Syk occurs through the interaction 
of the two SH2s with immunoreceptor tyrosine-based activation motifs (ITAMs) located on 
immune response receptors (Turner et al., 2000; Sada et al., 2001). Syk has been implicated 
in numerous signal transduction pathways linked to the innate immune response (Turner et 
al., 2000). Studies conducted by Stenton et al., (2000) employed the aerosol delivery of Syk 
antisense oligodeoxynucleotides to rat lungs causing the suppression of Syk activation. This 
was in turn linked to the downstream suppression of macrophage activation and decreased 
pulmonary inflammation. This work was further supported by studies which have 
demonstrated that Syk antisense oligodeoxynucleotides have also been effective at 
supressing Syk expression and chemokine production in human nasal polyps (Yamada et al., 
2001). While much work is still needed to further elucidate and map the signalling pathways 
employed by Syk and it’s downstream effects, there is compelling evidence that this kinase 
is involved in the activation of the innate immune response in respiratory epithelium and 
that inhibiting Syk’s actions results in a blunting of this immune response. 
 
1.9.7.2.4 Rational for kinase combination therapy  
 
The concept of using kinase inhibitors, either alone or in combination, has already 
been examined, and found to be effective, as part of various cancer treatment regimes with 
promising preliminary results primarily with respect to controlling the immunopathologies 
associated with certain forms of cancer (Karashima et al., 2014; Donahue et al., 2013; Porta, 
2011; Seliger et al., 2010). A similar approach in using a specific combination of narrow 
spectrum kinase inhibitors might prove far superior than employing just one, to achieve a 
good balance between inhibition of viral replication and cytokine dampening. Furthermore, 
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the benefit of employing such kinases may prove even more beneficial when used in 
combination with currently licenced antivirals.  
 
 
1.10 Aims of Thesis 
 
1. Determine if the kinase inhibitor RV1088 supress cytokine/chemokine expression 
induced by the influenza virus and what, if any, affect RV1088 has on viral replication. 
  
2. Determine if the results observed in cell culture systems holds true in the animal model. 
 
3. Optimize delivery of the influenza virus using a nebuliser system to simulate natural 
occurring infections and test the usability of such a system to deliver drugs to directly to 
the respiratory tract.     
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Chapter 2. Evaluation of RV1088s properties  in vitro 
 
 
2.1 Introduction    
The drug compound, RV1088, was provided by RespiVert with preliminary findings 
that indicated that this compound was able to control the expression of cytokines following 
viral infection in vitro in immortalized cell lines with RSV (Ito, 2010). In addition the 
published patent information for this group of compounds (patent WO/2010/067130, June 
17, 2010) showed RV1088 to be a p38 alpha and p38 gamma inhibitor. 
 
2.2 Confirmation of the inhibitory effect of RV1088 on p38 MAPK activity  
 
While the aim of this project was not to determine and assess the kinase targets of 
RV1088 (as this work has previously been conducted by collaborators at RespiVert), before 
proceeding with more complex models, we wished to confirm an effect in our hands of 
RV1088 on the reported kinase targets.  Of the three kinases reported to be targeted by 
RV1088 (c-SRC, Syk and p38α/γ) (Ito, 2010), p38 was chosen for analysis due to the large 
body of evidence supporting its activation following an influenza infection (Börgeling et al., 
2013; Ludwig, 2007; Lee et al., 2005) and because of the availability of established 
commercial, non-radioactive, reagents. 
A549 cells were infected with influenza A virus A/England/195/2009 in the presence 
or absence of RV1088. At 4 hours or 24 hours after infection, cells were lysed and subjected 
to immunoprecipitation with a p38 specific antibody (Figure 12). The precipitates were 
tested for their ability to phosphorylate the ATF-2 substrate of p38 MAPK at Thr 71 using a 
Western Blot. There was no difference in total amounts of p38 immunoprecipitated in 
presence or absence of drug. In the absence of drug the phosph-ATF-2 band showed an 
increase in intensity with time after infection indicating activation of the kinase upon 
infection. Band intensity was decreased at both time points by 1088 and by another drug X 
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not discussed further here. The control compound SB203580, a known p38 MAPK inhibitor, 
decreased the phosph-ATF-2 band intensity at 4 hours post infection but at the effect was 
not sustained and high levels of phospho-ATF-2 were detected after incubation with p38 
from cell lysates obtained by 24 hours pi in the presence of this drug. Control blots showed 
no difference in protein loading (vinculin) or total p38 MAPK content in lysates under any 
condition. 
 
 
Figure 12: Western blot demonstrating RV1088 knock-down of p38 MAPK activity induced by 
A/England/195/2009. A549 cells were infected with A/England/195/2009 (moi =3) in the presence 
or absence of drug. Drug compounds included: RV1088 (1.73nM), DMSO (0.5%) and SB203580 
(2.5μM). The compound marked “X” is a new drug compound which is proprietary knowledge and 
can not be discussed. 24hrs p.i., cells were lysed and p38 MAPK was precipitated out. An in vitro 
kinase assay was performed using ATF-2 as a substrate. a) Vinculin and, b) Total p38 MAPK acted as 
loading controls while c) Phosphorylated ATF-2 was then detected by western blotting using 
Phospho-ATF-2 (Thr71) antibody. Section d) is a diagram demonstrating the major steps involved in 
determining the phosphorylation activity of p38 MAPK. 
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The drug also inhibited p38 MAPK activity induced following infection with influenza 
B virus strain B/Florida/04/2006 (data not shown). Once again, the effects of drugs RV1088 
and drug X were sustained until 24 hours post infection whereas the effect of SB control 
compound had decreased by that time. 
 
2.3 Assessment of RV1088 for cytotoxic properties 
In order to demonstrate that the anti-influenza effects observed in presence of 
RV1088 were not simply due to general cytotoxicity of the compound, a series of tests to 
elucidate the cytotoxicity profile of RV1088 were undertaken. Three different parameters 
were used in this assessment and include: examination of membrane integrity (Trypan Blue, 
Figure 13, a), analysis of apoptosis-inducing cysteine proteases (Figure 13, b) and 
quantification of cellular reductase activity (MTT, Figure 13, c). Staurosporine, a prototypical 
ATP-competitive kinase inhibitor that binds to many kinases with high affinity and is a 
known inducer of apoptosis, acted as a positive control. These experiments were run in two 
immortalized cell lines commonly employed in influenza research, A549s (adenocarcinomic 
human alveolar basal epithelial cells) and MDCKs (Madin Darby canine kidney epithelial 
cells). 
The results of all three experiments, each employing a different method for 
evaluating the viability of cells, indicate that RV1088 when used alone or in combination 
with a licensed antiviral (Relenza) did not exhibit any detectable toxicity or adversely affect 
cellular viability.   
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Figure 13: Results of toxicity assays.  
a) Trypan blue exclusion assay. Cells, A549 or MDCK cells after treatment with   
RV1088 (1.73nM) ± Relenza (3.009nM).  
b) Caspase 3/7 activity assay. Cells A549s or MDCKs were assessed for the activity  
level of the apoptosis-inducing cysteine proteases after treatment with RV1088 
(1.73nM) ± Relenza (3.009nM). Staurosporine (1μM) acted as the positive control 
c) MTT assay. The activity of cellular reductase in either A549 or MDCK cells after  
treatment with RV1088 (1.73nM) ± Relenza (3.009nM). Staurosporine (1μM) 
acted as the positive control; suppressing cellular reductase activity. 
All results are expressed as the mean ± standard deviation of triplicate samples 
from three  independent experiments. 
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2.4 Studying the effects of RV1088 on cytokine induction 
 
We used IFN as a model cytokine whose induction pathway is well understood. We 
first assessed the effect of treatment with RV1088 on the IFN response in immortalised cell 
cultures to determine at what level in the IFN signalling cascade RV1088 exerted its effects.  
We employed transfection system in which the particular biological pathway under study 
could be reconstituted and measured under controlled conditions. 
The plasmid vectors employed in such systems are introduced into the target cell, 
where they commandeer the cell’s own transcription and protein synthesis apparatus to 
translate mRNA and produce a desired protein. This protein is then free to exert its effect 
with in the cell. By manipulating the promotor sequence on the transfected plasmids it is 
possible to study the control of transcription of a particular gene. For example, by placing an 
IFN-β promotor on a plasmid encoding a luciferase gene, the quantifiable luciferase signal 
will accumulate when the pathway for IFN-β production is triggered (Figure 14). 
In addition to using plasmids whose mRNAS are only transcribed under specific 
stress-induced situations, we also employed a variety of plasmids encoding key components 
of signalling pathways (TBK-1, NFkB and MAVS for example).  These “over-expression” 
plasmids contained a pcDNA3 promotor which directs efficient transcription during the 
normal cellular state. By over-expressing a component of the cascade, the pathway is 
triggered. Thus in the presence of a reporter plasmid and drug compound of interest, it is 
possible to determine if the drug in question is acting to prevent IFN induction or signalling 
down-stream from the over-expressed protein.  
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Figure 14: Schematic representation of IFN-β luciferase assay.  A plasmid encoding 
luciferase with an IFN-β promotor, an over-expression plasmid for a member of the IFN 
cascade and a pCAGGs renilla expression control plasmid are all co-transfected into human 
293T cells. A drug compound can then be added to the cell culture. At specified time points 
post-transfection, cells are lysed and firefly luciferase activity and renilla expression are 
measured. Luciferase signal is a measure of activation of the IFN gene while renilla is a 
vector control containing a pCAGGs “constitutive” promotor. 
 
2.5 Suppression of the interferon response by RV1088 
 
A plasmid possessing an IFN-β promotor upstream of the firefly luciferase reporter 
gene and a plasmid directing Renilla luciferase from the powerful pCAGGS promotor, used 
here as transfection control, were co-transfected into 293T (human embryonic kidney) cells. 
Immediately after transfection the cells were infected with influenza A virus 
A/England/195/2009 (moi = 3) to stimulate a robust induction of interferon.  Immediately 
following infection, RV1088 was added to the overlaying media at a range of doses (1.73μM 
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– 0.0173nM). At 24hrs post transfection/infection, cells were lysed and the luciferase signals 
measured (Figure 15).  
 
Figure 15: Determination of an optimal 
RV1088 dose for suppressing IFN-β. A 
plasmid encoding firefly luciferase 
downstream of an IFN-β promotor and a 
pCAGGs renilla expression control 
plasmid were co-transfected into human 
293T cells. At the time of transfection, 
the cell cultures were infected with 
A/England/195/2009 (moi = 3) and 
treated with RV1088, at a range of doses 
(1.73μM to 0.0173nM), which was added 
to the overlying media. 24hrs post-
transfection/infection, cells were lysed 
and firefly luciferase activity (a) and 
renilla activity (b) were measured. 
Results are expressed as the mean ± 
standard deviation of triplicate samples 
from three  independent experiments 
(student t-test, *p<0.5, **p<0.001, 
ns=non-significant). 
 
 
 
 
Infection with influenza A/England/195/2009, a prototypic strain of the 2009 
pandemic, induced a strong interferon response (average 64.3 fold increase in luciferase 
signal over-mock infected cells, p-value 9.04x10-5). This response was suppressed by RV1088 
treatment in a dose-dependent manner. In addition, it was observed that at higher doses 
RV1088 also inhibited the expression of the Renilla luciferase gene indicating a possible 
global effect on host transcription. This effect is addressed further in Section 2.11. 
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Importantly, at a dose of 0.173nM the firefly luciferase signal indicating interferon gene 
induction was still suppressed (by 1.5 fold compared to no drug) while Renilla expression 
indicating basal host gene expression was unaffected. 
To further demonstrate the ability of RV1088 to suppress the interferon response 
and to determine whether this suppression was specific to pathways triggered by infection 
with influenza virus, a series of experiments employing transfected 293T cells exposed to 
other IFN inducing stimuli were performed. The first (Figure 16) employed a virus known to 
be a high-inducer of interferon, the Newcastle Disease Virus (NDV).  The second (Figure 17) 
was void of any viral material and relied instead on treatment with the synthetic double-
stranded RNA analogue Polyinosinic:polycytidylic acid (poly I:C) to induce an interferon 
response.  
 
Figure 16: Suppression of NDV’s IFN-β response by RV1088. A plasmid encoding luciferase 
downstream of an IFN-β promotor and a pCAGGs renilla expression control plasmid were 
co-transfected into human 293T cells. RV1088 (1.73μM or 0.173nM), was added to the 
overlying media at the time of transfection. Concurrently, Newcastle Disease Virus (NDV), a 
potent IFN-β stimulator, was added to the cells in either a 1:80 or a 1:20 dilution.  24hrs 
post-transfection/infection, cells were lysed and firefly luciferase activity (a) and renilla 
expression (b) was measured. Results are expressed as the mean ± standard deviation of 
triplicate samples from three  independent experiments (student t-test, *p<0.5, **p<0.001, 
ns=non-significant).  RLU: relative light units.  
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Figure 17: Suppression of IFN-β transcription by RV1088 is not virus-dependent. A plasmid 
encoding firefly luciferase downstream of an IFN-β promotor was transfected into human 
293T cells. RV1088 (1.73μM and 0.173nM), was added to the overlying media. At the time 
of transfection, the cell cultures were stimulated with the RNA analogue Poly-I:C (1μg/ml). 
24 and 48hrs post-transfection/stimulation, cells were lysed and firefly luciferase activity 
was measured. Results are expressed as the mean ± standard deviation of triplicate samples 
from three  independent experiments (student t-test, *p<0.5, **p<0.001). RLU: relative light 
units. 
 
In both of these experiments, the application of NDV or poly I:C resulted in a strong 
induction of the interferon response, as indicated by 215.1 or 83.4 fold increase in firefly 
luciferase signal over mock infected or mock-treated cells respectively. This response was 
blunted in a dose-dependent manner when in the presence of RV1088. Even at the lowest 
dose of 0.173nm at which Renilla expression was unaffected, RV1088 inhibited the induced 
response by 3.46 or 4.6 fold. Thus we concluded that RV1088 targeted a component of the 
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interferon induction pathway and that this effect was independent of the manner in which 
IFN had been induced. 
As RV1088 was shown to supress the induction of cytokines and chemokines 
secondary to an influenza infection, this compound might prove beneficial in the context of 
a virally-induced cytokine storm. To examine this potential, we induced the IFN-β response 
in 293T cells by infecting with a virus with a genotype known to induce high levels of IFN-β 
and other cytokines. This virus carried the internal gene segments from a highly pathogenic 
avianH5N1 virus (A/Turkey/Turkey/01/2005 combined with the two external antigen genes 
HA and NA from a laboratory adapted strain, A/PR/8/34. Since the PR8 virus has a long 
history of safe use, does not infect humans and shares some antigenic properties with the 
recent pH1N1 viruses to which most people are currently immune, this allowed us to 
conduct these experiments at containment level 2 or 3 rather than under SAPO 4 conditions 
as would be required for working with the full H5N1 HPAI virus itself (Health and Safety 
Executive, 2010). Infection with the Tky/05:PR8 (6:2, HA/NA) virus induced high levels of 
firefly luciferase expression in the transfected and infected cells. Luciferase expression was 
induced by more than 2 logs (Figure 18). RV1088 inhibited the induction of the IFN-pathway 
by the 6:2 virus in a dose-dependent manner. Finally, we examined if RV1088 was exerting 
its inhibitory effect on a target that was specifically human or whether this compound also 
inhibited IFN induction in avian cells. Chicken embryo fibroblasts (DF1 cells) were 
transfected with a luciferase reporter under the control of an avian IFN-β promotor and 
cultures were infected with A/England/195/2009 influenza virus in the presence or absence 
of RV1088 (Figure 19). The influenza virus induced expression of luciferase and this was 
inhibited by co-transfection of a plasmids directing expression of the NS1 protein from 
influenza A/Victoria/3/75 virus. RV1088 also reduced luciferase expression but not to the 
same extent as the NS1 protein. The results of these experiments indicated that the target 
for RV1088 is conserved between avian and human species.  
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Figure 18: Suppression of H5N1-induced IFN-β by RV1088 occurs in a dose-dependent 
manner. A plasmid encoding luciferase with an IFN-β promotor and a pCAGGs renilla 
expression control plasmid were transfected into human 293T cells. RV1088, at a range of 
doses (0.0173nM to 1.73μM), was added to the overlying media. At the time of transfection, 
the cell cultures were infected in high containment with A/Turkey/Turkey/01/2005:PR8 (6:2, 
HA/NA) virus (moi = 3). At 18 and 24hrs post-transfection/infection, cells were lysed and 
firefly luciferase activity was measured. Levels of significance illustrate difference between 
the DMSO control and a particular treatment group (Student T-Test). RLU: relative light 
units.  
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Figure 19: RV1088 is effective at suppressing the IFN-β response in avian cells. A plasmid 
encoding luciferase with an avian IFN-β promotor and a pCAGGs renilla expression control 
plasmid were co-transfected into avian DF1 cells. RV1088 (0.0173nM), was added to the 
overlying media. At the time of transfection, the cell cultures were infected with either 
A/England/195/2009 (moi = 3). Transfected plasmids encoding for NS1 (either belonging to 
A/England/195/2009 or A/Victoria/3/1975) acted as positive controls. At 18 and 24hrs post-
transfection/infection, cells were lysed and firefly luciferase activity and renilla expression 
was measured. Results are expressed as the mean ± standard deviation of triplicate samples 
from two independent experiments (student t-test, *p<0.5, **p<0.001). RLU: relative light 
units.  
 
2.6 RV1088 and the IFN induction pathway  
 
We next sought to determine at which level of the IFN pathway RV1088 exerted its 
effect. Figure 20b, illustrates the various components of this pathway that we were able to 
examine. Over-expression plasmids for various components of the IFN induction pathway 
were individually transfected into 293T cells along with pCAGGs Renilla expression control 
plasmid, and the IFN-β promotor-luciferase reporter plasmid.   
Briefly, the IFN induction pathway is activated by the detection of viral PAMP 
(believed to be viral RNA that possess a 5’ triphosphate naked end) by the pattern 
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recognition receptors (PRRs) retinoic acid inducible gene-I (RIG-I) or Toll-like receptor-3 
(TLR-3) (Rehwinkel et al., 2010; Kawai & Akira, 2008). Following recognition of viral nucleic 
acids, these PRRs initiate signalling pathways that lead to the synthesis of type I IFNs (a 
family comprised of several IFN-α subtypes and single IFN-β, IFNω, IFNε ,or IFNκ, members) 
and inflammatory cytokines such as IL-6, TNF-α, and IL-12 (Kimura et al., 2013). 
Constitutively expressed at low levels, RIG-I expression is enhanced by activation of 
IFN- α/β signalling creating a positive feed-back loop (Co et al., 2011).  In the absence of 
stimulation, RIG-I exists in an inactive conformation, preventing access to the N-terminal 
CARDs and the helicase domain. The recognition and binding of the RNA PAMP by RIG-I’s 
RNA-binding domain (RBD) facilitates subsequent conformational changes and activation of 
RIG-I downstream signalling (Beckham et al., 2013).  Upon binding the PAMP, RIG-I 
undergoes the transition from the inactive conformation to an active conformation and this 
facilitates interactions between the N-terminal caspase activation and recruitment domains 
(CARDs) and mitochondrial antiviral signalling (MAVS) (Sun et al., 2006).  
MAVS activation in turn, results in signalling through the IFN kinases TBK-1/IKKε, 
which are responsible for the phosphorylation of IFN regulatory factors 3/7 (IRF3/7). IRF3 
and 7 are transcription factors that, upon phosphorylation, dimerise and translocate to the 
nucleus where they act on the IFN promoter to stimulate IFN-α/β production (Grandvaux et 
al., 2002; Yoneyama et al., 1998).   
While the exact activation mechanisms of the transcription factor NFkB are still 
under investigation, TLR-3 binding of viral PAMP is believed to activate signalling via TRIF 
and TRAF6 which then are free to activate NFkB directly or via TBK-1 (Abe & Barber, 2014).  
In another branch of the RIG-I-induced signalling cascade, MAVS has been demonstrated to 
interact/activate with TBK-1 which in turn is then free to activate NFkB (Liu et al., 2011). 
Furthermore, the transfer of a phosphate group from IKKβ has also been implicated in NFkB 
activation by displacing regulatory proteins called inhibitors of κB (IκB) (Batra et al., 2011; 
Ghosh & Baltimore, 1990).  In reality, it is likely that all three of these pathways play a role in 
NFkB activation to various degrees. Once activated, NFkB translocates from the cytosol to 
the nucleus where it has been shown to lead to the induction of gene expression including 
that of IFN-β (Wang et al, 2010).   
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Plasmids encoding for the NS1 proteins from two different influenza strains were 
used in these assays as positive controls since they have been previously shown capable of 
inhibiting interferon induction pathway (Shelton et al., 2013). It is currently believed that all 
influenza A virus NS1 proteins can inhibit IFN induction by interfering with recognition of 
viral PAMP by RIG-I. In addition some NS1 proteins, typified by the NS1 protein from 
A/Victoria/3/75 virus, exert an additional inhibitory effect at the level of IFN gene 
transcription through its binding of cleavage and polyadenylation specificity factor (CPSF). 
Overexpression of the mitochondrial antiviral signaling protein (MAVS) induced an 
IFN response, with luciferase signal increasing more than 200 fold by 24 hours post 
transfection (Figure 20a). Cultures transfected with the NS1 protein from A/Victoria/3/75 
demonstrated a significant block of MAVS induced IFN response measured by the luciferase 
reported presumably because the induced mRNA was not properly processed and exported 
for expression.  The IFN response following MAVS overexpression was significantly 
supressed at 24hrs post transfection by RV1088 (0.173nM). This result suggests that RV1088 
exerts its effect on the IFN signalling pathway at a level below that of MAVS.  This result was 
not surprising as RV1088 was able to block the induction of IFN when stimulated by either 
Poly-I:C or NDV indicating that this inhibitory effect is not reliant on viral entry, the presence 
of replicating virus or is limited specifically to the influenza virus. 
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Figure 20: Suppression of the MAVS induced IFN-β response by RV1088. An over-
expression plasmid for MAVS, a plasmid encoding luciferase with an IFN-β promotor and a 
pCAGGs renilla expression control plasmid were co-transfected into human 293T cells. 
Transfected plasmids encoding for NS1 (belonging to A/Victoria/3/1975) acted as positive 
controls. RV1088 (0.173nM), was added to the overlying media at the time of transfection. 
24hrs post-transfection/infection, cells were lysed and firefly luciferase activity (a) was 
measured. Results are expressed as the mean ± standard deviation of triplicate samples 
from three  independent experiments (student t-test, *p<0.5, **p<0.001). RLU: relative light 
units.  
 
Using a TBK-1 over-expression plasmid demonstrated that RV1088 was able to 
supress IFN stimulation induced by TBK-1 (Figure 21). These results indicated that, in part, 
RV1088 might be targeting at or below the level of TBK-1. However, as interferon induction 
by either IRF-3 or IKKβ was unaffected by RV1088 (Figure 22), an examination of drug on 
NFkB induced signalling was the logical next step. 
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Figure 21: RV1088 suppresses the IFN-β response by acting at the level of TBK-1. An over-
expression plasmid for TBK-1, a plasmid encoding luciferase downstream of an IFN-β 
promotor and a pCAGGs renilla expression control plasmid were co-transfected into human 
293T cells. Transfected plasmids encoding for NS1 (either belonging to A/England/195/2009 
or A/ Victoria/3/1975) acted as positive controls. RV1088 (0.173nM), was added to the 
overlying media at the time of transfection. 24hrs post-transfection, cells were lysed and 
firefly luciferase activity (a) and renilla expression (b) was measured. c) is a diagram of the 
interferon induction pathway being investigated with over-expression plasmids (TBK-1 is 
encircled in green). Results are expressed as the mean ± standard deviation of triplicate 
samples from three  independent experiments (student t-test, *p<0.5, **p<0.001, ns=non-
significant). RLU: relative light units.   
To more accurately assign the effects of RV1088 to molecules further down the IFN 
induction cascade, over-expression plasmids for IKKβ, IKKε, IRF-3 and IRF-7 were used. In all 
of these experiments, overexpression of these molecules induced high activation of the 
interferon promoter but RV1088 failed to cause any significant suppression of the IFN 
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response for any of these stimuli (Figure 22). Taken together these results suggest that 
RV1088 exerts effects on a molecule downstream of MAVS and TBK1 and upstream of NFkB 
and IRF-3/7. 
           
 
Figure 22: Inability of RV1088 to suppress the induction of the IFN-b response by over-
expression of IKKβ, IKK𝓔, IRF-3 or IRF-7. An over-expression plasmid (either: IKKβ, IKK𝓔, IRF-3 or 
IRF-7), a plasmid encoding luciferase with an IFN-β promotor and a pCAGGs renilla expression 
control plasmid were co-transfected into human 293T cells. Transfected plasmids encoding for NS1 
(either belonging to A/England/195/2009 or A/ Victoria/3/1975) acted as positive controls. RV1088 
(0.173nM), was added to the overlying media at the time of transfection. 24hrs post-
transfection/infection, cells were lysed and firefly luciferase activity was measured. Results are 
expressed as the mean ± standard deviation of triplicate samples from three  independent 
experiments (student t-test, *p<0.5, **p<0.001, ns=non-significant). RLU: relative light units.   
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Of interest was the observation relating to the differences in ability of the NS1 
proteins from A/England/195/2009 and A/Victoria/3/1975 to block components of the IFN-
induction pathway. Specifically, when compared to un-treated mocks, the England-derived 
NS1 was unable to suppress signalling via IKKε, IRF-3 and IRF-7 but was able to supress 
signalling via IKKβ which is surprising as this NS1 has been shown to primarily exert its 
inhibitory effects by blocking at the level of RIG-I (Wu et al., 2012) suggesting that this NS1 
might also inhibit a greater range of targets than previously thought.  
In contrast, the Victoria-derived NS1 was able to supress the IFN-induction pathway 
at all levels tested except for IKKε. This result is rather surprising as this NS1 has been shown 
to have strong CPSF binding ability which, should have prevented the IKKε signal from 
activating the transcription of IFN-β. It is possible that the signal from IKKε is strong enough 
to “push through” and overwhelm the CPSF-binding inhibitory effect.  In both 
circumstances, the data warrant further examination.  
 
      
 
Figure 23: Suppression of NFkB by RV1088 occurs in a dose-dependent manner. A plasmid 
encoding luciferase with an NFkB-promotor was transfected into human 293T cells. RV1088, 
at a range of doses (0.0173nM to 1.73μM), was added to the overlying media. At the time of 
transfection, the cell cultures were infected with A/England/195/2009 (moi = 3). At 8, 16 
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and 24hrs post-transfection/infection, cells were lysed and firefly luciferase activity was 
measured. As the stimulation of the NFkB induction pathway was driven by a viral infection 
and not though the transfection of expression plasmids, renilla was not included. Results are 
expressed as the mean ± standard deviation of triplicate samples from one experiment that 
is representative of two independent experiments (student t-test, *p<0.5, **p<0.001). RLU: 
relative light units.  
 
A reporter plasmid encoding the firefly luciferase gene downstream of an NFkB 
responsive element was triggered following infection of transfected cells with influenza A 
virus A/Eng/195/2009. Treatment withRV1088 supressed induction of this NFkB responsive 
promoter in a dose-dependent manner at all the time points examined (Figure 23) and to a 
significant extent at the dose at which no effect of basal host gene transcription was 
measured (0.173nm). Based on this and other results described above, RV1088 likely exerts 
its IFN supressing affects by inhibiting a molecule that activates NFkB, which could be TBK1. 
 
2.7  Polymerase function as measured by the 3-5-8 Luciferase reporter construct 
 
In order to determine if RV1088 has any effect on viral replication, we employed a 
specialised luciferase reporter. In this experiment, A/England/195/2009 virus (moi = 3) was 
used to infect 293T cells which have previously been transfected with the 3-5-8 luciferase 
(3-5-8luc) reporter construct. This luciferase reporter contains a triple mutation in the 3’ 
non-coding region of the viral promoters that flank the reporter gene. This 3-5-8 mutation 
was shown by Neumann & Hobon (1995) to increase expression when driven by the 
influenza virus. The mechanisms for this is not clear but may be by increasing the ability of 
polymerase proteins produced during virus infection to bind to the altered viral promoter. 
In this assay carried out in the context of virus infection, the more active a viral polymerase 
is, the greater the resultant luciferase signal. The luciferase signal was measured after 6 and 
24hrs.  At 6 hours after infection insufficient replication had occurred for a luciferase signal 
to accumulate. Figure 24 shows a RV1088 dose-dependent inhibition of the luciferase signal 
at 24 hours post infection, supporting previous results that this drug exerts an anti-viral 
action at the level of viral replication. Since in this assay the viral polymerase is not 
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expressed from plasmids but rather during virus infection, any decrease in luciferase signal 
is not due to decrease polymerase expression resulting from the nonspecific effects of 
RV1088 on host gene expression. 
 
                          
Figure 24: Effect of kinase inhibitors on viral transcription/replication of a 3-5-8 luciferase 
plasmid in human cells (293T). A plasmids encoding for a firefly luciferase gene with a 3-5-8 
triple mutation in the 3’ non-coding region of the promotor was transfected into human 
293T cells. After an over-night incubation, cultures were infected for 1hr with 
A/England/195/2009 (moi=3) after which, DMSO (0.5%), SB203580 (0.4nM, pan-p38 
inhibitor), Dasatinib (100nM, Src inhibitor), BIRB-796 (12nM, pan-p38 inhibitor), Syk R343 
(100nM, Syk inhibitor) or RV1088 (0.173nM, targets p38, Src and Syk) were added to the 
overlying media either singularly or in combination. 24hrs post-infection, cells were lysed 
and firefly luciferase activity was measured. Results are expressed as the mean ± standard 
deviation of triplicate samples from three  independent experiments (student t-test, *p<0.5, 
**p<0.001). RLU: relative light units.   
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2.8 RV1088 does not affect virus HA binding  
  
 In order to determine if RV1088 has any effect on other aspects of virus replication, 
such as virus binding and entry, we tested its effect in a haemagglutinin (HA) assay (Figure 
25). This assay examines the ability of a virus to bind red blood cells using HA to attached to 
sialic acids that are exposed on the red cell surface. Drug was titrated into the assay to see if 
it could interfere with HA:SA interaction. Even at the high dose of 1.73μm the drug did not 
affect the ability of virus to crosslink red blood cells. 
 
 
Figure 25: RV1088 does not affect HA binding. Virus (A/England/195/2009) was diluted in 
PBS (± RV1088, 1.73μM) from neat to -5 in a 2-fold dilution series. 50μl chicken red blood 
cells were added to every well and the plate was incubated on ice for 1hr. Positive control, 
A/England/195/2009+PBS. Negative controls, PBS alone and RV1088 alone. 
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2.9 The effects of RV1088 on activity of the viral polymerase  
 
 The data above suggest that RV1088 is affecting cytokine expression through 
inhibition of the activation of NFkB. Interestingly NFkB has also been reported to affect virus 
replication directly. Kumar and colleagues (2008), reported a decrease in viral RNA 
replication when NFkB was blocked. They and others have postulated that NFkB must be 
associated with one, or more, viral-supportive functions the suppression of which can 
negatively impact viral replication. Such supportive functions expoused in the literature 
have included: the generation of pro-apoptotic factors which help to facilitate the release of 
vRNPs from the nucleus, suppression of IFN-induced gene (ISG) expression via cytokine 
signalling-3 (SOCS-3) and the regulation of vRNA synthesis (Ruckle et al., 2012; Kumar et al., 
2008; Pauli et al., 2008; Mazur et al., 2007; Wei et al., 2006).  
 
 
 
Figure 26: Minireplicon assay to measure polymerase activity in human cells (293T). 
Plasmids encoding the PB1, PB2, PA and NP proteins are co-transfected with a virus-like RNA 
expression plasmid (either vRNA or cRNA) encoding luciferase and a pCAGGs Renilla 
expression control plasmid in human 293T cells. Drugs are applied to the transfected cells 
and at various times post-transfection, cells are lysed and firefly luciferase activity is 
measured. Adapted from A. Cauldwell (unpublished). 
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 To examine whether RV1088 had an effect on the replicative ability of the influenza 
virus, a “minigenome” reporter assay was employed using the vRNP complex re-constituted 
from A/England/195/2009 virus.  In this assay vRNP or cRNP complexes are generated from 
the minimal set of constituents (PB1, PB2, PA and NP) encoded on expression plasmids 
together with a negative sense viral-like RNA reporter encoding the luciferase gene (termed 
here the “minigenome”) and transcribed with authentic termini by human polymerase I 
(Figure 26). The coding sequence of the “minigenome” reporter is flanked by conserved 
non-coding sequences that are considered to be the minimal viral promoters required for 
transcription and replication of viral RNA. Viral replication and transcription of the negative-
sense “minigenome” RNA take place in the nucleus and occur only in the presence of a 
reconstituted functional influenza virus polymerase. Upon replication of the “minigenome”, 
a luciferase signal is readily quantified. The addition of a drug compound, such as RV1088, 
into this system allows us to determine if the drug has any affect on the functionality of the 
viral polymerase.  
 Two different virus-like RNA expression plasmids driving in situ production of either 
vRNA or cRNA-like RNAs were utilized. Luciferase signals from the vRNA minigenome could 
result from transcription alone, but may be amplified by rounds of replication whereby the 
vRNA is replicated to cRNA, back to vRNA and then used a template for more mRNA. 
Luciferase signal from the cRNA minigneome requires both replication of the cRNA template 
to a negative sense vRNA and then transcription to generate mRNA. The signal following 
introduction of the negative reporter/vRNA (Figure 27a) was unaffected by RV1088 at any 
dose where the Renilla control was unaffected. On the other hand, the signal from the 
positive reporter/cRNA (Figure 27b) was suppressed in a dose-dependent manner by 
RV1088. At a dose of 0.173nm the minigenome luciferase signal was significantly 
suppressed but the Renilla control signal was not. Thus, in addition to effects on host 
pathways, RV1088 appears to suppress viral genome replication.   
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Figure 27: Effect of RV1088 on viral transcription/replication of a minigenome by A/England/195/2009 viral polymerase complexes in 
human cells (293T). Plasmids encoding the PB1, PB2, PA and NP proteins derived from A/England/195/2009 were co-transfected together with 
a virus-like RNA expression plasmid  (either vRNA (a) or cRNA (b)) encoding luciferase and a pCAGGs Renilla expression control plasmid in 
human 293T cells. c) represents the stages of influenza virus replication. At 24hrs post-transfection, cells were lysed and firefly luciferase 
activity was measured. Results are expressed as the mean ± standard deviation of triplicate samples from one experiment that is 
representative of two independent experiments. 
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2.10 Comparison of suppressive activity of RV1088 against specific kinase inhibitors 
 
After demonstrating the ability of RV1088 to supress the induction on interferon as 
well as directly affecting the replicative capability of the viral polymerase, we were 
interested in comparing RV1088 to other known kinase inhibitors. As previously discussed, 
RV1088 is a specially designed narrow spectrum kinase inhibitor that has been shown by our 
RespiVert colleagues to target the kinases c-SRC, Syk and p38α/γ. To evaluate the principle 
of using a single compound to target a group of kinases versus using single compounds for 
each specific target, either used alone or in combination, A549 cells stably expressing an 
IFN-inducible Gaussia luciferase were infected with A/England/195/2009 and treated either 
with RV1088 or a series of commercially available kinase inhibitors employed at their IC50s. 
As the results demonstrate (Figure 28), RV1088 was able to achieve a greater level of 
significant inhibition when compared to the DMSO control (p= 0.007, student t-test) with 
only Dasatinib (Src inhibitor), BIRB-796 (pan-p38 inhibitor) and the combination of 
Dasantib+BIRB-796+Syk R334 also obtaining statistical significance when compared to 
DMSO control (p-values of 0.019, 0.01, 0.033 respectively, student t-test). Of particular note 
is the observation that RV1088 induced a greater degree of suppression when compared to 
the tri-compound treatment of Dasantib+BIRB-796+Syk R334 (p=0.026, student t-test), a 
combination which covers the three main targets of RV1088. This result indicates that 
RV1088, as a single compound, is either more effective than using individual compounds or 
that RV1088 supresses other targets yet to be identified.  
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Figure 28: Comparison of the ability of kinase inhibitors to suppress IFN induction. A549 
cells stably expressing IFN-inducible gaussia luciferase were infected with 
A/England/195/2009 (moi =3). DMSO (0.5%), RV1088 (0.173nM, targets p38, Src and Syk), 
SB203580 (0.4nM, pan-p38 inhibitor), Dasatinib (100nM, Src inhibitor), BIRB-796 (12nM, 
pan-p38 inhibitor) or Syk R343 (100nM, Syk inhibitor) were added to the overlying media, 
singularly or in combination, at the time of infection. At 24hrs post-infection, culture 
supernatant samples were taken and the level of gaussia luciferase was quantified. 
Treatment groups were compared to DMSO controls  (student t-test, *p<0.5, **p<0.001). 
RLU: relative light units. 
 
2.11 Discussion and Conclusions 
 
This chapter presents results detailing the analysis of the activity of RV1088 in vitro 
in inhibiting induced cytokine responses and influenza virus replication using a variety of 
assays. We have attempted to localize the point in the interferon induction pathway where 
the compound interferes with host cell signalling and viral replication. 
Personal communication from RespiVert colleagues revealed that RV1088 targets 3 
host kinases (p38, Syk, and c-Src), we wanted to confirm that, in our hands and cell culture 
systems, that we are able to observe a specific knock-down of one of these named targets. 
As such, we chose to specifically examine the ability of RV1088 to affect the kinase activity 
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of p38. This target was chosen due to the general availability of well-established reagents 
that did not require radio-labelling. As expected, when cell cultures were infected with 
either A/England/195/2009 or B/Florida/04/06, we observed a strong activation of 
phosphorylated (i.e. active) p38; however, in the presence of RV1088, the level of activity 
was suppressed.  
Our results demonstrate that RV1088 has the ability to supress transcription of not 
only induced IFN-β mRNA but also inhibits the expression of the Renilla control gene 
expressed from a polymerase II promoter on a transfected plasmid. This phenomenon has 
been observed by other groups examining the effect of different kinase inhibitors that are 
known/designed to target other signalling pathways (Martinez-Gil et al., 2013; Ludwig, 
Personal Communication).  Based on discussions with others in the field, and our ability to 
analyse Renila expression, we decided that the best course of action was to only carry out 
experiments with a dose of RV1088 that was effective at supressing IFN-β but not the 
Renilla control. Using this technique, we found that a dose of 0.173nM fit the profile and is 
the dose used in the majority of our further experiments (Figure 15).  The basis for Renilla 
inhibition at higher concentrations remains unknown. 
The suppressive effects of RV1088 on interferon induction were not specific for 
influenza virus and did not require a replicating virus to be the inducer for the effect to be 
observed. Since the compound also inhibited IFN induction by Newcastle Disease Virus 
(NDV) and Polyinosinic:polycytidylic acid (poly I:C) (both well-known, stimulators of the IFN 
pathway). We can therefore conclude that there should be an effect of RV1088 on 
interferon induction that is separate from any effect if this compound in inhibiting virus 
replication, and in this way the drug likely has dual activity against this pathway. As RV1088 
is believed to act by inhibiting the phosphorylation of key kinases involved in 
cytokine/chemokine signaling cascades normally up-regulated during productive influenza 
infections, we sought to examine its potential to counteract the cytokine response induced 
by a highly pathogenic virus. 
One such virus that has been implicated in the generation of a cytokine storm within 
the host is A/H5N1. This particular strain is a highly pathogenic virus infecting aquatic birds 
and poultry. Sporadic incidences of species-barrier crossings of the virus into humans have 
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been documented and are associated with significant morbidity and mortality; causing an 
estimated mortality rate between 2003 and 2014 of ~60% for the 600 or more confirmed 
cases (WHO, 2014).  
Examinations of plasma taken from A/H5N1-infected patients demonstrated 
significantly increased levels of macrophage and neutrophil-attractant chemokines as well 
as a range of pro-inflammatory and anti-inflammatory cytokines (Abdel-Ghafar et al., 2008). 
While post-mortem examinations of several individuals revealed: organizing diffuse alveolar 
damage with interstitial fibrosis, extensive hepatic central lobular necrosis, acute renal 
tubular necrosis and lymphoid depletion (To et al., 2001). 
Whilst the exact pathogenic mechanism(s) employed by the virus are not completely 
understood, hypercytokinemia is thought to play an important role (Sakabe et al., 2011). 
Initially, it was suggested that this hyperinduction of cytokines/chemokines was directly 
related to the replicative ability of the virus but more recent work has shown this does not 
entirely explain the situation (Abdel-Ghafar et al., 2008; Sakabe et al., 2011).  
In our experiments, we chose to use the A/Turkey/Turkey/01/2005 virus strain which 
had its HA and NA gene segments swapped for those of A/Puerto Rico/8/1934 (PR8, 
A/H1N1) to serve as our prototypic high cytokine-inducing virus. The swapping of the viral 
HA and NA gene segments was performed in order to facilitate easy viral uptake by cells in 
culture and to make the virus more safe for laboratory work as our adaptive immune 
systems have already been primed to recognize the PR8 HA/NA via vaccination with the 
pH1N1 2009 strain that shares antigenicity with PR8 (Skountzou et al., 2010). All 
A/Turkey/Turkey/01/2005:PR8 experiments were conducted in Cat 3 containment facilities. 
Our results (Figure 18) demonstrate that, in 293T cells transfected with a luciferase 
plasmid encoding an IFN-b promotor, the A/Turkey/Turkey/01/2005:PR8 (6:2, HA/NA) virus 
induces a strong IFN response which is partially suppressed by the NS1s of 
A/Victoria/3/1975 and A/England/195/2009 (a reduction of 15.5- and 6.4-fold respectively 
when compared to DMSO treatment group). With respect to the RV1088 treatment groups, 
treatment with 0.0173nM failed to inhibit interferon induction while treatment with 
0.173nM was able to significantly inhibit this response (2.6 fold decrease, p value = 0.0003, 
Chapter 2 │Results 
 
 
- 118 - 
student t-test, at 18hrs p.i). These results indicate that RV1088 may prove beneficial in 
controlling the over-induction of the IFN response in cases of A/H5N1.  
In order to examine if RV1088’s inhibitory activity relies on targeting a species-
specific factor or whether this compound’s target is common across birds and humans, we 
examined the ability of RV1088 to supress the induction of IFN- β in avian cells. Chicken 
embryonic fibroblasts (DF1 cells) were transfected with a luciferase reporter containing an 
avian IFN-β promotor. Cultures were infected with A/England/195/2009 both in the 
presence and absence of RV1088 and after a set incubation time, the luciferase signal was 
quantified. The results demonstrated that RV1088, at least in part, exerts its inhibitory 
actions on targets/pathways that are conserved between the avian and human species. 
Unfortunately, further examinations were considered to be beyond the scope of this project 
however, a more detailed examination may be warranted at a later date.  
By employing a series of plasmids possessing a pCMV5 promoter upstream of a 
sequence which encode for a key components of the IFN-β signalling pathway, we have 
mapped RV1088’s activity to a level at or below that of MAVS with some of its potential 
effects occurring via TBK-1 resulting in the suppression of NFkB activation and IFN induction. 
Furthermore, we have shown that his interference occurs in a dose-dependent manner. 
These results are in line with already published information that has demonstrated 
that p38 is up-regulated during influenza infections (Ludwig, 2007; Lee et al., 2005). 
Furthermore, this kinase has been implicated in the induction of the IFN response via the 
NFkB signalling pathway (Hui et al., 2009; Saccani et al., 2002; Uddin et al., 1999).  
Additional sources have shown that NFkB, a transcription factor, has been shown to control 
the expression of numerous genes and is involved in an array of physiological responses to 
viral attack  (including acute phase inflammatory responses, cell adhesion, oxidative stress 
response, apoptosis and generation of the antiviral state (Ludwig & Planz, 2008; Pahl, 1999). 
However, despite this, some studies have demonstrated that when NFkB signalling is 
blocked, the production of progeny viruses is impaired, indicting that the influenza virus 
may exploit NFkB signalling to its own advantage (Wurzer et al., 2004; Nimmerjahn et al., 
2004). Specifically, NFkB has been shown to be involved in the generation of pro-apoptotic 
factors which help to facilitate the escape of vRNPs from the nucleus, suppression of IFN-
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induced gene (ISG) expression via cytokine signalling-3 (SOCS-3) and through the regulation 
of vRNA synthesis have all been proposed (Ruckle et al., 2012; Kumar et al., 2008; Pauli et 
al., 2008; Mazur et al., 2007; Wei et al., 2006).  
In addition to exerting effects on host cell signalling, we have also demonstrated that 
in our “minigenome” assay (discussed in detail in Section 2.9) RV1088 is able to supress the 
transcription of the vRNA (+) reporter but not the cRNA (-) reporter. This indicates that 
RV1088 does indeed affect the viral polymerase at the level of viral replication. It is 
important to note that this system relies on the transcription of transfected plasmids each 
of which encode for a component of the viral polymerase and it is possibly that the 
inhibitory effect observed in the mini-replicon assay results from a general suppression by 
RV1088 of transcription activity in the transfected cells rather than a specific anti-
polymerase activity. This conundrum has been previously described in the literature by 
Martinez-Gil and colleagues (2013) in which, the authors ascribed the effect to possible and 
specific inhibition of host RNA synthesis or to a nonspecific cytotoxicity effect and simply 
looked at the relative difference in the suppression levels seen between the Renilla 
transfection control and their polymerase reporter assay. They reported observing 
inhibition in the replication of viral RNA as well as suppression of the transfection control 
however, the suppression of the former was significantly greater than the later leading 
them to conclude that the suppression of viral RNA was not simply a result of general 
transcription suppression. While this interpretation is open to debate, no consensus yet 
exists in the field regarding how reliable such results may be and what is the best way to 
interpret such results. 
Our observation that RV1088 does have an effect on viral RNA replication was 
further confirmed through the suppression by RV1088 of the transcription of a 3-5-8 
luciferase reporter plasmid. The 3-5-8 reporter plasmid, when actively transcribed by the 
viral polymerase, produces a quantifiable luciferase signal. Unlike the mini-genome assay, 
the 3-5-8 reporter system is driven directly by replicating virus and not by the expression of 
polymerase-encoding plasmids. In this assay system, RV1088 also was observed to 
significantly supress the replicative ability of the viral polymerase. Our findings are 
consistent with the results reported by another group where the kinase inhibitors 
ON108110 was found to supress influenza viral replication in a dose-dependent manner 
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(Martinez-Gil et al., 2013). The inhibitory action of this kinase inhibitor was also mapped to 
preferentially inhibit vRNA replication indicating that this stage in viral replication may 
prove to be an effective target for intervention.  
The mechanism by which RV1088 is able to exert an inhibitory effect on the viral 
polymerase has yet to be elucidated. However, other groups in the field have suggested that 
kinases are involved in the process of nuclear release of vRNP complexes during the latter 
stages of viral replication (Ludwig et al., 2009; Pleschka et al., 2008). Supporting this 
hypothesis is the observation that when certain kinase pathways (for example, p38) are 
over-stimulated in cell culture, recovered viral titers are generally higher when compared to 
non over-stimulated cultures (Marjuki et al., 2007; Olschlager et al., 2004; Ludwig et al., 
2004). Furthermore, if such a pathway is blocked via specific kinase inhibitors, there is a 
striking impairment of viral growth for both types (A and B) of influenza (Olschlager et al., 
2004; Ludwig et al., 2004; Pleschka et al., 2001). It has been hypothesised the this anti-viral 
effect may be due, in part, to the ability of the kinase inhibitors to prevent the 
phosphorylation of the viral proteins NEP and NP, two of the viral proteins in the viral 
phosphoson. A detailed examination of this postulated mechanism this has yet to take place 
(Planz, 2013; Hutchinson et al. 2012). 
Furthermore, we have demonstrated that the suppression of IFN induction and 
vRNA synthesis by RV1088 is not due to a general cellular toxicity effect. This is concluded 
based on the observations that at the concentrations we have used in our work, RV1088 
does not adversely affect cellular reductase activity, cell wall integrity, or increase the 
expression/activity of the known apoptosis-inducer Caspase 3/7 (Figure 13).  
Finally, we examined whether RV1088 has any effect on the viruses ability to bind to 
host cell surface receptors.  Previous studies have demonstrated that prior to host cell 
entry, PRR recognition of the residue on the surface of the influenza virion stimulates 
MyD88, which, in turn, activates p38 and subsequently host cellular internalization 
machinery (Marchant et al., 2010). As RV1088 has been shown to inhibit the activity of p38, 
we felt that an evaluation of viral-host receptor binding was warranted. The levels of 
activation of p38 during the first 10min of infection were found to be approximately 10-fold 
higher than for other respiratory viruses and may represent an effective adaptation 
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mechanism to augment viral uptake by the host cell. Thus, by supressing p38 activation, 
RV1088 may be having an indirect suppressive effect on viral entry. 
To examine any effect that RV1088 might have on receptor binding, we employed 
the haemagglutination assay (HA assay), a universally used technique in the field of 
influenza research that measures the ability of a virus to agglutinate red blood cells (RBCs) 
via sialic acid receptor binding. This assay was performed in the presence or absence of 
RV1088 and it was discerned that RV1088 dose not effect the ability of A/England/195/2009 
to bind RBCs (Figure 25).  
Finally, we compared the IFN suppressive activity of RV1088 against other specific 
kinase inhibitors (employing previously reported IC50 values) and determined that RV1088 
was able to achieve a greater level of significant inhibition when compared to the DMSO 
control (p= 0.007, student t-test) (Figure 28). In contrast, only Dasatinib (Src inhibitor), BIRB-
796 (pan-p38 inhibitor) and the combination of Dasantib+BIRB-796+Syk R334 also obtaining 
statistical significance in terms of supressing IFN-induction when compared to DMSO 
control (p-values of 0.019, 0.01, 0.033 respectively, student t-test).  
In addition, it was noted that RV1088 induces a greater degree of suppression in 
terms of IFN-induction when compared to the tri-compound treatment of Dasantib+BIRB-
796+Syk R334 (p=0.026, student t-test) - a combination which covers the three main targets 
of RV1088. This result indicates that RV1088, as a single compound, is either more effective 
than using individual compounds or that RV1088 supresses other targets yet to be identified 
and warrants further investigation beyond the scope of this project.  
Taken together, this chapter’s results, indicate that RV1088 does not directly effect 
viral attachment to host cells and that the suppressive effects we have previously observed 
are not due to inhibition of the virus’ ability to infect target cells rather, RV1088 must be 
exerting its effect directly at the level of cell signalling and/or viral replication.  
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Chapter 3. Evaluating the activity of RV1088 against the influenza virus 
 
3.1 Treatment of influenza-infected CALU-3 with RV1088  
 
To examine the potential of RV1088 to supress the replication of influenza and/or 
affect the cytokine response, we first performed assays in CALU-3 cells (an immortalised 
human-epithelial, lung adenocarcinoma line). Since the HAE 3D cell cultures are very costly 
we wished to ask whether the drug had any effect at all in a simpler culture system. The 
virus chosen for these experiments was A/England/195/2009 (A(H1N1)pdm09) as it is 
representative of  currently circulating virus. Monolayer cultures were infected in the 
presence or the absence of RV1088 (1.73nM) and, at specified time points (24 and 48hrs 
p.i.), culture supernatants were harvested to determine viral titers by plaque assay on 
MDCK cells (Figure 29a). At either time point, no significant difference was observed 
between the RV1088 and non-treatment groups. At 24 hours, the titres of virus released 
were the same in presence or absence of drug. At 48hrs, there was an average 2.57-fold 
decrease in viral titres as measured by plaque assay. On the other hand, qRT-PCR analysis on 
cell lysates collected at 48 hours p.i. revealed that RV1088 significantly suppressed 
cytokine/chemokine mRNA levels induced by A/England/195/2009 (A(H1N1)pdm09 (p≤ 0.05 
for both IFN-β and RANTES) (Figure 29b-d). There was an average 1.58- and 4.76-fold 
decrease in IFN-β and RANTES mRNAs respectively. In addition qRT-PCR for viral M gene 
mRNA (normalized to 18S) indicated that treatment with RV1088 also suppressed levels of 
M-gene message by an average 3.78-fold, which may account for the same decrease in viral 
titres measured in supernatant at that time point.  
Unfortunately, mRNAs for viral or host genes were not measured at 24hrs p.i. and as 
such, it was not possible to extrapolate if the observed cytokine mRNA decrease at 48hrs 
resulted from a decrease in viral titers or was a direct effect of RV1088 on the cytokine 
induction pathway. 
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Figure 29: Growth curve results of RV1088 in CALU-3s. 
CALU-3 cells were infected with A/England/195/2009 (moi 
= 0.0001) in the presence or absence of RV1088 (1.73nM). 
Culture supernatant was harvested at specified time points 
and used in the determination of viral replication by being 
plaqued on MDCKs (a)  and at 48hrs p.i. total RNA was 
extracted for quantification of cytokine/chemokine mRNA 
expression via qRT-PCR (b-d). Results are expressed as the 
mean ± standard deviation of triplicate samples (student t-
test, *p<0.5, **p<0.001). RLU: relative light units.   
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3.2 Air-liquid interface primary cell cultures 
 
We wished to study the effect of the kinase inhibitor RV1088 on influenza virus 
replication and cytokine induction in a cell system that most closely represented the target 
cells in the human respiratory tract. 
Traditional cell culture, typically used for the study of influenza virus replication, 
comprises a single type of cell, usually immortalized, grown in a two dimensional plastic dish 
with complete submersion of cell in liquid media. There is an increasing demand for in vitro 
models that capture the relevant in vivo tissue complexity which the traditional 2-D 
monocultures are unable to achieve.  In vivo, the response of individual cells to stimuli is 
regulated by spatio-temporal cues that reside in the local environment or the extracellular 
matrix and from signals from neighbouring and distant cells of a variety of cell types, soluble 
factors and physical forces, lacking in the 2-D systems but available in the 3-D primary cell 
cultures (BeruBe, 2010). 
Cells of the respiratory tract have been cultured with an air liquid interface (ALI) and 
these contain ciliated surface cells in the same or even greater numbers as basal and goblet 
cells, whereas submerged cultures contain significantly fewer-to-no cilia on their apical 
surface (Figure 30). Furthermore, submerged cultures can exhibit different permeabilities to 
substances (such as drugs) when compared with cultures grown at the ALI (BeruBe, 2010).  
One worry in employing primary cells for basic science studies would be that 
variation may exist between cells obtained from different donors, and also that even using 
these primary cultures creates a different cell environment than in vivo. However, these 
misgivings appear to be unfounded: In a study conducted by Pezzulo and colleagues (2011), 
cells harvested from tracheal and bronchial brushings of 16 individuals were isolated and 
each sample was divided into two lots. Immediate transcriptional analysis via microarray 
was performed on one sample lot while the second sample lot was used to grow separate 
tracheal and bronchial air-liquid interface (ALI) cultures for each donor and subjected to the 
same microarray analysis as the first lot two weeks later. The transcriptional profiles of the 
brushing samples were subsequently compared to that of the ALI cultures for each donor. 
Within each donor, a comparison was made between the profile of their tracheal cells and 
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bronchial cells, and the differences between donor-to-donor were also examined for both 
cell types (i.e. tracheal and bronchial).  The profiles of Calu-3 cultures grown at both the ALI 
and submerged manner were also examined and compared to the profiles to both primary 
cell lots. 
         
Figure 30: Schematic representation of the Human Airway Epithelial (HAE) cultures. 
Primary human airway donor biopsies reconstituted in a transwell are commercially 
available (Epithelix, CH). Cultures are maintained at an air-liquid interface and contain basal 
cells, non-ciliated columnar cells (often called pre-ciliated) active ciliated columnar cells, and 
mucus secreting goblet cells. 
 
Their results demonstrated that primary cultures of human airway epithelia 
maintained a very high degree of similarity of gene expression patterns as in vivo airway 
epithelial samples and that these similarities relied on both culture of primary non-
immortalised cells and the presence of an ALI. 
They also found a very high degree of similarity between the transcriptional profiles 
of the airway epithelium from different donors and further, that the airway epithelia from 
trachea and bronchi samples had very similar expression profiles (both within each donor 
and between all donors). Thus normal/healthy human airway epithelium showed an 
exceptionally constant transcriptional profile that sometimes prevailed despite inter-donor 
and environmental variability.  This suggests that using a small number of biological 
replicates to study the transcriptional profile of the airway is an acceptable approach.   
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The above conclusions are further supported by the work of Dvorak and colleagues 
(2010) who, using a similar approach as Pezzulo, compared the transcriptome of epithelial 
brushings from 12 donors to that of primary cell cultures grown from the original samples. 
They determined that 81% of the gene sets expressed in both cell types showed similar 
expression profiles between cultured and brushed cells. The majority of those genes with 
differential expression were again linked to the different proportion of cell types expressed 
as well as the lack of certain effector immune cells (primarily macrophages).  Signalling 
pathways were also examined and while differences did exist between the brushing samples 
and the primary cell cultures, overall a remarkable level of similarity exists.  
In recent years, a wealth of studies using primary cell-derived, highly differentiated 
airway cultures have been undertaken to examine viral replication and virally-induced 
responses. In studies conducted by Wan and Perez (2007), HAE cell cultures were effectively 
employed to demonstrate how specific viral molecular traits (e.g. L-226 in the HA protein 
mediating strong binding for α26SA) can have strong implications in terms of viral host 
range and viral growth. By employing these culture systems, it was possible to identify the 
specific cell type targeted by the virus and that are necessary for the initiation of infection. 
Furthermore, investigations into how specific molecular changes can alter the binding 
specificity (i.e tropism) of the virus have also been examined.  
In work conducted by Matrosovich et al., (2004) and others the HAE culture system 
has been instrumental in demonstrating the difference in binding patterns that exist 
between human and avian viruses in the human respiratory tract and thus have greatly 
aided in studies wishing to examine components of the host-range barrier. Interestingly, 
influenza A viruses which have the ability to transmit between people, appear to target 
primarily the non-ciliated cells in these cultures of human airway epithelium (Matrosovich 
et al., 2004; Thompson et al., 2006). This is in contrast to some other respiratory viruses 
such as SARS, coronavirus or RSV that seem to preferentially infect ciliated cells (Pickles, 
2004; Zhang et al., 2002; Bartlett et al., 2008).  
With respect to examinations of the virally-induced cytokine/chemokine response, 
the HAE culture system has proved to be a instrumental and reliable tool. Schaap-Nutt et al., 
(2012) demonstrated in HAE cultures that human parainfluenza virus serotypes (PIV1 and 2) 
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differ in their replication kinetics and cytokine secretion helping to shed light on some of the 
serotype-specific differences in PIV pathogenesis and epidemiology. Additional work 
conducted by Zhang et al., (2011) found that PIV5 infection of HAE occurs preferentially at 
the apical surface and that in comparison to RSV and PIV3, PIV5 was unexpectedly more 
cytopathic, as characterized by enhanced shedding of infected cells and extensive formation 
of syncytia. Work along similar lines has also been conducted in the HAE culture system for 
human Coronavirus (Dijkman et al., 2013; Dominguez et al., 2013), Respiratory Syncytial 
Virus (Wright et al., 2005), Human Rhinovirus (Hao et al., 2012) and Human Bocavirus 1 
(Deng et al., 2013; Dijkman et al., 2009). 
HAE cultures are also also proving to be a useful system for the testing of efficacy 
and delivery of various therapeutic agents. DAS181, a sialidase fusion protein that acts by a 
host-targeting entry-blocking mechanism, was successfully evaluated against influenza in 
HAEs by Hedlund et al., (2010) and Triana-Baltzer et al., (2009). In these studies, DAS181 
was found to effectively desialylate HAE cultures and ex-vivo bronchi tissues indicating its 
potential to inhibit replication of different influenza strains. Furthermore, Frieman et al., 
(2011) employed HAE cultures to assess and differentiate the in vitro efficacy of NSC158362 
(a small molecule identified to inhibit the activity of the papain like protease) against SARS-
CoV and influenza.  
Finally, the delivery of therapeutic genes to the diseased airway epithelium 
represents a promising avenue for the treatment of numerous genetic lung diseases (e.g. 
cystic fibrosis, α-1-antitrypsin). The ability of adeno-associated virus (AAV) serotypes 1–9 as 
well as numerous other vectors have been evaluated for genetic cargo delivery in HAE 
cultures (Limberis et al., 2009). All these studies exemplify the utility and versatility of the 
HAE culture system for evaluating viral pathogenesis and the ability of pharmacological 
compounds to combat such infections. 
 
 
 
 
Chapter 3 │Results 
 
 
- 128 - 
3.2.1 Treatment of influenza-infected HAEs with the corticosteroid Fluticasone  
 
Before examining the effects of RV1088 on viral replication and cytokine/chemokine 
suppression, we sought to first examine how a corticosteroid (Fluticasone) would act in the 
human airway epithelium culture system in the context of an influenza infection as this 
steroid is specifically indicated for treating inflammation associated with the upper 
respiratory tract. As the results in Figure 31 demonstrate, steroid treatment resulted in 
significant increases in viral replication levels with cytokine/chemokine levels either 
unchanged or increased when compared to DMSO controls. 
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Figure 31: Results ofPre-infection treatment with Fluticasone in HAEs infected with A/England/195/2009. HAE cell cultures were pre-treated 
for three days both apically and basally with Fluticasone (0.1μg/ml) or DMSO (0.5%). Cultures were infected with A/England/195/2009 (moi = 
0.0001, 1hr 37°C). After infection, fresh drugs were applied apically (2hrs, 37°C then removed) and added to the basal media for the duration 
of the experiment. Culture supernatant was harvested at specified time points and used in the determination of viral replication by being 
plaqued on MDCKs (a) and for quantification of cytokine/chemokine protein expression via Luminex (b-e). Results are expressed as the mean ± 
standard deviation of triplicate samples (student t-test, *p<0.5, **p<0.001). RLU: relative light units.   
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3.2.2 Treatment of HAE cultures with RV1088 prior to infection with A(H1N1)pdm09 and 
B/Florida/04/2006 
 
To evaluate the effect of RV1088 on viral replication and the innate immune 
response in the primary HAE cultures, cells were pre-treated (apically for 2hrs each day and 
basally) with RV1088 in DMSO (0.5%) for three days then infected with either 
A/England/195/2009 (Figure 32) or B/Florida/04/2006 (Figure 33) at an moi of 0.0001 to 
allow multiple replication cycles to occur. At the time of infection, the drug containing basal 
media was replaced with drug-free media which remained in place until the end of the 
experiment. Samples collected from the apical surface were titrated for infectious virus by 
plaque assay in MDCK cells. When compared to DMSO control, RV1088 significantly 
decreased the titre of virus released at the apical surface only in the case of 
B/Florida/04/2006 at 24hrs p.i. (p≤0.05). For all other time points any inhibitory effect was 
not statistically significant (with fold decreases ranging from 0 to 4.3) (Figure 33).  
The same apical washings were used to quantify cytokine/chemokine protein level 
using a Luminex™ platform. The results demonstrated that RV1088 significantly suppressed 
cytokine/chemokine protein levels induced by A/England/195/2009 (A(H1N1)pdm09) 
(Figure 23).  Indeed under these conditions no induced protein responses were detected at 
all. RV1088 predominantly no significant effect on replication of the influenza B virus strain 
B/Florida/04/2006 in HAE cultures (save for the 24hr time point, p≤0.05) (Figure 33), but did 
significantly suppress cytokine/chemokine protein levels induced by B/Florida/04/2006, 
mirroring the results previously described for the type A virus.  
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Figure 32: Results of Pre-infection treatment with RV1088 in HAEs infected with A/England/195/2009. HAE cell cultures were pre-treated for 
three days both apically and basally with RV1088 (1.73nM) or DMSO (0.5%). Cultures were infected with A/England/195/2009 (moi = 0.0001, 
1hr 37°C). After infection, fresh drugs were applied apically (2hrs, 37°C then removed) and added to the basal media for the duration of the 
experiment. Culture supernatant was harvested at specified time points and used in the determination of viral replication by being plaqued on 
MDCKs (a) and for quantification of cytokine/chemokine protein expression via Luminex (b-e). Results are expressed as the mean ± standard 
deviation of triplicate samples (student t-test, *p<0.5, **p<0.001). RLU: relative light units. 
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Figure 33: Results of pre-infection treatment with RV1088 in HAEs infected with B/Florida/04/2006. HAE cell cultures were pre-treated for 
three days both apically and basally with RV1088 (1.73nM) or DMSO (0.5%). Cultures were infected with B/Florida/04/2006 (moi = 0.0001, 1hr 
37°C). After infection, fresh drugs were applied apically (2hrs, 37°C then removed) and added to the basal media for the duration of the 
experiment. Culture supernatant was harvested at specified time points and used in the determination of viral replication by being plaqued on 
MDCKs (a) and for quantification of cytokine/chemokine protein expression via Luminex (b-e). Results are expressed as the mean ± standard 
deviation of triplicate samples (student t-test, *p<0.5, **p<0.001). RLU: relative light units.   
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3.2.3 Treatment of HAE cultures with RV1088 delays the onset of A(H1N1)pdm09-related 
CPE  
 
Cytopathic effects (CPE) are observable, structural changes in cell morphology 
resulting from virally induced changes in the cells physiology and perturbation of cellular 
biosynthesis. Common morphological changes include: rounding of infected cells, the 
formation of syncytia (polykaryocytes) and disruption of confluent monolayers.  
In order to determine if RV1088 had any effect on the development of CPE caused by 
A/England/195/2009 (A(H1N1)pdm09) in the HAE culture system, cells were examined 
under 20x microscopy each day for the duration of the experiment. Representative 
microgrpahs (Figure 34) demonstrate that RV1088 treatment delayed the onset of 
observable CPE to day 2 p.i, one day later than for the DMSO treatment group. 
Furthermore, the extent of CPE in infected cells treated with RV1088 at day 2 p.i. was less 
than the CPE seen for the DMSO treatment group on the same day. 
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Figure 34: RV1088 delays the onset of viral-induced cytopathology when added after the 
initiation of infection. HAE cell cultures were infected with A/England/195/2009 (moi = 
0.0001). One hour post infection, RV1088 (1.73nM) or DMSO (0.5%) was applied apically 
(2hrs, 37°C then removed) and added to the basal media for the duration of the experiment. 
At set time point, cultures were examined and representative samples photographed at 20x 
magnification.. Arrows mark sites of evident CPE. Results presented are from one 
representative well from a set of three. 
 
 
 
 
 
Chapter 3 │Results 
 
 
- 135 - 
3.2.4 Treatment of HAE cultures with RV1088 during an active A(H1N1)pdm09 infection 
 
The previous experiments employed pre-treatment of the HAE cultures with RV1088 
for 3 days before virus infection to give the compound every possible chance of modifying 
the cellular environment. We next performed an assay in which the drug was added after 
influenza virus infection. As before, a slight decrease in viral titre released at the apical 
surface was noted after RV1088 treatment but the small 3.22 and 4.54 (corresponding to 48 
and 72hrs p.i. respectively) fold decrease was not statistically significant (Figure 35, a). The 
cytokine/chemokine protein analysis of the apical washings (Figure 35, b-d) demonstrated 
that post-infection treatment of HAE cultures with RV1088 resulted in suppression of 
cytokine/chemokine proteins when compared to the DMSO control group. However, it 
should be noted that this suppression, while significant, was not the same extent (i.e. it did 
not flatline) as that seen in the pre-infection treatment experiments.  
 
3.2.5 Treatment of HAE cultures with RV1088 after infection with B/Florida/04/2006  
 
As seen for influenza A virus, treatment with RV1088 at one hour post infection of 
HAE cells had little effect on virus yields (1.2 fold decrease in titre at 24 hours p.i.) but did 
suppress the cytokine response elicited by a type B virus (B/Florida/04.2006), although not 
to the same extent as in cells that had been pre-treated with drug for 3 days before 
infection (Figure 36). 
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Figure 35: Results of post-infection treatment with 
RV1088 in HAEs infected with A/England/195/2009. HAE 
cell cultures were infected with A/England/195/2009 (moi = 
0.0001). One hour post infection, RV1088 (1.73nM) or 
DMSO (0.5%) was applied apically (2hrs, 37°C then 
removed) and added to the basal media for the duration of 
the experiment. Culture supernatant was harvested at 
specified time points and used in the determination of viral 
replication by being plaqued on MDCKs (a) and for 
quantification of cytokine/chemokine protein expression 
via Luminex (b-d). Results are expressed as the mean ± 
standard deviation of triplicate samples (student t-test, 
*p<0.5, **p<0.001). RLU: relative light units.   
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Figure 36: Results of post-infection treatment with 
RV1088 in HAEs infected with B/Florida/04/2006. HAE 
cell cultures were infected with B/Florida/04/2006 (moi 
= 0.0001). One hour post infection, RV1088 (1.73nM) or 
DMSO (0.5%) was applied apically (2hrs, 37°C then 
removed) and added to the basal media for the duration 
of the experiment. Culture supernatant was harvested at 
specified time points and used in the determination of 
viral replication by being plaqued on MDCKs (a) and for 
quantification of cytokine/chemokine protein expression 
via Luminex (b-d). Results are expressed as the mean ± 
standard deviation of triplicate samples (student t-test, 
*p<0.5, **p<0.001). RLU: relative light units.   
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3.2.6 Cytokine responses in human PBMCs infected with A(H1N1)pdm09 and treated with 
RV1088  
 
In vivo the cytokine response induced by influenza virus will be contributed to by 
cells of the respiratory epithelium and also by specialist immune cells that are exposed to 
virus in the lung.  
The pathways that lead to the cytokine response in immune cells are different than 
those in epithelial cells and so it was important to assess the effects of RV1088 on immune 
cell responses to influenza. Since knowledge regarding the specific role certain immune cells 
might play during the initial stages of an influenza infection is as yet unclear, we opted to 
isolate and employ a heterogeneous mixture of immune cells (PBMCs) in order to ensure 
that we were able to observe the effects of RV1088 across the full spectrum. Cytokine 
responses were measure by specific qRT-PCR for cytokine genes.  
In order to evaluate the effect of RV1088 on the immune response, peripheral blood 
mononuclear cells (PBMCs) were isolated from donor human whole blood and subsequently 
infected with A(H1N1)pdm09. One hour post-infection, cultures were treated with RV1088 
(either 1.73μM (high dose) or 0.0173nM (low dose)). Serum free media (SFM) with DMSO 
(0.5%) acted as a no-treatment control while another set of cells were left uninfected to 
determine baseline levels of cytokine gene expression. At 24 and 48hrs p.i., total RNA was 
extracted from PBMC cultures and qRT-PCR was performed for cytokines (Figure 37, parts a-
c) and viral M-gene (Figure 37, part d). At 24hrs p.i., both doses of RV1088 suppressed 
cytokine/chemokine mRNA transcription (with 1.73μM being more effective than 
0.0173nM). However, by 48hrs p.i., in the presence of 0.0173nm RV1088, the 
cytokine/chemokine levels reached levels seen in untreated cells. In contrast, the higher 
dose 1.73μM RV1088 suppressed the cytokine response throughout the experiment.  
RV1088 also suppressed viral M-gene mRNA transcription in a dose dependent manner at 
24hrs p.i. and continued to suppress viral gene accumulation at 48hrs p.i.  
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Figure 37: qPCR results of human PBMCs infected with A/England/195/2009 and treated 
with RV1088. Human PBMCs isolated from donors were infected with A/England/195/2009 
(moi = 3). One hour post infection, RV1088 (1.73μM or 0.0173nM) was added to the cell 
cultures. At 24 and 48hrs p.i., total RNA was extracted from cultures and qRT-PCR was 
performed for cytokines (a-c) and viral M-gene (d). Results are expressed as the mean ± 
standard deviation of triplicate samples.  
  
3.3 Discussion and Conclusions 
  
There exists considerable debate as to the efficacy and wisdom of employing 
steroids in cases of influenza-induced ALI/ARDS with evidence existing on both sides of the 
argument (Agarwal, 2007; Tang, 2009; Steinberg, 2006; Salomon, 2007; Xu, 2009; Kumar, 
2009; Dominguez-Cherit, 2009). One of the major concerns regarding using 
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immunomodulators in cases of influenza infection is that by inhibiting the natural host 
response, mechanisms which restrict viral replication could be inactivated leading to an 
augmented rate of viral replication to the host’s detriment. Before examining the effects of 
RV1088 on viral replication and cytokine/chemokine suppression, we sought to first 
examine how a corticosteroid (Fluticasone) would act in our culture system in the context of 
an influenza infection. As the results in Figure 31 demonstrate, steroid treatment resulted in 
significant increases in viral replication levels with cytokine/chemokine levels either 
unchanged or increased when compared to DMSO controls.  
There exists surprisingly little information in the literature with respect to the in vitro 
effects of the corticosteroid fluticasone against influenza. What virological studies have 
been conducted have primarily employed either RSV or rhinovirus. Several groups have 
reported that in primary human cells, fluticasone was able to supress RSV-induced cytokines 
(IL-6, IL-8, RANTES) without any reported effects on viral titers (Van Ly et al., 2011; Noah et 
al., 1998). However, in one paper a strong, yet non-significant trend can be seen with 
fluticasone-treated cells producing higher viral titers than their non-treated counterparts 
(Noah et al., 1998).  Further supporting this result is the observation by Puhakka et al., 
(1998) that in patients, treatment of rhinovirus infections with fluticasone resulted in a 
significant decrease in some symptoms (e.g. reduced nasal congestion and cough) but also 
had the undesired effect of resulting in prolonged viral shedding. An additional study 
conducted by Ruohola et al., (2000) found that in children infected with rhinovirus, 
significantly more subjects developed acute otitis media when treated with fluticasone 
when compared to placebo group. In summary, there is divided opinion as to the efficacy of 
using fluticasone in the context of an upper respiratory infection initiated by either RSV or 
rhinovirus. Unfortunately, we were unable to locate any peer-reviewed studies that looked 
at the effects of fluticasone when used during an influenza infection. However, the use of 
other steroids in cases of influenza infection have been published with Hu et al., (2013), for 
example, describing how employing corticosteroids led to antiviral treatment failure, the 
emergence of Oseltamivir resistance and adverse clinical outcome. It is possible that our 
results indicate that this steroid is ineffective against this virus and that a more targeted 
approach might prove more beneficial. RV1088’s targeting of certain key innate immune 
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response regulatory pathways may prove to be superior strategy, when compared to global 
suppression tactics, leading to a more favourable outcome for the host. 
In this chapter we examined the effects of RV1088 in cell cultures infected with 
influenza viruses. In the first instance, CALU-3 cells were infected at a low moi with 
A/England/195/2009 and it was determined that, while RV1088 used alone did not have a 
significant effect on viral titres, cytokine expression induced by virus infection was 
supressed at the level of transcription (1.58- and 4.76-fold decrease in IFN-β and RANTES 
respectively). M-gene, a marker of viral replication, was also supressed (3.78-fold decrease) 
but this suppression did not seem to be enough to significantly affect viral titers as 
measured by plaque assay (2.57-fold decrease). The qRT-PCR results suggest that a several 
fold difference in RNA levels have little effect on viral titres as measured by infectious unit 
on a log scale. This discrepancy could simply be explained by the innate difference in 
sensitivity that exists between these two techniques and the fact that qRT-PCR is a method 
for determining mRNA levels with no distinction made between replicative and non-
replicative viruses.  
CALU-3 cells are an immortalised lung epithelial cell line and may have alterations in 
their signalling pathways which could alter their ability to respond to pathogenic insult. 
Therefore we further assessed the effect of RV1088 on virus replication and cytokine 
induction in primary airway cells. We employed commercially available highly differentiated 
human airway epithelial cells (HAEs) as the viral target cells. These cultures are maintained 
at an air-liquid-interface, recapitulate the cellular 3-D morphology of the airways, with 
active ciliated cells and mucus secreting goblet cells. Our lab and others have previously 
shown that there exists remarkably little differences between these cultures and airway 
biopsies in terms of there transcriptional profiles and gene expression (Pezzulo et al., 2011; 
Dvorak et al., 2010). In terms of evaluating both virus replication kinetics and virally-induced 
cytokine/chemokine responses produced by the airway epithelium, highly-differentiated 
culture systems has proven to be an important and reliable tool (Schaap-Nutt et al., 2012; 
Crotta et al., 2013; Zhang et al., 2011).   
When RV1088 was applied to HAE cultures, either pre- or post-infection with low 
moi of influenza A or B virus, A/England/195/2009 or B/Florida/04/2006, there was no 
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overall significant suppression of viral replication as measured by viral titres harvested from 
the apical surface (save for the case of B/Florida/04/2006 at 24hrs p.i. when cultures pre-
treated with RV1088 resulted in a significant decrease in viral titers, p≤0.05), although 
consistently a slight trend in decreased replication was seen for the RV1088 treatment 
groups when compared to the DMSO controls. The most striking results were with respect 
to the suppression of cytokine/chemokines released from the infected cultures in apical 
washings.  In all cases, RV1088 significantly suppressed chemokine/cytokine induction. This 
is in line with work conducted by Salomon et al., (2007) where corticosterone treatments 
were found to have cytokine/chemokine suppressive properties but also had little-to-no 
effect on viral replication or survival outcome in H5N1 infected mice. 
Although RV1088 inhibited the innate immune response to the virus, we did not 
observe any increase in viral replication in this in vitro system. This might be taken to 
suggest that viral titre in not greatly regulated by the innate response induced under natural 
conditions. However, in studies where patients hospitalized with seasonal A/H1N1 and 
treated with corticosteroids, higher viral titers and prolonged viral shedding were found 
when compared to non-glucocorticoid-treated patients Lee et al., (2009). These finding are 
further reiterated in patients infected with A/H7N9 (Hu et al., 2013) and in mice infected 
with A/H5N1 (Xu, 2009) where treatment with corticosteroids resulted in an increase in viral 
titers.  Therefore an alternative explanation for our findings is that, unlike corticosteroids 
which acts by preventing the downstream transcription of genes encoding for the majority, 
if not all, proinflammatory mediators (Annane, 2011; Ehrchen et al., 2007), RV1088 is a 
narrow spectrum kinase inhibitor; targeting only a cluster of key regulatory kinases believed 
to play a role in the over-induction of the host’s innate immune response. By only targeting 
this “cluster” an over-induction of cytokines/chemokines may be prevented while leaving a 
sufficient section of the immune response untouched and thus allowing for a proportionate 
response to viral insult.  However, RV1088 did decrease the secretion of all 
cytokines/chemokines assessed (save for the protein levels of the chemokine CXCL1 which 
were unaltered, data not shown). In order to determine if any additional protein(s) are also 
unaffected, it might be necessary to perform a microarray of proteomic analysis to discover 
their identity. The other explanation is that the virus has been inhibited in addition to the 
cytokines so that on the one hand the drug removes the inhibitory cytokine that would 
Chapter 3 │Results 
 
 
- 143 - 
cause rebound of virus titre (Cyclosporine A in the context of encephalomyocarditis, for 
example (Miyamoto et al., 2001)) but at the same time the drug affects virus itself and 
inhibits virus titres. 
Upon microscopic examination of the cultures, it was apparent that RV1088 was able 
to protect infected airway cells from the development of virus induced cytopathic effects 
(CPE). In all instances, the application of drug delayed the appearance of observable CPE by 
a minimum of one day. Moreover the extent of CPE was greatly reduced when compared to 
the DMSO controls. Several groups have explored the interaction of p38 MAPK (a target of 
RV1088) with Bcl-2, a molecule with a widely recognized cellular protective mechanism 
against virally-induced apoptosis (De Chiara et al., 2006; Reed, 1994; Hinshaw et al., 1994). 
p38 MAPK-directed phosphorylation of the Thr-56 and Ser-87 residues of Bcl-2 have been 
shown to adversely affect the ability of this factor to regulate apoptosis. As reported in 
Chapter 2 employing three different methods, we did not observe any negative effects of 
RV1088 on cell viability or metabolic state potentially indicating that RV1088 has been able 
to prevent an over-induction of the apoptotic pathway by blocking the p38 MAPK-directed 
phosphorylation of Bcl-2.  
In addition, the inhibitory effect of RV1088 on virus replication, albeit mild, may also 
have contributed to delayed CPE by staving accumulation of damaging viral products. p38 
MAPK has been show to be beneficial to the virus in terms of viral entry (Marchant et al., 
2010) and viral replication (Nencioni et al., 2009). The decreased appearance of CPE in HAE 
cultures could represent the combined effects of all of these factors.  
There is mounting evidence that innate immune cells (such as lymphocytes, 
monocytes and macrophages), play a significant role in the pathogenesis of severe cases of 
influenza. Lee et al., (2009) have reported that ex vivo human PBMCs infected with seasonal 
influenza actively express cytokines and chemokines and that these levels were significantly 
correlated to plasma levels from infected individuals. Moreover, these levels dynamically 
changed throughout the course of infection. Their results indicate that immune cells may, in 
part, contribute to the host’s overall cytokine/chemokine response to an influenza infection.  
Despite the importance of cytokines and chemokines in the development of 
influenza-related pathogenesis, remarkably little is know about the cellular origin of many of 
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these vital small signalling proteins. While it is generally accepted that numerous cell types, 
including pneumocytes, macrophages, and dendritic cells, produce interferon in response to 
an influenza infection, the timing and their relative contributions were unknown (Hogner et 
al., 2013; Kaminski et al., 2012; Cheung et al., 2002). Kallfass et al., (2013) have sought to 
address the cellular origin of interferons and have reported that during the course of an 
influenza infection, vigorous interferon production is undertaken by a surprisingly small 
number of cells. The specific cell types responsible for the virally-induced synthesis of 
interferon depends on the infection time-course with various subsets of macrophages being 
the primary synthesisers at early time points (peaking at 24-48hrs p.i.) after which time, 
epithelial cells were found to take over as the major IFN-synthesis cell type. The authors 
hypothesize that the synthesis of other cytokines/chemokines in response to an influenza 
infection may follow a similar cell/time response pattern. 
This work is further supported by studies conducted by Song et al., (2013) where 
PBMCs were isolated from severely ill patients infected with A(H1N1)pdm09 and an analysis 
of their microRNA levels was performed. Their results indicate that, when compared to 
healthy controls, the microRNA levels found within PBMCs can be markedly different in 
severely ill patients. Of specific interest, was their reported finding that several miRNAs 
(miR-769-5p, miR-146b-5p, let-7g, miR-30b, miR-31, miR-361-3p, and miR-362-3p) 
implicated in supressing p38 MAPK expression were themselves suppressed in severe 
influenza cases, creating a situation where p38 might be overexpressed in those severely ill. 
The authors suggest that supressing p38 could thus be of benefit in inhibiting viral 
replication and over-induction of the innate immune response in this subset of severely ill 
patients.  
Given these findings, we investigated if RV1088 was able to suppress cytokine 
induction in immune cell types infected with pandemic H1N1. Primary peripheral blood 
mononuclear cells (PBMCs) were isolated from fresh blood acquired from human donors. 
We purposely did not further sort between cell types as there is still considerable debate in 
the field as to what role each cell type actually has during the course of an influenza 
infection (Iwasaki & Pillai, 2014; Levy et al., 2011; Thomas et al., 2006). The isolated PBMCs 
from several different donors were pooled in order to achieve a representative response. 
RV1088 suppressed cytokine/chemokine mRNA transcription and viral M-gene mRNA 
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transcription in a dose-dependent fashion. These results mirror those seen in the HAE 
culture system and thus we can propose that in both epithelial and immune cells, RV1088 
maybe targeting the virus directly as well as targeting key components of the 
cytokine/chemokine signaling cascades. Determining the exact immune cell subtype 
responsible for the production of the cytokines/chemokines that are in turn supressed by 
RV1088 could prove to be an interesting avenue for future investigation. 
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Chapter 4. RV1088 as a component of combination therapy  
 
4.1 Introduction    
 
4.1.1 Combination therapy  
 
RV1088 is capable of suppressing the transcription of cytokines and chemokines 
induced by the influenza virus in an immortalised cell line, and also in primary human airway 
cultures, without rebound in viral titre.  Any novel agent for influenza therapy is unlikely to 
be employed in a treatment setting on its own, but will rather be employed as a component 
of combination therapy in conjunction with a currently licensed antiviral. In the context of 
influenza, it is unlikely that a novel drug would be given in the absence of Tamiflu today. As 
such, we next examined how employing RV1088 in conjunction with a licensed antiviral 
might affect both viral replication and cytokine/chemokine expression. 
One approach to help combat the rise of antiviral resistance in a patient is to employ 
combination chemotherapy consisting of two or more drugs that target different viral 
components and/or host factors for which the mechanism by which resistance can arise 
differs. Using combination therapy may reduce the likelihood that resistance to a single drug 
will emerge and also lessen the potential clinical effect of that single drug resistant strain in 
the patient. The principle behind multi-drug combination therapy is that two or more drugs 
are combined to produce interactions defined as “synergistic,” “additive,” or “antagonistic” 
whereby their combined effect either exceeds, equals or is less than the sum of their 
individual effects, respectively (Suhnel, 1990).    
An additional benefit to the patient of a combination therapy approach is the 
potential for potentiation of antiviral activity and enhancement of clinical outcome by 
allowing for the doses of individual drugs to be reduced which, in turn, reduces dose-related 
toxicities and side-effects.  The use of multidrug therapy for the treatment of viral diseases 
is not novel, and the pharmacological rationale for such an approach is typified by the 
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combination treatment regime used in cases of HIV. This strategy known as HAART (highly 
active antiretroviral therapy) keeps plasma viral loads below the level of detection, prevents 
the emergence of resistance and allows for stabilization of the patient’s immune system 
(Raboud et al., 2002; Gulick, 1998). 
The aim of any combination therapy is to inhibit the selection and outgrowth of 
resistant viruses by reducing the number of overall replication cycles and by reducing the 
proportion of virions carrying the resistance mutations.  Using a mathematical model, 
Perelson et al., (2012) estimated the probability of producing drug-resistant variants during 
infection. Their results indicate that all possible single mutants are produced hundreds of 
thousands of times during the infection of a single host. While the maintenance of such 
variants within the host depends on numerous factors (drug sensitivity, fitness costs of the 
mutation, state of the host’s immune response, etc.), they predict that if antiviral therapy is 
given to enough infected individuals and the selective pressures are strong enough, drug-
resistant mutants are inevitable. If, however, one uses a dual-combination therapy, such 
that the single point mutations confer resistance to only one of the two compounds the 
odds of resistance arising is decreased and is likewise is further decreased when a triple 
therapy is employed.  
Several studies have been conducted to assess the effects of both double and triple 
drug combinations on influenza infection in vitro using drugs previously shown to have anti-
influenza properties (Table 4). 
Currently, the mouse model is the most accepted animal model for the evaluation of 
antiviral drug combinations (Govorkova & Webster, 2010). Leneva et al., (2000) conducted 
one study where Oseltamivir was used in conjunction with either amantadine or 
Rimantadine in mice inoculated with either A/H5N1 or A/H9N2. Their results demonstrated 
that combination therapy was more effective than monotherapy in preventing death and 
further support similar results seen by other groups (Ilyushina et al., 2008; Wilson et al., 
1980). 
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Table 4. Effect of double drug combinations on different influenza subtype infections in 
vitro. Adapted from: Govorkova & Webster, 2010.  
 
 
A different and relatively new approach has been to combine directly acting antiviral 
agents with use of an immune modulating agent with the rational being that such an 
approach could simultaneously tackle excessive vial replication and excessive cytokine 
induction that leads to the cytokine storm driven immunopathology. 
In a paper by Zheng et al., (2008), mice were inoculated with a high titre of A/H5N1 
and treated with either triple therapy, including a combination of Relenza and two inhibitors 
of inflammation (Celecoxib and Mesalazine), or just Relenza alone. The triple therapy group 
had a significantly better survival rate, survival time and levels of inflammatory markers 
than the group receiving only the monotherapy. This result is further supported by a study 
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conducted in the cotton rat model where a neuraminidase inhibitor was used in conjunction 
with a range of doses of corticosteroids. The effect was the inhibition of inflammatory cell 
recruitment to the lung and suppression of proinflammatory mediators in a dose dependent 
manner without an effect on viral clearance (Ottolini, 2003). Importantly for the current 
study, Haasbach et al., (2013) have reported a synergistic inhibition of virus replication 
when A(H1N1)pdm09 was treated with a combination of Oseltamivir plus a MEK (mitogen-
activated protein kinase kinase)-inhibitor in vitro although a mechanism has yet to be 
proposed. While preliminary, this result indicates that conventional treatments in 
combination with kinase inhibitors specific for host targets could have a role in influenza 
chemotherapy strategies.   
It is important to note however, that most drug studies involving 2 or more drugs 
have employed viruses that are sensitive to all drugs administered; rarely has a resistant 
strain been employed (Govorkova & Webster, 2010). One study conducted by Smee et al., 
(2009) found that using amantadine and Oseltamivir carboxylate, in combination against the 
amantadine-resistant strain of A/H5N1 (A/Duck/MN/1525/81), had no additive or 
synergistic effect on viral replication in MDCK cells. 
A few clinical trials have also sought to examine the potential of using combination 
therapy in patients infected with the flu virus. Ison and colleagues (2003) conducted a 
double-blind, randomized, placebo-controlled trial to access the efficacy of using 
Rimantadine plus either nebulized Relenza or nebulized saline to treat patients infected with 
non-resistant A/H3N2. The results of this study demonstrated that patients treated with the 
Rimantadine plus Relenza combination therapy had a non-significant trend towards fewer 
days of virus shedding and improved symptomology scores when compared to the 
monotherapy plus saline group. Furthermore, two out of eleven patients in the 
monotherapy group developed resistance to Rimantadine while no resistance arose in the 
combination therapy group. Another study conducted by Morrison et al., (2007) importantly 
indicates that the pharmacokinetics of Oseltamivir (75mg po bd) are not affected by 
concomitant use of amantadine (75mg po bd) and vice versa. Furthermore, there was no 
evidence of an increase in reports of adverse side-effects when these two classes of drugs 
were used in combination at normal dosing levels. 
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4.2 Results    
4.2.1 Identification of synergistic activity 
There are numerous examples of anti-influenza agents working either additively or 
synergistically when used in combination. To examine the potential of RV1088 to work in 
combination with known and proven anti-influenza drugs, CALU-3 cells (human epithelial, 
lung adenocarcinoma line) and HAE cultures (primary airway cell culture were employed.  
A method commonly used to analyse the synergistic effect of a drug when used in 
combination with other drugs is the combination index (CI) theorem of Chou-Talalay. This 
test used the quantitative definitions of antagonism (CI >1), additive effect  (CI=1), and 
synergistic effect (CI < 1) in drug combination (Chou, 2010).  The median-effect equation 
(MEE) works by combining enzyme kinetics and specific mechanisms from hundreds of 
individual equations and reduces them to a single general equation. Both left and right sides 
of the MEE are dimensionless quantities. When the m (slope) and Dm (half-affected dose) 
are determined, the full dose-effect curve is defined. As the median-effect plot yields 
straight lines, the theoretical minimum of only two data points allow the drawing of the full 
dose-effect curve. Using a specific software program which employs the Chou-Talalay 
theorem equations (CalcuSyn, Biosoft - Cambridge, UK), we examined the relationship 
produced by RV1088 when used in combination with Relenza.  
The presence of synergy against A/England/195/2009 (A(H1N1)pdm09) (moi = 
0.0001) was determined from the results of 9 experimental drug combination each in 
triplicate performed in airway cells. In terms of drug doses, the Relenza dose was held 
constant at 3.009nM while the concentration of RV1088 were varied until the ED50, ED75 
and ED90 was determined (0.75nM, 1.0nM and 1.73nM respectively – data not shown).  
These predetermined drug combinations were applied to the airway cell cultures for three 
days prior to infection. 48hrs post infection, culture supernatants were taken and used to 
determine viral titer levels via plaque assay in MDCK cells. The results from these plaque 
assays was then in turn inputted into the Chou-Talalay theorem software. As indicated in 
Table 5, a combination of RV1088 and Relenza led to very low CI  values indicating that a 
very strong synergistic anti-viral effect exists when these two drugs are used in combination. 
This synergistic effect is also represented visually by the median-effect plot (Figure 38).  
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Table 5: Combination index for RV1088 and Relenza when used against influenza virus 
replication. 
 
CI  values at: 
   Drug ED50 ED75 ED90 Dm m r 
       RV1088  ----  ----  ---- 3.83E+08 0.597 0.918 
Relenza  ----  ----  ---- 8.62E+05 0.414 0.995 
RV1088+Relenza 1.76E-06 1.48E-07 1.25E-08 7.94E-01 6.289 0.917 
For each drug, and combination there of, the Chou-Talalay method for drug combination was used to calculate 
the median effect equation. The resulting combination index (CI) theorem of Chou-Talalay offers quantitative 
definition for antagonism (CI >1), additive effect  (CI=1), and synergistic effect (CI < 1) in drug combination. 
ED50, 75 and 90 are the dose at which 0.75nM, 1.0nM and 1.73nM of RV1088 in the presence of a constant 
concentration of Relenza (3.009nM) respectively inhibited viral growth, Dm = the median-effect dose signifying 
potency, m = an exponent signifying the sigmoidicity (shape) of the dose-effect curve and r = linear correlation 
coefficient of the goodness of fit for the data to the median-effect equation (a value of r>0.90 is typically 
expected when tissue/cell cultures have been employed). 
                                  
Figure 38: The median-effect plot of RV1088 when used in combination with Relenza. The 
transformation of data using the median-effect equation allows for the calculation of the level of 
growth inhibition at a given dose. The dose-response relationship is displayed as a linear regression 
line (for RV1088+Relenza, r = 0.917). The x-intercept of the median effect-plot represents the 
median effect dose (Dm, ED50) at which a 50% growth inhibition (Fa = 0.5) occurs. Fa, affected 
fraction; Fu, unaffected fraction; D, dose. 
 
Chapter 4 │Results 
 
 
- 152 - 
Further combination experiments were undertaken employing RV1088 in 
combination with several other licenced antivirals. The known antivirals chosen for these 
experiments were Relenza, Rimantadine and Oseltamivir that are representative of the two 
major classes of anti-influenza agents (the NA-inhibitors and the M2-inhibitors). The virus 
chosen for these experiments was a mutated variant of A/England/195/2009 
(A(H1N1)pdm09) known as M2S31N. During 2009 H1N1 pandemic, a mutation in the M2 
gene (N31S) naturally arose conferring sensitivity to Rimantadine while at the same time not 
adversely effecting viral replication. We back engineered this mutation into our prototypic 
A(H1N1)pdm09 virus (A/England/195/2009)  to render it susceptible to Rimantidine for the 
purposes of being able conduct our synergy studies with the same virus that was sensitive to 
Relenza, Rimantadine and Oseltamivir. As expected, the virus carrying this mutation did not 
display any adverse effects in terms of replication (data not shown). 
 
In our synergy experiments, the concentrations for each licensed drug employed was 
based on previously reported IC50 values and the concentration of RV1088 was chosen 
through consultation with our collaborators at RespiVert as 1.73nM. In Calu-3 cells, all three 
licensed drugs inhibited viral replication. At time point where maximal inhibition was 
observed, Relenza, Oseltamivir and Rimantadine treatments resulted in an average log 
reduction in titers of 3.8, 4 and 4.22-fold respectively (Figure 39).  On the other hand, the 
maximum fold reduction from RV1088 when used on its own was 1.23, thus reinforcing the 
results in Section 3.2 that the drug has a small but insignificant antiviral effect. In contrast 
there was a significant suppressive effect of RV1088 when used in combination with a 
licenced anti-viral. In each instance, the use of combination treatment resulted in a dramatic 
suppression of viral replication with the combinations of Relenza+RV1088, 
Oseltamivir+RV1088 and Rimantadine+1088 resulting in average maximum log fold 
reductions in titers of 5.44-, 1.85- and 5.65-fold respectively. 
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Figure 39: Inhibition of influenza virus replication by combinations 
of drugs. CALU-3 cells were infected with A/England/195/2009 ± 
N31S mutation to confer sensitivity to Rimantadine (moi = 0.0001) 
in the presence or absence of various drug combinations: (a) 
RV1088 (1.73nM) ± Relenza (3.009nM), (b) RV1088 (1.73nM) ± 
Rimantadine (40uM) and, (c) RV1088 (1.73nM) ± Oseltamivir 
(12nM). Culture supernatant was harvested at 24 and 48hrs p.i. and 
plaqued on MDCKs. Results represent the averge of triplicate 
samples from two independent experiments. 
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4.2.2 Studying the effects of combination treatment on cytokine/chemokine induction in 
CALU3s 
 
To examine the effect of the drug combination therapies on cytokine/chemokine 
expression, total RNA was extracted from cultures at 24hrs p.i and qRT-PCR was performed 
(Figure 40).  What is evident from these results is that the strong induction of transcription 
of mRNAs for cytokines and chemokines by virus alone was significantly reduced in the 
presence of RV1088, or Rimantadine, when used on their own, but not by the NA inhibitors. 
Specifically, RV1088 reduced the transcription of IFN-β by 1.43-fold and RANTES by 3.4-fold 
while Rimantidine was able to inhibit IFN-β and RANTES transcription by 1.1- and 1.87-fold 
respectively.  Oseltamivir when used alone, in fact, had the opposite effect and was 
responsible for an increase in cytokines/chemokine mRNA levels (a 0.8-fold increase with 
respect to IFN-β transcription).  However, regardless of the antiviral used, the suppressive 
action of RV1088 plus a licensed anti-viral against the transcription of cytokine/chemokine 
mRNA was either greater than, or equal to, the suppressive effect generated by using two 
antivirals (an M2-inhibitor + and an NA-inhibitor) in combination (Figure 40, part b).  
Specifically, the combination of Rimantadine+Oseltamivir resulted in a 3.38-fold decrease in 
the transcription of IFN-β mRNA and a 1.38-fold decrease for RANTES mRNA. In contrast the 
combinations of RV1088+Rimantadine resulted in a 2.88-fold reduction for IFN-β and a 2.22-
fold reduction for RANTES mRNA while the RV0188+Oseltamivir combination resulted in a 2- 
and 10.6-fold reduction for IFN-β and RANTES mRNAs respectively.  
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Figure 40: Quantitation of induced mRNAs for representative cytokine and chemokine 
following infection of CALU-3 with influenza virus in presence of drug combinations. Total 
RNA was extracted from CALU-3 cells 24hrs p.i.  with A/England/195/2009  M2 N31S mutant 
at moi = 0.0001 and qRT-PCR was performed using standardised primers and probes. At the 
time of infection, cells were treated with either (a) RV1088 (1.73nM) ± Oseltamivir (12nM) 
or (b) RV1088 (1.73nM) ± Rimantadine (40μM). Results are expressed as the mean ± 
standard deviation of triplicate samples.  
 
 
 
Chapter 4 │Results 
 
 
- 156 - 
4.2.3 Treatment of HAE cultures with RV1088 in combination with licenced antivirals prior 
to infection with A(H1N1)pdm09. 
 
To further examine the potential of using RV1088 as a component of a combination 
therapy, HAE cell cultures were employed. A/England/195/2009 (A(H1N1)pdm09, N31S or 
wild-type depending on the specific drug being tested) was chosen to act as the 
representative type A virus. As seen previously, RV1088 had a small inhibitory effect on viral 
replication that was not significant when used alone while Relenza was able to significantly 
reduce the level of viral replication by 1000-fold at 48 hours post infection. When these two 
drug compounds were used in conjunction, there was a significant suppression of viral 
replication which was greater than the level observed for either individually resulting in a 
1.55x105-fold reduction in titers at 48hrs p.i. (Figure 41, part a).  
The same apical washings were used to quantify cytokine/chemokine protein levels 
quantification using a Luminex™ platform (Figure 41, parts b-d). The results demonstrated 
that RV1088, when used alone, significantly suppressed cytokine/chemokine protein levels. 
In comparison, Relenza when used on its own suppressed protein expression for IP-10 and 
IL-6 to varying degrees but had no significant effect on the expression levels of IL-8. 
Combination treatment, on the other hand, resulted in near complete suppression of the 
expression of IP-10 and IL-6 while IL-8 expressions levels remained around those seen in the 
RV1088 alone treatment group.    
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Figure 41: Virus replication after pre-infection treatment with 
RV1088±Relenza in HAEs infected with A/England/195/2009. HAE cell 
cultures were pre-treated for three days both apically and basally with 
RV1088 (1.73nM) ± Relenza (3.009nM) or DMSO (0.5%). Cultures were 
infected with A/England/195/2009 (moi = 0.0001, 1hr 37°C). After infection, 
fresh drugs were applied apically (2hrs, 37°C then removed) and added to 
the basal media for the duration of the experiment. Culture supernatant 
was harvested at specified time points and used in the determination of 
viral replication by being plaqued on MDCKs (a) and for quantification of 
cytokine/chemokine protein expression via Luminex (b-d). Results are 
expressed as the mean ± standard deviation of triplicate samples. 
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4.2.3.1 Treatment of HAE cultures with combination therapy delays the onset of 
A(H1N1)pdm09-related CPE 
 
In order to determine if the combination of RV1088 with Relenza had any effect on 
the development of CPE in the HAE culture system caused by A/England/195/2009 
(A(H1N1)pdm09), cells were examined under 20x microscopy each day for the duration of 
the experiment. Representative micrographs (Figure 42) demonstrate that in this culture 
code RV1088 treatment delayed the onset of observable CPE to day 3 p.i, one day later than 
for the Relenza alone treatment group. Furthermore, the extent of CPE in infected cells 
treated with RV1088 at day 5 p.i. was less than the CPE seen for the Relenza group on day 2 
p.i. Quite remarkably, in the RV1088/Relenza combined treatment group, the emergence of 
observable CPE was prevented until day 4 p.i. and even then was quite limited in nature.       
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Figure 42: RV1088 delays the onset of viral-induced cytopathology in HAE cultures 
infected with A/England/195/2009. HAE cell cultures were pre-treated for three days both 
apically and basally with RV1088 (1.73nM) ± Relenza (3.009nM) or DMSO (0.5%). Cultures 
were infected with A/England/195/2009 (moi = 0.0001, 1hr 37°C). After infection, fresh 
drugs were applied apically (2hrs, 37°C then emoved) and added to the basal media for the 
duration of the experiment. At set time point, cultures were examined and representative 
samples photographed at 20x magnification. Arrows mark sites of evident CPE. Results 
presented are from one representative well from a set of three. 
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4.2.4 Treatment of HAE cultures with RV1088 in combination with licenced antivirals prior 
to infection with B/Florida/04/2006. 
 
The effectiveness of combination therapy employing RV1088 was examined against 
a type B influenza virus. B/Florida/04/2006 was chosen as a representative type B virus of 
the currently circulating B Yamagata lineage. RV1088 had no significant effect on type B viral 
replication when used alone. Interestingly, Relenza when used alone, did not decrease 
replication at the earliest time point. However, when these two drug compounds were used 
in conjunction, there was a significant suppression of viral replication (Figure 43, part a).  
The same apical washings were used to quantify cytokine/chemokine protein levels 
quantification using a Luminex™ platform (Figure 43, parts b-d). The results demonstrated 
that RV1088 alone significantly suppressed cytokine/chemokine protein levels. In 
comparison, Relenza used on its own, suppressed protein expression for IP-10 and IL-6 to 
varying degrees but had no significant effect on the expression levels of IL-8. Combination 
treatment, on the other hand nearly completely suppressed the expression of IP-10 and IL-6 
while IL-8 expressions levels remained around those seen in the RV1088 alone treatment 
group.    
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Figure 43: Virus replication after pre-infection treatment with 
RV1088±Relenza in HAEs infected with B/Florida/04/2006. HAE cell 
cultures were pre-treated for three days both apically and basally 
with RV1088 (1.73nM) ± Relenza (3.009nM) or DMSO (0.5%). 
Cultures were infected with B/Florida/04/2006 (moi = 0.0001, 1hr 
37°C). After infection, fresh drugs were applied apically (2hrs, 37°C 
then removed) and added to the basal media for the duration of the 
experiment. Culture supernatant was harvested at specified time 
points and used in the determination of viral replication by being 
plaqued on MDCKs (a) and for quantification of cytokine/chemokine 
protein expression via Luminex (b-d). Results are expressed as the 
mean ± standard deviation of triplicate samples. 
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4.2.4.1 Treatment of HAE cultures with combination therapy delays the onset of 
B/Florida/04/2006-related CPE 
 
To assess the ability of RV1088±Relenza to delay the development of CPE in the HAE 
culture system caused by B/Florida/04/2006, cells were examined under 20x microscopy 
each day for the duration of the experiment. Representative micrographs (Figure 44) 
demonstrated that, RV1088 treatment delayed the onset of observable CPE to day 4 p.i, 2 
days later than for the Relenza treatment group. Furthermore, the extent of CPE in infected 
cells treated with RV1088 at day 5 p.i. was far less than the CPE seen for the Relenza group 
on day 2 p.i. For the RV1088/Relenza combined treatment group, the emergence of 
observable CPE was prevented until day 2 p.i. and even then, was quite limited in nature 
and its progression, indeed until day 4 p.i. was greatly restricted.  
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Figure 44: RV1088 delays the onset of viral-induced cytopathology in HAE cultures 
infected with B/Florida/04/2006. HAE cell cultures were pre-treated for three days both 
apically and basally with RV1088 (1.73nM) ± Relenza (3.009nM) or DMSO (0.5%). Cultures 
were infected with B/Florida/04/2006 (moi = 0.0001, 1hr 37°C). After infection, fresh drugs 
were applied apically (2hrs, 37°C then removed) and added to the basal media for the 
duration of the experiment. At set time point, cultures were examined and representative 
samples photographed at 20x magnification. Arrows mark sites of evident CPE. Results 
presented are from one representative well from a set of three. 
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4.2.5 Treatment of HAE cultures with RV1088 in combination with licenced antivirals prior 
to infection with A/Sydney/5/1997 (A/H3N2). 
 
To further augment the evaluation of combination therapy treatments employing 
RV1088 against influenza, we expanded the viral panel to include another type A virus, 
A/H3N2 (A/Sydney/5/1997).  Using HAE cultures (reconstituted from a different donor due 
to supply issues), we conducted the experiment in an identical manner as previously 
described. RV1088 and Relenza displayed similar patterns as before (Sections 4.2.3 and 
4.2.4) having no effect and a minor suppressive effect on virus replication respectively 
(Figure 45). While not as pronounced as seen for either A/England/195/2009 
(A(H1N1)pdm09) or B/Florida/04/2006, the combination treatment group 
(RV1088+Relenza) followed a similar trend, suppressing viral replication to an extent greater 
than either drug when used alone. 
                           
 Figure 45: Viral replication after pre-infection treatment with RV1088 in HAEs infected 
with H3N2. HAE cell cultures were pre-treated for three days both apically and basally with RV1088 
(1.73nM) ± Relenza (3.009nM) or DMSO (0.5%). Cultures were infected with A/Sydney/5/1997 
(H3N2, moi = 0.0001, 1hr 37°C). After infection, fresh drugs were applied apically (2hrs, 37°C then 
removed) and added to the basal media for the duration of the experiment. Culture supernatant was 
harvested at specified time points and used in the determination of viral replication by being 
plaqued on MDCKs. Results are expressed as the mean ± standard deviation of triplicate samples. 
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In addition to viral quantification, the same apical washings were also used for 
cytokine/chemokine protein level quantification using a Luminex™ platform (Figure 46). The 
results demonstrated that RV1088 significantly suppressed cytokine/chemokine protein 
levels induced by A/Sydney/5/1997. Relenza when used to treat cells on its own, suppressed 
protein expression of RANTES and of IL-6, and IP-10 at early time points. However, Relenza 
was found to have no significant effect on the expression levels of IL-8 and at later time 
point, actually resulted in increased levels of IL-6, IL-8, and IP-10 production when 
compared to the untreated infected group. Combination treatment, on the other hand, 
nearly completely suppressed the expression of IL-6, IL-8, IP-10 and RANTES to the level 
secreted from uninfected cells.  
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Figure 46: Cytokine and chemokine protein levels after pre-infection treatment with 
RV1088 in HAEs infected with H3N2. HAE cell cultures were pre-treated for three days both 
apically and basally with RV1088 (1.73nM) ± Relenza (3.009nM) or DMSO (0.5%). Cultures 
were infected with A/Sydney/5/1997 (H3N2, moi = 0.0001, 1hr 37°C). After infection, fresh 
drugs were applied apically (2hrs, 37°C then removed) and added to the basal media for the 
duration of the experiment. Culture supernatant was harvested at specified time points and 
used for quantification of cytokine/chemokine protein expression via Luminex. Results are 
expressed as the mean ± standard deviation of triplicate samples.  
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4.2.6 Treatment of HAE cultures with RV1088 in combination with licenced antivirals prior 
to infection with B/Malaysia/2506/2004. 
 
Expanding the viral panel even further, an additional type B virus, 
B/Malaysia/2506/2004 that is representative of the other circulating lineage B Victoria, was 
employed.  Using HAE cultures reconstituted from the same donor as those used in Section 
4.2.5, the experiment was conducted following previously described protocols. RV1088 and 
Relenza displayed similar patterns demonstrated previously (Sections 4.2.3 and 4.2.4) 
having no effect and only a minor suppressive effect on virus replication respectively. The 
combination treatment group (RV1088+Relenza) suppressed viral replication to a greater 
extent than either drug when used alone to a similar proportion seen for A/H3N2 
(A/Sydney/5/1997) (Figure 47). Intriguingly for both viruses (A/Sydney/5/1997 and 
B/Malaysia/2506/2004) the complete suppression of viral replication observed for other 
viruses in the RV1088+Relenza treatment groups was not seen. As both of these former 
viruses were tested in HAE wells derived from the same donor, it is possible that these 
results might represent donor-to-donor variation. In the future, it might be advisable for 
these viruses to be tested in a mixed donor set.     
Apical washings were also used for cytokine/chemokine protein level quantification 
using a Luminex™ platform (Figure 48, parts b-d). The results demonstrated that RV1088, 
significantly suppressed cytokine/chemokine protein levels induced by 
B/Malaysia/2506/2004. Relenza, when used to treat cells on its own, suppressed protein 
expression for RANTES but had no significant effect on the expression levels of IP-10 at the 
majority of time points examined. Strikingly and as noted above, Relenza actually resulted in 
increased levels of IL-6, and IL-8 protein production when compared to the untreated 
infected group. Combination treatment, on the other hand, suppressed the expression of IL-
6, IL-8, IP-10 and RANTES almost to the level of the uninfected cells.  
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Figure 47: Viral replication after pre-infection treatment with RV1088 in HAEs infected 
with B/Malaysia/2506/2004. HAE cell cultures were pre-treated for three days both apically 
and basally with RV1088 (1.73nM) ± Relenza (3.009nM) or DMSO (0.5%). Cultures were 
infected with B/Malaysia/2506/2004 (moi = 0.0001, 1hr 37°C). After infection, fresh drugs 
were applied apically (2hrs, 37°C then removed) and added to the basal media for the 
duration of the experiment. Culture supernatant was harvested at specified time points and 
used in the determination of viral replication by being plaqued on MDCKs. Results are 
expressed as the mean ± standard deviation of triplicate samples. 
 
 
 
 
Chapter 4 │Results 
 
 
- 169 - 
                       
 
 
Figure 48: Cytokine and chemokine protein levels after pre-infection treatment with 
RV1088 in HAEs infected with B/Malaysia/2506/2004. HAE cell cultures were pre-treated 
for three days both apically and basally with RV1088 (1.73nM) ± Relenza (3.009nM) or 
DMSO (0.5%). Cultures were infected with B/Malaysia/2506/2004 (moi = 0.0001, 1hr 37°C). 
After infection, fresh drugs were applied apically (2hrs, 37°C then removed) and added to 
the basal media for the duration of the experiment. Culture supernatant was harvested at 
specified time points and used for quantification of cytokine/chemokine protein expression 
via Luminex. Results are expressed as the mean ± standard deviation of triplicate samples.  
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4.2.7 Treatment of HAE cultures with RV1088 in combination with licenced antivirals prior 
to infection with A/Turkey/2005:PR8 (6:2) (A/H5N1). 
 
The final virus assessed in HAE for combination treatment was an A/H5N1 
(A/Turkey/05:PR8-6:2 reassortment) virus.  This particular virus was chosen due to its 
reported ability to be a high inducer of the human innate immune response.  Using HAE 
cultures reconstituted from the same donor as those used in Section 4.2.3, the experiment 
was conducted following previously described protocols under a high containment setting. 
RV1088 and Relenza had no effect and a minor suppressive effect respectively on virus 
replication (Figure 49). Importantly, when RV1088 and Relenza were used in combination, 
they suppressed viral replication to a significant extent and were far superior than the effect 
observed for either drug when used alone. Due to high containment (CAT-3) requirements 
and regulations, an examination of cytokine/chemokine protein levels via Luminex™ was 
not possible. 
                            
Figure 49: Viral replication after pre-infection treatment with RV1088 in HAEs infected 
with A/Turkey/05:PR8 (6:2). HAE cell cultures were pre-treated for three days both apically 
and basally with RV1088 (1.73nM) ± Relenza (3.009nM) or DMSO (0.5%). Cultures were 
infected with A/Turkey/Turkey/05/2005 (moi = 0.01, 1hr 37°C). After infection, fresh drugs 
were applied apically (2hrs, 37°C then removed) and added to the basal media for the 
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duration of the experiment. Culture supernatant was harvested at specified time points and 
used in the determination of viral replication by being plaqued on MDCKs. Results are 
expressed as the mean ± standard deviation of triplicate samples. 
  
4.3 Discussion and Conclusions. 
 
Within this chapter, we sought to examine the potential of using RV1088 in 
conjunction with licenced influenza antivirals, evaluating this potential in both terms of 
cytokine/chemokine suppression quantified via qRT-PCR and Luminex and effect on viral 
replication as measured by plaque assay.  
The use of combination therapy might potentiate antiviral activity, decreasing the 
likelihood of resistant strains emerging and enhancing clinical outcome (Raboud et al., 2002; 
Gulick, 1998; Suhnel, 1990). Furthermore, combination therapy often allows for lower doses 
of the individual constituents in order to obtain an effect superior to either constituent used 
alone at a higher dose thus decreasing dose-related toxicities and side effects. As discussed 
in the chapter introduction, numerous studies have been performed examining the 
potential of employing combination therapy in cases of influenza. Thus far, the published 
reports have been very favourable but surprisingly this practise is rare in the clinic, with 
antivirals often being used singly and one after the other in severe cases. Most studies have 
combined directly acting antivirals. To our knowledge, however, no clinical study has yet 
been undertaken which has examined the potential effects on cytokine/chemiokine 
expression and viral replication by a kinase inhibitor used in conjunction with a licenced 
antiviral.  
Our first set of experiments were based in CALU-3 cells and employed RV1088 used 
in combination with Relenza, Rimantadine or Oseltamivir. The doses chosen were based on 
the specific drugs’ reported IC50.  In these experiments, we opted to employ A(H1N1)pdm09 
(A/England/195/2009) into which we engineered a mutation in the M2 gene (N31S). The 
S31N mutation in the M2 protein arose naturally during in swine viruses prior to the 
emergence of 2009 influenza pandemic and confers resistance to Rimantadine.  By reverse 
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genetics we generated a back mutant that restored sensitivity to the M2 inhibitors. The 
rational behind this approach was to allow synergy testing against a currently circulating 
virus that was sensitive to both classes of antivirals (M2- and NA-inhibitors). Importantly this 
mutation does not adversely effecting viral replication (Elderfield and Cocking personal 
communication).  
All three licenced drugs suppressed viral replication by several logs as expected. 
RV1088, when used alone, resulted in very little virus suppression, in line with previous 
results. However, when a conventional antiviral and RV1088 were used jointly, a striking 
and almost complete suppression of viral replication was noted. A qRT-PCR analysis of 
cytokines/chemokines mRNA levels demonstrated that infection of the CALU-3 cultures with 
A/England/195/2009 resulted in a strong induction of cytokines and chemokines that was 
supressed by RV1088 and, to an even greater extent, when RV1088 was used in conjunction 
with another antiviral. Furthermore, this level of inhibition observed in the RV1088+antiviral 
group was greater than that observed in the group where two antivirals were used in 
combination (Oseltamivir and Rimantadine). Interestingly, in some cases where NA 
inhibitors were used alone, the level of cytokines/chemokines was either unchanged or 
greater than the virus alone groups. This lack of change or increase in cytokines/chemokines 
in the antiviral treated conditions occurred despite viral replication concurrently being 
decreased. This phenomenon, while en face may be viewed as being counterintuitive, has 
previously been documented in the literature (Zheng et al., 2008; Ilyushina et al., 2008).  
This phenomenon may hold significant implications in terms of treating severe cases 
influenza with this class of antiviral which, could potentially potentiate an over-induction of 
the innate immune response resulting in a “cytokine storm”. This progression to an un-
regulated innate immune response has been linked to detrimental clinical prognosis and 
outcomes especially when bacterial co-infection occurs (Annane, 2011; Small et al., 2010; 
Madhi et al., 2008; Seki et al., 2007).  
While puzzling at first, this phenomenon, may be explained by examining how this 
drug class (NA-inhibitors) is believed to work. The neuraminidase inhibitor class of antivirals 
acts by inhibiting the activity of the NA glycoprotein preventing the release of progeny 
viruses from the replicative cell. This results in the accumulation of numerous virions both 
within the cell and on the cellular surface (Lee et al., 2012; Gubareva, 2004).  Each 
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“trapped” virion might then stimulate an immune response either by binding to some 
extracellular receptor, or by re-entering the same cells and being detected as a PAMP. The 
sum of these individual immunological-stimulating effects might overwhelm cellular 
suppressive effects resulting in an increased transcription of cytokine/chemokine mRNAs.  
Contradicting this explanation are results from a recent Cochrane review (Jefferson 
et al., 2014) which has suggested that Oseltamivir carboxylate, may reduce the symptoms of 
influenza via a manner believed to be unrelated to the inhibition of influenza virus 
replication and thus contrary to commonly held beliefs. Citing Hayden et al., (1999), the 
authors put forward evidence that the main symptomatic relief of Oseltamivir stems from 
the drugs ability to suppress components of the host’s innate immune response. This 
suppression including certain pro-inflammatory cytokines (including: IL-6, TNF-α and IFN- γ) 
that, when Oseltamivir is administered 28 hours after experimental inoculation of influenza 
virus, complete suppression occurs while the reduction of viral titre in nasal lavages is only 
partial. In further support of this is work conducted by Ono and colleagues in which they 
postulated that the potential hypothermic or antipyretic effect observed in in mice treated 
with Oseltamivir may be due to the ability of this drug to act as a central nervous system 
depressant; and in this way contribute to the apparent reduction of host symptomology 
(Ono et al., 2013; Ono et al., 2008).   
Despite this mounting evidence, the Cochrane reviewers admit that the majority of 
their postulates and conclusions about interactions with Oseltamivir and the immune 
system are based on data collected from animal experiments (primarily mice).  Evidence 
from human trials is sparse and data for influenza negative population conducted by the 
pharmaceutical companies during initial testing of Oesltamivir has not been released. Until a 
full review of all data can be conducted, the questions whether NAIs do affect the immune 
response and how remain. 
To date, we have been unable to find any reports in the literature that have 
examined the effect of Oseltamivir on cytokine/chemokine levels in HAEs infected with 
influenza. As the HAE system does not contain immune cells (e.g. macrophages) which, in 
response to influenza infections, are believed to be the major producers of 
cytokines/chemokines (Kallfass et al., 2013) it is possible that the immunosuppressive 
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effects reported in the Cochrane review (inferred from in vivo models) do not apply to 
epithelial cells but rather target these immune effector cells. As such, any 
immunomodulation would be missed in this particular in vitro model.  An examination of 
potential immunomodulatory effect of Oseltamivir in PBMC cultures infected with influenza 
virus could help address this issue and represents a potential avenue for future study. An 
additional area of investigation would employ using Oseltamivir (either alone or in 
combination with RV1088) in the presence of an Oseltamivir-resistant influenza virus and 
quantify cytokine/chemokine expression as well as viral replication kinetics. 
In order to determine if the inhibitory effect on virus replication observed when 
RV1088 and Relenza was used in combination was additive or synergistic, we employed the 
well-established principles of the combination index (CI) theorem of Chou-Talalay (Chou, 
2010). This test uses the median-effect equation (MEE) and works by combining enzyme 
kinetics and specific mechanisms from hundreds of individual equations and reduces them 
to a single general equation. Both left and right sides of the MEE are dimensionless 
quantities. When the m (slope) and Dm (half-affected dose) are determined, the full dose-
effect curve is defined. By using a specific software program which employs the Chou-
Talalay theorem equations (CalcuSyn, Biosoft - Cambridge, UK), we were able to determine 
that the relationship produced by RV1088 when used in combination with Relenza is very 
strongly synergistic in nature (Table 5 and Figure 38).  
After ascertaining the effectiveness of combination therapy in the CALU-3 system, 
we progressed to test the efficacy of combinations of RV1088 and the neuraminidase 
inhibitor drug Relenza to inhibit replication and induced cytokines in highly differentiated 
human airway epithelial cells (HAEs). We have previously demonstrated that in this system 
RV1088, when used alone, in cells infected with A/England/195/2009 of B/Florida/04/2006 
supressed the induction of cytokines/chemokines but had no significant effect on viral 
replication.   
For both A/England/195/2009 and B/Florida/04/2006 we observed significant 
suppression of cytokine/chemokine induction at, or below, the level seen for RV1088 or the 
antiviral when used alone. In addition, and mirroring the results seen in the CALU-3 culture 
system, combination therapy resulted in significant suppression of viral replication. Upon 
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examination of the cultures under magnification, a remarkable level of cellular protection by 
RV1088 was observed in comparison to the Relenza treatment group. The level of cellular 
protection was greatly augmented in the combination treatment cells. This result may 
indicate much of the cell damage during infection of the HAE cells is mediated by the 
cytokine response induced rather than directly by replicating virus.  The moderation of 
cellular damage could play an important role in vivo by decreasing recruitment signals for 
extra immune cells that otherwise may mediate immunopathology.  
     
 Chapter 5 │Results 
   
- 176 - 
 
Chapter 5. RV1088 in the animal model 
 
5.1 Introduction    
5.1.1 The animal model for influenza 
 
After demonstrating that RV1088 was capable of suppressing cytokines and 
chemokines as well as virus replication in an immortalised cell line and primary human 
airway cultures, we wanted to examine how this compound might affect viral replication 
and cytokine/chemokine expression in vivo. 
Animal models have been employed by researchers to explore normal physiology 
states, the pathophysiology of diseases, both infectious and inborn, and the safety and 
efficacy of novel therapies in preclinical studies. In terms of lung-related biomedical studies, 
animal models have been developed for an array of human diseases including asthma, 
pneumonia, cystic fibrosis, acute lung injury and respiratory infections including influenza. 
All animal models have inherent limitations as the normal anatomy and physiology of the 
lung differs among species as does the innate and adaptive immune responses to pathogen 
insult. 
Animal models for influenza are vital to understanding the pathogenicity of the 
influenza virus and therapeutic treatments. Despite the diverse array of mammalian species 
susceptible to the influenza virus, only a few species are considered amenable for study in 
the laboratory. These species, which includes the ferret, the mouse, the cotton rat and the 
guinea pig, have their own inherent advantages and limitations that must be carefully 
considered before use. 
The first human influenza virus was isolated from ferrets in 1933 by Smith, Andrews 
and Laidlaw after the ferrets were intranasally inoculated with filtered throat washings from 
patients with influenza (Smith, 1933). Since then, the ferret model has been used 
extensively for studying the transmission and pathogenesis of influenza viruses (O’Donnell & 
Subbarao, 2011). Ferrets are susceptible to a wide array of human influenza viruses that do 
not require prior adaptation to the species (in contrast to mouse models). Like humans, 
   Chapter 5 │Results 
 
 
- 177 - 
ferrets demonstrate primarily an upper respiratory tract infection when infected with 
seasonal strains. This is most likely due to the ferret having the similar distribution as 
humans do of sialic acids along their respiratory tract (Jia et al., 2014). The distribution of 
SAα2,6 and SAα2,3 within the respiratory tract varies from species to species and is an 
important factor in the modelling of influenza infection and transmission.  While the ferret 
is widely accepted as the most suitable model for influenza study, its large size, specialized 
handling techniques, required facilities and general high cost cause many researchers to opt 
to use murine models instead (Table 6).  
 
Table 6. Animal models commonly employed in the study of influenza. Adapted from: 
O’Donnell & Subbarao, 2011 
 
 
5.1.2 The mouse model for influenza 
 
Laboratory mice strains have been used extensively as human surrogates in health 
research for understanding the pathological progression of numerous diseases and for 
studying the therapeutic efficacy and toxicity of drug treatments. 
Their small size, low maintenance costs, and short generation times, make mice an 
ideal candidate for controlled laboratory studies.  Adding to their value is the fact that mice 
have the highest level of genetic and immunological characterization of any laboratory 
animal. The availability of in-bred, transgenic and knockout strains has been a significant 
factor in advancing our understanding of the immunological response of the host to 
pathogenic insult as well as vaccine development and therapeutic evaluations (Davidson & 
   Chapter 5 │Results 
 
 
- 178 - 
Rolfe, 2001; Brodie & Deng, 2001; Hock & Lamb, 2001). However, in interpreting mouse 
experiments one should bear in mind the innate differences between the mouse and human 
immune systems (Shay et al., 2013) and in particular for influenza studies the fact that most 
inbred mouse lab strains lack a functional Mx protein, one of the most potent antiviral 
genes induced by the interferon response (Verhelst, et al., 2012). 
The intranasal method of instilling a liquid directly into the nose of the test subject is 
another method frequently employed to either inoculate with a virus or administer a 
pulmonary drug.  This method is performed on an anaesthetised mouse kept in either a 
supine or vertical position (Southam, 2002). With the aid of a micropipette, the solution of 
interest is slowly administered onto the opening of the nostrils and is taken in by normal 
respiration.  
With respect to influenza, commonly employed laboratory mouse strains express 
both SAα2,6 and SAα2,3 receptors along their respiratory tracts, making them an 
appropriate model for both human and avian influenza viruses. The exact distribution and 
relative quantities of the two different SA-receptor types is still being evaluated although 
some differences have already been noted (Table 7). 
 
Table 7. Influenza-specific host factors in animal models.                                                                      
Adapted from: O’Donnell & Subbarao, 2011. 
 
The predominance of SAα2,3 in murine respiratory tract may explain why numerous 
humanized influenza A virus subtypes often have to undergo passage in eggs to adapt them 
to the mouse host while several avian viruses are able to replicate efficiently in the mouse 
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model without having to undergo adaptation first (Belser, 2009; Joseph, 2007; van Riel, 
2006).  Specifically, it has been found that mouse adapted strains are needed to model 
seasonal A/H3N2 and A/H1N1 virus infections while the 1918 A/H1N1 pandemic strain 
(Tumpey, 2005), highly pathogenic avian influenza (HPAI) A/H5N1 strains (Belser, 2009; Lu, 
1999; Gao, 1999), some H7 subtypes (Belser, 2009; Joseph, 2007) and A(H1N1)pdm09 
(Besler, 2010; Maines, 2009) strains  (all strains that retain some avian like virus binding) do 
not require adaptation. 
A virus’ pathogenicity and the severity of its associated clinical signs in mice, 
depends upon the specific virus employed and the challenge dose administered. In most 
cases, when a lethal dose is administered, the resultant severe disease is characterised by 
huddling, ruffled fur, lethargy, weight loss and ultimately death.  It is important to note, 
however, that unlike humans, mice do not develop a fever following an influenza infection; 
rather, hypothermia has been reported (Yang, 1961). Thus, the parameters most commonly 
used to access and monitor the pathogenesis in the mouse model are body weight loss and 
mortality and on necropsy, viral titers, pathology scores and cytokine/chemokine levels. 
Whilst studies performed in animal models are fundamental for the evaluation of 
disease processes and therapeutic regimes, extrapolation of the results to the human 
condition is not straightforward due to the significant anatomical and physiological 
differences that exist between our species. These differences must be kept in mind when 
attempting to make cross-species comparisons. 
 
5.2 Results 
 
5.2.1 Evaluation of RV1088 in lone & combination use in the mouse model 
 
In a first experiment in vivo, drugs and virus were administered by the intranasal 
route. The challenge virus chosen for the in vivo work was the prototypic strain of 
A(H1N1)pdm09, A/England/195/2009. Being a recently introduced pandemic strain, this 
virus was already shown by us and others to infect mice, ferrets and pigs without prior 
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adaptation (van Doremalen et al., 2011). Moreover, this virus is clinically relevant as related 
strains are still in circulation to date. 
Female BALB/c, 6-8 week-old mice divided into five treatment groups composed for 
15 mice each were employed in this study. RV1088+Relenza acted as the drug combination 
group, groups employing each drug individually were also tested, and a vehicle alone group 
of infected mice acted as a negative control for drug treatment whilst a mock-infected 
group of mice were the negative control for virus and cytokine induction. Each group of 15 
mice was pre-treated with a specified drug combination or vehicle for three days prior to 
infection (days -3 to -1). This pre-treatment was conducted in order to give the compound 
every possible chance of modifying the cellular environment. On the day of infection (day 0), 
the mice were once again given specified treatments and infected intranasally under 
anaesthesia with 40μl of a 2x105 pfu solution (thus, 8x103 pfu actually instilled) of 
A/England/195/2009 (A(H1N1)pdm09 [an inoculation dose of 1x104 pfu for 
A/England/195/2009 has previously been demonstrated by our lab to induce a robust and 
measurable infection in the mouse model (Shelton et al., 2012)]. Daily weights were 
recorded. A severity limit of 20% weight loss was established and any mice dropping below 
this limit were culled as specified in the Home Office License for this work. On days +3, +7 
and +11, five mice from each treatment were culled and their lungs harvested. Lungs were 
subsequently homogenised and used for determining viral lung load via plaque assay and 
IFNα levels via ELISA (Figure 50). 
The mice infected with the A/England/195/2009 virus in the absence of antiviral 
treatment lost weight in two distinct phases, between days 1 and 3 post infection and then 
again between days 5 and 7 (Figure 50 & 51). The mean weight loss in the infected group 
was 10%. After day 7 infected and untreated mice gained weight as they recovered. 
Interestingly, while all groups gained a demonstrable amount of weight from day 7 p.i., the 
vehicle alone (i.e. non-infected group) did not display this weight gain and infact kept a near 
constant weight for the entierty of the experiment. While the reason for this late-stage 
weight gain by the infected groups is not know, it is possible that once the infection had 
been cleared, these mice attempted to recuperate the caloric deficit aquired during their 
illness and as food and water was provided ad-libitum, simply gordgeed themselves.   
Treatment with Relenza did not significantly change the weight loss in infected mice under 
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these conditions. In contrast, infected mice treated with RV1088 either alone or in 
combination with Relenza lost substantially less weight than the vehicle treatment group. 
This analysis was conducted by means of examining the area under the curve (AUC) for each 
treatment group which was then in turn normalised to the vehicle alone goup (no virus) - 
with higher numbers indicating less weight loss and visa versa.  The RV1088 treatment 
group experienced far less weight loss than the Relenza only treatment group yielding AUC 
values of 94.85 and 92.74, respectively and possibly indicating that RV1088 might represent 
an improvement to the current standard antiviral practise in terms of symptomology.  The 
combination of RV1088+Relenza resulted in less weight loss than observed for any of the 
single treatment groups (Vehicle, RV1088 or Relenza alone; AUC = 99.70 for combination 
treatment compared to 90.58, 94.85 and 92.74, respectively). 
Supporting these results are those of the survival curve. While no mice succumbed 
to their infection, if they reached the 20% weight loss mark, individuals were culled on 
humanitarian grounds and this is what is represented in Figure 50. The vehicle+virus group 
experienced a 46% loss of individuals due to this cut off point. In comparison, the Relenza 
group resulted in a 6.67% reduction starting on day 4 p.i. while both the RV1088 and the 
RV1088+Relenza groups required no culls due to severity limits.  
With respect to viral lung titres, virus was recovered from the lung on days 3 and 7 
for all infected mice, but virus was cleared by day 11 p.i. (Figure 50). Viral loads were highest 
on day 3 and there were no differences between the groups at this time point. On day 7, 
although statistical significance was not reached mice within the RV1088 alone and the 
RV1088+Relenza groups had less virus in their lungs than the other groups. Both the vehicle 
alone and Relenza alone groups had roughly equivalent levels of viral load in the lungs at 
this time.  
IFN-α levels in homogenised lungs was quantified using a specific commercial ELISA. 
IFN-α was highest in all groups on day 3 p.i. and declined over the course of the experiment 
but was still higher in any of the infected mice lungs than in uninfected mice lungs at day 11 
p.i. even though all virus was cleared by this time. RV1088 treatment alone resulted in a 
significant reduction in the levels of IFN-α levels on all days examined compared to any 
other group of infected mice. Surprisingly on day 3 p.i. the Relenza group experienced a 
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significant increase in lung IFN-α when compared to the vehicle+virus treatment group (p = 
4.8x10-5). The RV1088+Relenza group displayed mean IFN-α levels lower than this, at a 
similar level as the vehicle group, possibly indicating a moderating effect of RV1088 on the 
unexpected increase after Relenza treatment. Furthermore, the combination treatment 
group resulted in a significant suppression of IFN-α on day 11 p.i. (p= 9.2x10-7) when 
compared to the infected (vehicle treated) group. 
Homogenised lung samples were analysed on a multiplex plate for further 
cytokine/chemokine analysis (Figure 52 & 53). Specifically, FGF, IL-1β, IL-12, MCP1α, MCP1, 
IL-5, VEGF, IL-1α, IFNg, TNF-α, IP-10, MIG and KC were examined. Infection with influenza, 
when compared to non-infected controls, produced detectable increases in all 
cytokines/chemokines examined save for VEGF and FGF.  With respect to drug treatments, 
only IL-1β and IP-10 demonstrated any significant difference in protein levels of infected 
compared to mock infected mice.  No significant differences were noted except in the case 
of IL-1β and IP-10 where, RV1088 appeared to increase IL-1β on day 1 p.i., reaching 
statistical significance for the combination RV1088+Relenza treatment group (p= 9.0x10-4) 
while the RV1088 only and Relenza+RV1088 groups showed significantly decreased 
expression of IP-10 on day 5 p.i (p= 4.3x10-2 for both condition groups) when compared to 
the infected (vehicle treated) group. IP-10 was undetectable after RV1088 treatment on day 
5 p.i in contrast to the un-treated or Relenza group. 
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Figure 50: Effects of RV1088 in the mouse model. Female BALB/c (6-8 weeks) were pre-treated with RV1088 (2μg/mouse) ± Relenza 
(3μg/mouse) suspended in a 5% DMSO/Saline vehicle and infected intranasally with H1N1 virus (A/England/195/2009). a) Daily weights were 
taken at the same time during each trial day. b) Mean group weight loss was determined and area under the curve calculated. Any subjects 
which dropped below the 20% wight loss limit was culled (c). On set days (3, 7 and 11 p.i.), mice from each group were culled and viral titers 
(d) and IFN-α (e) in the lungs was assessed. Results are expressed as the mean ± standard deviation of each sample set (student t-test, *p<0.5, 
**p<0.001). Figure continued onto the next page. 
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Figure 50: Effects of RV1088 in the mouse model. Female BALB/c (6-8 weeks) were pre-treated with RV1088 (2μg/mouse) ± Relenza 
(3μg/mouse) suspended in a 5% DMSO/Saline vehicle and infected intranasally with H1N1 virus (A/England/195/2009). a) Daily weights were 
taken at the same time during each trial day. b) Mean group weight loss was determined and area under the curve calculated. Any subjects 
which dropped below the 20% wight loss limit was culled (c). On set days (3, 7 and 11 p.i.), mice from each group were culled and viral titers 
(d) and IFN-α (e) in the lungs was assessed. Results are expressed as the mean ± standard deviation of each sample set (student t-test, *p<0.5, 
**p<0.001). Continued from previous page. 
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 Figure 50: Effects of RV1088 in the mouse model. Female BALB/c (6-8 weeks) were pre-
treated with RV1088 (2μg/mouse) ± Relenza (3μg/mouse) suspended in a 5% DMSO/Saline 
vehicle and infected intranasally with H1N1 virus (A/England/195/2009). a) Daily weights 
were taken at the same time during each trial day. b) Mean group weight loss was 
determined and area under the curve calculated. Any subjects which dropped below the 
20% wight loss limit was culled (c). On set days (3, 7 and 11 p.i.), mice from each group were 
culled and viral titers (d) and IFN-α (e) in the lungs was assessed. Results are expressed as 
the mean ± standard deviation of each sample set (student t-test, *p<0.5, **p<0.001). 
Continued from previous page. 
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Figure 51: Separated out 
weight loss curves of mice 
dosed intranasally with 
RV1088±Relenza. Female 
BALB/c (6-8 weeks) were pre-
treated with RV1088 
(2μg/mouse) ± Relenza 
(3μg/mouse) suspended in a 5% 
DMSO/Saline vehicle and 
infected intranasally with H1N1 
virus (A/England/195/2009). 
Daily weights were taken at the 
same time during each trial day 
and a group survival cure was 
created. Results are expressed 
as the mean ± standard 
deviation of each sample set 
(student t-test, *p<0.5, 
**p<0.001). 
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Figure 52: Multiplex analysis of homogenised mouse lung. Female BALB/c (6-8 weeks) 
were intranasally inoculated with H1N1 virus (A/England/195/2009). On set days, mice 
from each group were culled and the lungs harvested. Lungs were subsequently 
homogenised and a multiplex analysis for cytokines/chemokines was conducted. All results 
were adjusted for lung weight. Results are expressed as the mean ± standard deviation of 
five samples (student t-test, *p<0.5, **p<0.001).  
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Figure 53: Additional 
m
ultiplex analysis of 
hom
ogenised m
ouse lung 
from
 intranasally treated and 
infected test subjects. Fem
ale 
BALB/c (6-8 w
eeks) w
ere 
intranasally inoculated w
ith 
H1N
1 virus 
(A/England/195/2009). O
n set 
days, m
ice from
 each group 
w
ere culled and the lungs 
harvested. Lungs w
ere 
subsequently hom
ogenised 
and a m
ultiplex analysis for 
cytokines/chem
okines w
as 
conducted. All results w
ere 
adjusted for lung w
eight.  
Figure continued onto the next 
page. 
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Figure 53: Additional multiplex analysis of homogenised 
mouse lung from intranasally treated and infected test 
subjects. Female BALB/c (6-8 weeks) were intranasally 
inoculated with H1N1 virus (A/England/195/2009). On set 
days, mice from each group were culled and the lungs 
harvested. Lungs were subsequently homogenised and a 
multiplex analysis for cytokines/chemokines was 
conducted. All results were adjusted for lung weight.  
Continued from previous page. 
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5.2.2 Evaluation of RV1088 in the ferret model 
 
In a study primarily conducted by Kim Roberts and Rebecca Cocking (both members 
of the Barclay lab group), female ferrets (26-30 weeks) were pre-treated with RV1088 
(2mg/kg) or placebo for one day prior to infection, and for four days p.i. – by intranasal 
administration conducted under isoflurane. On day 0, the ferrets were infected under 
anaesthesia intranasally with A/England/195/2009 (1x104 pfu).  Daily weights were recorded 
(Figure 54, a), and viral loads were determined via the plaquing daily nasal wash samples on 
MDCK cells (Figure 54, b). The results demonstrate that in this model, RV1088 did not 
significantly affect either weight loss or viral load when compared to the placebo control. 
Unfortunately, at the time of this experiment, the lack of ferret-based immunological 
reagents made cytokine/chemokine analysis unfeasible. However, with modern advances in 
this area, such work could fruitfully be undertaken in the near future. 
 
Figure 54: Effects of RV1088 in the ferret model. Female ferrets (26-30 weeks) were pre-
treated with RV1088 or placebo for one day prior to infection (and for four days p.i.  - all 
under isoflurane). On day 0, the ferrets were infected under anaesthesia intranasally with 
A/England/195/2009 (1x104 pfu). Daily weights (a) were taken at the same time during each 
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trial day. No significant difference in weight loss was observed between the drug treatment 
groups and the placebo group (right-hand weigh loss figure contains std dev bars). In 
addition, each day, the ferrets were nasal washed and these washings were plaqued on 
MDCKs (b) to determine viral shedding levels. No significant differences between the 
RV1088 and the placebo groups in terms of viral shedding was observed. 
 
Subsequent to this in vivo experiment in which we observed little-to-no 
demonstrable effect of RV1088 on either weight loss or viral shedding, we wanted to 
examine if RV1088 has any effect in a simpler in vitro model in ferret cells. In order to 
conduct these experiments, ferret airway (tracheal) primary cells were collected post 
mortem and used to create highly-differentiated, air-liquid interface ferret airway epithelial 
(FAE) culture. These cultures were established by Peter Stillwell under the auspices of an 
NC3R grant and closely resembled commercially acquired HAE cultures.   
FAE cultures were pre-treated in a fashion similar to the previously described HAE 
experiments with either RV1088 (1.73nM) or DMSO (0.5%) added to the basal media and to 
the apical surface of each well for three days prior to infection (day -3 to -1) with virus.  On 
the day of infection (day 0), wells were once again treated both apically (removed after 
2hrs) and basally (left in place for the remained for the experiment) and then infected with 
A/England/195/2009 (moi = 0.1). Culture supernatants were harvested at set time points 
and plaqued to quantify viral shedding (Figure 55, part a).  Additionally, at 48hrs p.i. total 
RNA was harvested from three wells from each treatment condition and used for qRT-PCR 
analysis for viral M gene and for ferret cytokine genes using primers based on available 
ferret genome sequence (Figure 55, part b). A qRT-PCR analysis revealed that RV1088 
significantly suppressed cytokine/chemokine mRNA levels induced by A/England/195/2009 
(A(H1N1)pdm09 (p≤ 0.05 for IP-10). There was an average 2.01-fold decrease in IP-10 mRNA 
levels for the RV1088 treatment group when compared to the DSMO treatment group. In 
addition qRT-PCR for viral M gene mRNA (normalized to GAPDH) indicated that treatment 
with RV1088 also suppressed levels of M-gene message by an average 5.2-fold (compared 
to DSMO treatment group), however, this decrease was not reflected in viral titres 
measured in supernatant by plaque assay at that time point (an occurrence previously 
observed and discussed in Chapter 2).   
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Figure 55: Results of Pre-infection treatment with RV1088 in FAEs infected with 
A/England/195/2009. FAE cell cultures were pre-treated for three days both apically and 
basally with RV1088 (1.73nM) or DMSO (0.5%). Cultures were infected with 
A/England/195/2009 (moi = 0.1, 1hr 37°C). After infection, fresh drugs were applied apically 
(2hrs, 37°C then removed) and added to the basal media for the duration of the experiment. 
Culture supernatant was harvested at specified time points and used in the determination 
of viral replication by being plaqued on MDCKs (a). At 48hrs p.i. total RNA was extracted and 
qRT-PCR analysis for IP-10 (b) and viral M-gene (c) was performed. Results are expressed as 
the mean ± standard deviation of triplicate samples (student t-test, *p<0.5, **p<0.001). 
 
 
5.3 Discussion and Conclusions 
 
Within this chapter, we sought to examine if the synergistic potential for RV1088 and 
a directly acting antiviral translated to an in vivo model. Several animal models for studying 
influenza currently exist with the most common animals including the mouse, ferret and 
guinea pig. As discussed above, each model has its own particular pros and cons with some 
animals considered to be more suitable for specific areas of investigation (the ferret model 
for transmission studies, for example). In our preliminary investigation, due to the number 
of animals required as well as the availability of standardised protocols and reagents, we 
employed the mouse model.  
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The parameters utilised to monitor the pathogenesis of the virus 
(A/England/195/2009) in this model were total body weight loss and mortality and on 
necropsy, viral titers, and cytokine/chemokine levels. The results demonstrated that RV1088 
(when used alone or as part of a combination therapy with a directly acting antiviral, 
Relenza) significantly reduced the amount of weight the mice lost following influenza 
infection. Furthermore, the combination treatment group (RV1088+Relenza) had the lowest 
amount of weight loss of any of the infected groups and this reduction was statistically 
significant when compared to either RV1088 or Relenza alone treatment groups, possibly 
indicative of a synergistic mechanism similar to that observed in vitro (detailed in Chapter 
4).  
Interestingly the weight loss in mice infected with A/England/195/2009 occurred in 2 
rather distinct phases, the first between days 1 and 4 and then the second between days 6 
and 8. The two cull days that allowed analysis of lung viral loads and lung cytokine levels 
were fortuitously spaced to be in each of these two temporal phases. This revealed that the 
decreased weight loss in the early phase seen in mice treated singly with RV1088 or 
receiving dual RV1088 plus Relenza treatment was not associated with less viral load but 
rather with a reduction in IFN-α levels. 
Despite the decrease in IFN levels induced in infected mouse lung in presence of 
RV1088 on day 7, the mice still cleared the virus more efficiently than untreated mice or 
mice treated with Relenza alone since viral loads by day 7 were lowest in RV1088 treated 
groups. As there was no difference in viral load in the mouse lungs at day 3 p.i. we infer that 
the reduced weight loss in RV1088 treated group(s) must be due to its immune modulating 
activities.  However, the higher IFN levels in lungs of Relenza treated mice on day 3 did not 
drive greater weight loss. 
In the later part of the weight loss curve, the two RV1088 treated groups again 
showed less weight loss than the other mice.  In this instance day 7 lung homogenates 
revealed that these groups also had lower lung viral loads as well as less IFN and less IP-10.  
It is not clear whether the lower cytokine levels here are a result of increased virus control 
and also why RV1088 appeared able to control viral load at late time points but not at early 
time points.  
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Multiplex data obtained from homogenised lung samples demonstrated that 
RV1088+Relenza treatment group resulted in significantly more IL-1β production on day 3 
p.i. These results are interesting as the cytokine IL-1β (also known as catabolin) is produced 
by activated macrophages and is considered to be an important mediator of the 
inflammatory response (Dinarello, 2010). Activation of the inflammasome results in the 
cleavage of pro-IL-1β by caspase-1 and produced the mature form of IL-1β (Hornung et al., 
2009). During an influenza virus infection, IL-1β has been demonstrated to mediate acute 
pulmonary inflammatory pathology (Schmitz et al., 2005). In addition, IL-1β (in conjunction 
with IL-1α) induces the expression of a variety of inflammatory mediators, which are 
believed in turn to initiate part of the inflammatory response cascade and to induce the 
activation of T cells (Acosta-Rodriguez et al., 2007; Luft et al., 2002). Further supporting the 
pivotal role of IL-1β in the context of an influenza infection is the work conducted by Liu et 
al., (2013) where they report that a single-nucleotide polymorphism (SNP) of IL-1β 
(rs1143627, allele C) increased the carriers’ susceptibility to infection with A(H1N1)pdm09. 
While more work in this area is required, it is postulated that the expression of IL-1β is lower 
in people who carry allele C, leading to weaker immune response in the face of viral insult. 
In terms of epidemiology, the frequency of the rs1143627 allele C is high in ethnic Han 
Chinese (minor allele frequency = 0.476) when compared to other ethnic groups (Liu et al., 
2013). However, the detailed significance of this polymorphism and its contribution to 
disease burden has yet to be fully established. 
IP-10 (also known as CXCL10) on the other hand, is an IFN-induced chemokine; 
attracting monocytes/macrophages, T cells, NK cells and dendritic cells to sites of 
inflammation.  The lower levels of IP10 at day 11 associated with RV1088 treatment might 
result in less immune infiltration in to the lung and less immunopathology. 
Research conducted by Wang et al., (2013) has demonstrated that in mice, a 
monoclonal antibody specific to IP-10 ameliorates influenza A (A/Beijing/501/2009, 105.5 
TCID50) virus induced acute lung injury and enhance survival. Taken together, these results 
exemplify the strategy behind employing drugs that specifically target key pathways of the 
innate immune response rather than a simply pan-suppressive approach. The ability of 
RV1088 to supress pathology-inducing IP-10 while increasing the protective IL-1E resulted in 
a marked protective effect in infected mice. 
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One potentially worrying set of results demonstrated that, under our experimental 
condition, Relenza did not prove to be greatly protective against an influenza infection with 
A/England/195/2009. Despite this group receiving 4 doses at 3μg/mouse/dose, little-to-no 
protective effect was seen in terms of weight loss and lung viral titers compared to the 
vehicle alone treatment group. Although fewer mice in the Relenza group lost more than 
20% body weight requiring cull, compared to the vehicle alone group, with respect to the 
cytokine/chemokine response, treatment with Relenza resulted in a significant increase in 
IFN-α levels on day 3 p.i. which may have contributed to an increased immunopathology 
driving weight loss, compared with the RV1088 treated groups. 
Recently, there has been a great deal of debate and controversy over the efficacy of 
employing neuraminidase inhibitors in the treatment of influenza infections. This debate 
has been spurred on by a new Cochrane Group Review released on April 10th, 2014 in which 
they concluded that oseltamivir (Tamiflu) and zanamivir (Relenza) have small, non-specific 
effects on reducing the time to alleviation of influenza symptoms in adults and that using 
neuraminidase inhibitors as prophylaxis can reduces the risk of developing symptomatic 
influenza (Jefferson et al., 2014). Complicating the debate has been the call from the 
Cochrane Group and the British Medical Journal for pharmaceutical companies to fully 
disclose all results of their clinical trials (both published and unpublished) as it has been 
alleged that the virus-specific mechanism of action proposed by these companies does not 
fit the currently available clinical evidence (Belluz, 2014). Our results have demonstrated 
that Relenza, when used on its own, has only a modest effect but the synergistic effect 
created by using Relenza in combination with RV1088 is markedly protective. The results 
presented in Chapter 4 indicate that this synergistic effect is not limited to Relenza alone 
but that it was also observed for oseltamivir and rimantadine and it is quite possible that 
these combinations might prove even more protective then that seen with Relenza and 
warrant further investigation at a later date.  
Unfortunately, in the ferret model, RV1088 failed to result in any significant 
reduction of weight loss or viral loads. This may be due to a number of factors including the 
quantity of drug in each dose and the adequacy of delivery of the drug to the animals’ 
respiratory tract and warrants further investigation. Complicating any additional analysis, 
specifically in terms of cytokine/chemokine levels, is the general lack of reliable reagents. 
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However, an increasing amount of work is currently being conducted in the field to address 
this problem and the hope is to have many of the key reagents available in the future.    
Interestingly, some preliminary work testing ferret nasal washes from infected or 
uninfected animals suggests that some proteins in ferret nasal wash cross-react with 
reagents in the canine commercially available kits. This option may provide an interim 
solution although the extent of cross-reactivity and the specificity of these reactions will be 
difficult to confirm. 
While we were not able to detect any appreciable effect of RV1088 in the ferret in 
vivo model, we were successfully able to measure an effect of the drug in highly-
differentiated, air-liquid interface ferret airway epithelial (FAE) cultures.  We showed that 
IP10 was induced by infection with A/England/195 and the level of IP-10 induction was 
significantly suppressed in the presence of RV1088 (p = 2.8x10-4). However, in accordance 
with our previously discussed HAE results, RV1088 failed to have any significant effect on 
viral replication. However, qRT-PCR analysis for viral M gene mRNA (normalized to GAPDH) 
indicated that treatment with RV1088 suppressed levels of M-gene message by an average 
5.2-fold when compared to DSMO treatment group.  A hypothesis of why this decrease was 
not reflected in viral titres measured in supernatant by plaque assay is discussed further in 
Chapter 3 where the M-gene, was also supressed (3.78-fold decrease) but this suppression 
did not seem to be enough to significantly affect vital titers as measured by plaque assay 
(2.57-fold decrease). The qRT-PCR results suggest that a several fold difference in RNA levels 
have little effect on viral titres as measured by infectious unit on a log scale. This 
discrepancy could simply be explained by the innate difference in sensitivity that exists 
between these two techniques and the fact that qRT-PCR is a method for determining 
mRNA levels with no distinction made between replicative and non-replicative viruses.  
Due to a limited amount of verified and published information pertaining to ferret 
cytokine/chemokine gene sequences at the time of the experiment, we were unable to 
perform as detailed an examination of cytokine/chemokine effects as with the HAE culture 
system. In this particular experiment, we examined mRNA level of ferret IP-10 and observed 
that RV1088 treatment significantly suppressed (p = 2.8x10-4) induction of this chemokine in 
comparison to the DMSO vehicle control group. These results indicate that in ferret airway 
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cells, RV1088 was able to supress the induction of innate signalling cascades but this did not 
result in increased viral shedding.  
As we have established that RV1088 is indeed effective at targeting a key chemokine 
in ferret-derived airway cultures, any future experiments should focus on the potential 
alleviation of symptoms in this model.  As the generation of fever in response to the virus is 
one of the hallmarks of an influenza infection, we suggest that any future studies employ 
intraperitneal implanted telemetry devices for the monitoring of changes in body 
temperature secondary to viral insult and to determine what, if any, effect RV1088 might 
have in reducing this symptom (see for example Roberts et al, 2012). This approach has the 
added benefit of producing non-biased, and quantifiable results that are directly relevant to 
the disease process. In addition, plethysmography to measure the ferret respiratory 
capacity during infection may be possible. 
Further complicating any analysis is the necessity to keep any species-specific 
responses in mind. The generation of an excessive cytokine/chemokine response in humans 
(and by extension in human-derived cell cultures) is often viewed as being detrimental and a 
key factor in the development of a pathological state. In mice, however, the picture might 
be more complicated. In work conducted by Connaris et al., (2014) the efficacy of using 
engineered carbohydrate-binding, sialic acid-specific, molecules as a means of preventing 
influenza from gaining access to its cell surface receptors and thus preventing infection was 
assessed. Intriguingly, despite their molecules having little-to-no effect on viral replication 
until day 9 p.i., mice dosed with these molecules were afforded protection against a lethal 
challenge with A/California/04/2009 (H1N1). A possible explanation for this lies in the 
cytokine/chemokine levels observed in mouse lung homogenates. Specifically, their 
molecules, rather than supressing the cytokine/chemokine responses, actually induced 
significantly stronger levels of certain cytokines such as IL-1β, MIP-2 (mouse homolog of IL-
8), IFN-γ, and TNF-α. It is possible that in this model, the higher levels of 
cytokines/chemokines afford greater protection to pathogenic insult resulting directly from 
virus replication in the lung. 
One disadvantage of the animal model in testing the efficacy of drugs and 
combination therapy is the inability to accurately score reductions in symptomology. While 
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we can make attempts to determine this through indirect measurements such as weight 
loss and cytokine levels, any effect on this parameter can only be inferred. In the case of 
RV1088, a drug compound that acts primarily by reducing/preventing an over-induction 
othe innate immune response, any alleviation of symptoms could prove of particular benefit 
to a patient with severe influenza. Unfortunately, only clinical trials in human subjects will 
answer these key questions definitively but the animal model does play a significant and 
crucial role in determining safety profiles, side-effect profiles and early stage efficacy 
assessments.  
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Chapter 6. The nebulisation of A(H1N1)pdm09 virus for inoculation of mice treated with nebulised RV1088  
6.1 Introduction    
 
6.1.1 The lung 
After demonstrating the effectiveness of RV1088 in the mouse model using 
intranasal instillation of both treatment compounds and virus, we were interested in 
seeing if RV1088 could be delivered successfully in vivo via the nebulised route and 
be effective against a virus delivered via the same route. This is partly driven by the 
knowledge that the RV compounds were designed to be bioavailable in the lung 
from a local delivery similar nebulization. 
In human infection studies using strains of either influenza A (PR8) or 
Influenza B (Lee) conducted by Henle et al., (1946) involving over 200 volunteer 
subjects, the route of inoculation (either intranasal drops or via aerosol) influenced 
the likelihood of developing fever. Eighty nine percent of 65 volunteers infected by 
inhalation developed fever while only 12% of 16 exposed to nasal drop instillation 
did.  In their analysis of this data, the authors speculated that the differences in 
symptomology with respect to method of viral inoculation indicate that the influenza 
virus may preferentially enter cells in the lower respiratory tract over those of the 
nasal epithelium. While more recent experiments have demonstrated that a number 
of factors including virus strain, dose and immune response (to name a few) are 
important determining factors for the influenza virus to initiate and develop a 
productive infection, it has also been shown that the estimated human infectious 
dose (HID50) for influenza is at least 5-10 fold lower when virus is delivered by 
aerosol when compared to intranasal inoculation (Hayden, 1996; Alford, 1966; 
Knight, 1965). This suggests that deep lung deposition of virus may be much more 
efficient at establishing an infection. 
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The delivery of drugs directly to pulmonary tissue allows for local drug 
targeting and thus, decreases systemic drug concentration levels, resulting in 
reduced side effects. The specific physiological and anatomical features of the lungs 
make them attractive targets for drug delivery. These specific features include a 
large epithelial surface area, thin alveolar epithelium and a high vascularization rate 
(Patton & Byron, 2007). 
During the course of its normal daily function, the human lung is continually 
assaulted by pathogens and particles that can harm its tissues. Indeed, it has been 
estimated that our airways are exposed to >7kg of pollutants each year (McWilliam 
& Holt, 1998). Thankfully, our lungs have in place a series of protective mechanisms 
to help remove such offending particles. These mechanisms include a successive 
bifurcation of the airways encouraging impaction, a rich overlay of mucus and the 
mucociliary clearance system (Figure 56).  
 
 
 
Figure 56: Schematic representation of the lateral view of cells and surface fluids 
that comprise the human respiratory tract from the bronchus to alveoli  (Figure 
from: Fernandes & Vanbever, 2009).  
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Produced by goblet cells lining the airways, the mucus is composed of mucins 
which are high molecular-mass glycoproteins with a protein backbone upon which 
oligosaccharide side chain are attached, producing a fibre-like structure which give 
mucus its gel-like consistency. This viscoelastic gel is composed of 95% water, 2% 
mucins, 1% albumin, 1% salts, enzymes and immunoglobulins and <1% lipids 
(Houtmeyers, 1999). The mucus forms a bilayer ~5-55μm thick and lies directly on 
top of the thin periciliary fluid layer which is responsible for lubricating the cilia (Lai, 
2009; Rogers, 2007). As the cilia beat rhythmically upward, the mucus layer and its 
entrapped particles are pushed further and further up the airways to the oropharynx 
where it is either expectorated or swallowed (Chilvers & O’Callaghan, 2000). 
Further down the respiratory tract is the alveoli region. The epithelial lining is 
protected by a thin (~20-80nm thick) overlay of surfactant fluid (Perez-Gil, 2008; 
Patton, 1996). Lung surfactant is composed of ~80% phospholipids, 5-10% neutral 
lipids and 8-10% proteins (Perez-Gil, 2008).  While surfactant plays an important role 
in reducing pulmonary surface tension, it also has been implicated in having an 
innate immune function (Wright, 2005). Specifically, some researchers have 
described the phenomenon whereby small insoluble proteins and particles 
aggregate in the surfactant that is then enveloped by alveolar macrophages (Nag, 
2007; Patton 1990). Large proteins (>40kDa) and soluble compounds can also be 
taken up by macrophages through the process of pinocytosis or “cell drinking” 
(Lombry, 2004; Matsukawa, 1997). In contrast, these same alveolar macrophages 
have no effect on small proteins and molecules (<25kDa), which diffuse across the 
mucus layer from the airspace within minutes (Lombry, 2004). Thus, the 
environment in which influenza viruses replicates in the lung might be quite different 
than in the upper airways. Since lung replication is generally associated with more 
severe disease, that would be more requiring of therapeutic intervention, it seems 
important to try to reproduce that site of infection in the animal models in which 
novel therapeutics are tested. 
It may also be that an aerosolised virus might gain access to endothelial cells 
of the respiratory tract more readily by establishing an infection in the deeper 
lung/alveolar regions than in the trachea or bronchi. This difference may, in part, be 
   Chapter 6 │Results 
 
 
202 
due to the decreased thickness of the airway mucus layer (secondary to a decrease 
in mucus-producing goblet cells) further down the respiratory tree. For example, it 
has been suggested that the thickness of airway surface liquid (ALS) between the 
trachea and bronchioles can differ by as much as 20- to 50-fold  (Widdicombe, 1997). 
Endothelial cells have been identified as the site of induction of the sphingosine-1-
phosophate (S1P1) signalling system that leads to the robust activation of cytokine 
expression (Teijaro et al., 2011). As such, it is plausible that a virus in the lung (as 
opposed to a virus in the conducting airways) would have greater access to epithelial 
cells, the subsequent infection of which, might result in a profound triggering of 
numerous cytokine/chemokine signalling cascades to such a strong degree that the 
conditions for the generation of a cytokine storm are created. Supporting this 
supposition is the observation that viruses (such as the D225G mutants isolated in 
Norway) that have a greater ability to infect cells of the lungs by possessing an 
enhanced ability to bind α2-3 SA have been implicated in more severe cases during 
the pH1N1 2009 pandemic (Kilander et al., 2010). 
 
6.1.2 An alternative route of inoculation in the mouse model 
 
The most common method to either inoculate with a virus or administer a 
pulmonary drug remains the intranasal method. This method involves instilling a 
liquid directly into the nose of the test subject and is performed on an anaesthetised 
mouse kept in either a supine or vertical position (Southam, 2002). With the aid of a 
micropipette, the solution of interest is slowly administered onto the opening of the 
nostrils and is taken in by normal respiration. Despite its wide use, this method has 
inherent limitations and problems which can be addressed by alternative methods. 
Ideally since influenza viruses are acquired by transmission through the air, 
this route of inoculation for an animal model might be preferred to reproduce the 
correct site of infection. Delivery of an aerosol to the murine pulmonary system can 
be quite challenging because of their relatively small tidal volumes. In addition, while 
the position of the lungs in humans is vertical, it is horizontal in mice during 
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inhalation. Furthermore, mice, as well as rats, guinea pigs and hamsters, are obligate 
nose breathers due to the close apposition of their epiglottis to the soft palate (Rao 
& Verkman, 2000). The smaller tidal volumes result in a smaller volume of aerosol 
reaching the lower respiratory tract which, in turn, results in lower aerosol 
deposition rates (Rao & Verkman, 2000).  In general terms, the lung deposition of an 
aerosol in any host depends on the aerosol particle size which is dependent on a 
number of factors including the method of aerosol generation, formulation 
parameters and the subjects breathing pattern (McCallion, 1996; Finlay, 2001).  
Taking all this into account, it has been proposed that for tidal breathing, the optimal 
aerosol particle size for deposition in the alveolar region is 3μm for both humans and 
mice and that for tracheobronchial deposition, the optimal particle size is 6μm for 
humans and 4μm for mice (Hsieh, 1999; Stahlhofen, 1989). 
There are two widely-used methods for administering an aerosol to the 
murine model: the whole-body approach and the more targeted nose only 
approach. For the whole-body approach, the mice are placed in an exposure 
chamber into which an aerosol is delivered and the mice are allowed to inhale with 
their entire bodies, including eyes, being exposed to the aerosol cloud. This method 
has the benefits of being simple to employ, not requiring the use of either restraints 
or anaesthesia and numerous animals can be exposed to the same cloud at the same 
time.  However, the disadvantages to this system are the large deposition of aerosol 
onto the animals fur, leading to over-exposure and subsequently skewing results, 
and the possibilities for inequitable distribution of the aerosol between all the test 
subjects due to the common practice of their huddling within the chamber (Phalen, 
1984). Alternatively, the nose-only exposure method avoids many of these issues 
and ensures an equal distribution of the aerosol cloud to all subjects. However, the 
high cost specialized equipment and use of restraint and technical skill involved are 
distinct disadvantages (Lore, 2011).  
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6.1.3 Nebulisation 
 
The delivery of drugs directly to pulmonary tissue allows for local drug 
targeting and thus, decreases systemic drug concentration levels, resulting in 
reduced side effects. The specific physiological and anatomical features of the lungs 
make them attractive targets for drug delivery. These specific features include a 
large epithelial surface area, avoidance of “first-pass metabolism” associated with 
parenteral medications, thin alveolar epithelium and a high vascularization rate 
(Patton & Byron, 2007; Nadithe, 2003). The direct pulmonary route might also prove 
to be an attractive method for vaccine delivery due to the large number of dendritic 
cells and macrophages localized in the mucosal surface (Nadithe, 2003).  
Ultrasonic nebulizers generate an aerosol using vibrations from a crystal that 
are transmitted to the surface of the overlaying liquid where standing waves are 
formed. Droplets subsequently break free from the tops of these waves creating a 
fine aerosol mist. The size of the aerosol particle generated is inversely proportional 
to two thirds of the power of the acoustic frequency. In a method similar to jet-style 
nebulizers, baffles within the system remove the largest of the droplets as well as a 
significant proportion of the aerosol, returning them to the liquid reservoir –only the 
smallest particles are allowed to escape (O’Callaghan & Barry, 1997). 
In delivering aerosolized virus, particle size must be considered. Scott & 
Sydiskis (1976) have shown that in the mouse model, large-particle aerosols of 10μm 
median diameter or greater, primarily localized to the upper respiratory tract and 
require a large dose to initiate infection. Particles of 2μm or less primarily localised 
in the lower respiratory tract and required less virus to establish an infection than 
virus delivered in large particles. Reinforcing this is the observation that mice 
immunized by infection with small particles containing virus (A/Aichi/2/68) and later 
challenged with a lethal dose of the same virus were protected, while the group 
receiving immunization by infection with a large particle virus aerosol were not 
afforded protection – protection being afforded only when the initial large particle 
exposure dose was increased by several fold (Scott & Sydiskis, 1976). A similar study 
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showed that serum neutralizing and haemagglutination inhibition (HAI) antibodies 
reached detectable levels in mice 28 days after exposure to small particle aerosols 
(2um) containing A/H3N2 virus while the large particle (8um) exposed group did not 
demonstrate any detectable antibody response (Jemski & Walker, 1976). Taken 
together, these studies suggest that a smaller quantity of virus is required to 
stimulate a robust immune response when the virus is delivered to the mouse lungs 
in a small particle form when compared to its large particle counterpart – the latter 
requiring a higher titre to initiate the same degree of response.  
Smith and colleagues (2011) demonstrated that aerosol inoculation with the 
X31 strain of influenza virus caused a larger degree of lung pathology and enhanced 
morbidity and mortality compared to intranasal inoculation. Upon histopathological 
examination, the lungs of the aerosol-inoculated mice exhibited severe 
bronchointerstitial pneumonia across all lung lobes with evidence of acute alveolar 
injury and necrosis. Interestingly, lung pathology in the intranasal inoculated group 
was often confined to a single lung lobe with substantial pathology not being seen 
until 3 days post infection (much later than with the aerosol inoculated group). Their 
results also suggest that an aerosol infection induces predominately a Th-2 type 
cytokine response. The authors attributed the difference in pathology between the 
two inoculation groups to the levels of activation of granular cell infiltrates and IL-6 
levels, both of which were found to be higher (6-fold higher in the case of IL-6) in 
BAL fluid in the aerosol inoculated mice group. In other studies employing other 
animal models (Svitek, 2008; Kobasa, 2004) and humans (Hayden et al., 1996), the 
pathological effect of severe influenza infections has been associated with increased 
levels of IL-6 in nasal wash fluids and sera, especially at day 3 post infection. 
In a study conducted by Nadithe et al., (2003) where C57BL/6 mice were 
exposed in a nose-only fashion to jet aerosolized 99mTc-labeled human serum 
albumin (HSA), they calculated that no more than 0.27 ± 0.67% of the aerosol 
delivered to the chamber was deposited in the mice and that only 0.0216 ± 0.005% 
reached the lungs. This study demonstrates that only a small proportion of an 
aerosolised virus or drug may reach the lungs and that an adequate and equal air 
flow through an exposure chamber must be maintained. Both of these concepts 
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should be taken into account when trying to achieve adequate virus or drug levels in 
nebulisation experiments.  
 
6.1.4 Development of a working nebulisation system  
 
The generation of an aerosol was performed with the Aeroneb nebulizer 
(EMMS, Hants, UK). This device includes a concave aperture plate that is surrounded 
by a vibrational element. Receiving an electronic signal of 128 kHz from a control 
unit, the aerosol generator vibrates at a rate of  ~120,000 vibrations per second. 
These rapid vibrations result in the formation of an aerosol cloud within the 
nebulisation chamber with particles sizes ranging from 4 to 6μm. 
The even distribution of the aerosol cloud throughout the entire system 
(Figure 57 and 58) is achieved by the generation of a constant airflow. This is carried 
out by a bias airflow generator (EMMS, Hants, UK) that transports compressed air 
with a flow rate of 10 L/min from the nebulisation chamber (Figure 59) to the 
exposure chamber. Additionally, 5 L/min of aerosol cloud is also sucked out of the 
exposure chamber and further transported through virkon cleaning traps, filters and 
silica traps before being released through the class II biological safety cabinet’s air-
extraction system (undergoing further HEPA filtering in the process). 
The nose only exposure of aerosols to mice was carried out with a 6-port 
inhalation tower. The functional design of the tower consists of an inner and outer 
tower. The inner tower conveys the aerosol through the system while the outer 
tower connects the inner tower with restrained mice in the Perspex tubes (Figure 
60) (EMMS, Hants, UK). This internested two-tower design ensures equal distribution 
of the aerosol cloud to all exposure ports.  
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Figure 57: Schem
atic representation of the nebuliser system
 em
ployed in RV1088 m
ouse experim
ents. 
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Figure 58: Actual set-up of the nebuliser system employed in RV1088 mouse 
experiments. 
 
Sampling of the aerosol cloud was made through one of the exposure 
chamber ports using a modified bung that permitted the passage of a small diameter 
tube. This tube was place roughly in the same location that a mouse’s nose would 
occupy.  The tubing was then connected to a midget impinger (Figure 61) containing 
PBS through which the pulled air would flow, entrapping any viral particles in the 
PBS. To pull the aerosol cloud through the impinger, we employed a small variable 
pump (Air sampling pump 2223-229(230)A, SKC, Dorset, UK) which was programmed 
to simulate the breathing patterns of a female BALB/c mouse. We devised this set up 
to try to ascertain how many infectious particles a mouse might inspire during an 
exposure period (Results section 6.2.1).  
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Figure 59: Generation of an aerosol cloud in the                                                                                         
nebuliser chamber. 
 
 
 
 
Figure 61: Sampling of the 
nebulant cloud by midget 
impinger. 
Figure 60: View of a non-anesthetised,                                                                                          
restrained mouse in a nose-only exposure                                                                                   
tube. 
 
 
6.2 Results 
6.2.1 Determining aerosolisation rates using the midget impinger  
 
In order to determine the quantity of replicating virus that the nebulisation 
system was capable of depositing in a mouse lung during normal respiration, we 
used a series of well-established mathematical equations (Bowen et al., 2012) and a 
midget impinger to sample the aerosol.   
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Determination of the virus particle (here PFUs) concentration in an aerosol cloud as 
measured by midget impinge:  
 
Employing the equation directly below, we were able to calculate the 
number of infectious viral particles (PFU) suspended in the aerosol cloud with the aid 
of a midget impinger. The impinger contained 10ml of PBS and was connected 
directly to the nebuliser’s exposure chamber (i.e. where an animal subject would be 
exposed to the aerosol cloud). Downstream of the impinger was a small 
programmable pump that was set to mimic the normal respiratory rate of an 
average female BALB/c mouse (volumetric flow set to = 0.6L/min) drawing the 
aerosol cloud through the PBS for 10min thus trapping any aerosolised virus in the 
PBS. The trapped virus was later titred via plaque assay and gave an impinger 
concentration of 300 pfu/ml. Inserting this value into the equation below we 
estimate that the concentration of infectious virus achieved in the aerosol was 
500pfu/L.  
  
Ac = [(Ci x Vi)/(Qi x Ts)]   
Ac = Aerosol concentration (pfu/L)                                                                                                      
Ci = Impinger concentration (pfu/ml)                                                                                                    
Vi = Final Vol of PBS in impinge (ml)                                                                                                   
Qi = Impinger volumetric flow (L/min)                                                                                                
Ts = Sample collection duration (min)  
Ac = [[(300pfu / ml) x (10mls)]/[(0.6L/min) x (10min)]] 
Ac =500 pfu / L  
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Determination of virus deposition into mouse lungs based on known aerosol 
concentration:  
 
After determining the concentration of active viral particles in the aerosol 
cloud, we next sought to calculate what concentration of virus might be deposited 
into the lungs of a normal and healthy female BALB/c mouse.  We achieved this via 
the equation below and employed our previously calculated virus aerosol 
concentration (Ac) of 500pfu/L, the normal ventilation rate for the test subjects 
(0.6L/min) and the experimental exposure time (10min). Thus, from these 
calculations, we can expect a typical BALB/c female mouse to inhale approximately 
3000pfu over the course of 10min of normal respiration.  
 
 ID = [Ac x Vm x Tc]   
ID = Inhaled lung deposition (pfu)                                                                                                      
Ac = Aerosol concentration (pfu/L)                                                                                                   
Vm = Ventilation rate (L/min)                                                                                                               
Tc = Challenge duration (min) 
 
ID = [(500pfu / L) x (0.6L / min) x (10min)]  
ID = 3000pfu 
 
Determination of the percentage of liquid virus solution (i.e. nebuliser input) that 
becomes deposited into a mouse lung:  
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Building on the results above, we were able to determine what percentage of 
the nebuliser input actually reaches the test subjects lungs using the equation 
directly below.  
 
Ip = [(ID / In) x 100]  ID = Inhaled lung deposition (pfu)                                                                                                                     In = Nebuliser virus input (pfu)                                                                                                                             Ip = Inhaled percentage of input (%)   
Ip = [(1.154x104 pfu / 4.50x107 pfu) x (100)] 
Ip = 0.026% 
Averaging the results of three separate experiments, we calculated that 
approximately 0.026% (std dev 0.0006%) of the liquid virus concentration added to 
the nebuliser system was inhaled by a test subject.  
 
6.2.2 The nebulisation of A(H1N1)pdm09 virus 
 
The first step in validating the nebuliser system was the determination of 
what input viral dose/titer was required to create quantifiable clinical signs (weight 
loss) consistent with an influenza infection. In order to achieve this, groups of 5 mice 
were exposed to a range of nebulised input virus amounts (ranging from: 2x104 to 
1x108 pfu) via the nose-only exposure method (a full description of this can be found 
in section 8.2.6.4). In addition, an intranasally instilled viral dose of 2x105 pfu was 
employed to act as the comparator (Figure 62). The first experiment (Figure 62, part 
a) did not result in any weight loss in mice given virus by the nebulized route. Two 
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possible reasons may account for this, the first being that the input amount of virus 
was simply too low, bearing in mind the losses of virus titre in the system and the 
level of 0.026% that reached the mouse lung and the second was that, due to the 
trapping of infections particles in condensing droplets within the system’s tubing 
very little virus was actually delivered to the mice (Figure 63). The latter of these 
issues was addressed in subse quent experiments by employing new and shorter 
tubing for each nebulising event.  Ultimately, it was determined that in the system, 
an input amount of 1x108 with a calculated lung deposition of 2.6x104 pfu was 
capable of inducing a weight loss curve of similar magnitude as the 2x105 intranasal 
instillation (Figure 62, part b).  The weight loss in the animals who received virus 
through the nebulized route also occurred in two distinct stages, as observed 
previously for the intranasal inoculation route. This level of input virus was chosen to 
serve as baseline for pharmacological intervention.  
 
 
Figure 62: Determination of nebulant input required for creation of desired 
weightloss curve. Female BALB/c (6-8 weeks) were exposed to nebulised H1N1 virus 
(A/England/195/2009). Two experiments (a&b) were conducted in which each 
treatment group was exposed to different quantity of input virus a) 10^4, 10^5 and 
10^6 and b) 10^6, 10^7 and 10^8 pfu. In addition, each group also contained an 
intranasal instillation group (input = 2x10^5 pfu) acting at the control. Daily weights 
were taken at the same time during each trial day. Weight loss curves were 
generated and compared to the intranasal control group. It was determined that an 
input of 10^8 pfu in the nubulised system produces a weight loss curve similar to 
that seen in the intranasal instillation group. 
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Figure 63: Condensation in nebuliser tubing. 
 
6.2.3 The nebulisation of RV1088 
 
Next, the feasibility of delivering nebulised RV1088 to mice infected by the 
same route was assessed. Groups of 15 mice were infected with 
A/England/195/2009 (A(H1N1)pdm09) with a calculated viral lung deposition of 
2.6x104 pfu. Three days prior to infection, a treatment group were exposed daily to 
nebulised RV1088 (1.5mg/ml in 5 mls of vehicle) or drug vehicle alone [Tween20 
(1mg/ml), Span20 (0.2mg/ml), Monosodium phosphate dihydrate (9.4mg/ml), 
Dibasic sodium phosphate anhydrous (1.75mg/ml), Sodium chloride (4.2mg/ml), 
500ml H2O, 5ml/exposure]. An additional group received only nebulised drug vehicle 
but remained uninfected. The quantity of drug used was determined after 
discussions with our colleagues at RespiVert and are partially based on previously 
unpublished work involving Guinea Pigs conducted at the University of Cardiff 
(Personal communication with RespiVert). Post infection, daily weights were 
recorded and at days 1, 3 and 5 p.i., 5 mice from each group were culled and their 
lungs removed (Figure 64, part a). Lungs were subsequently homogenised and used 
to quantify viral loads via plaque assay on MDCKs, as well as lung IFNα levels by 
ELISA (Figure 64, parts b&c). Finally, whole lung specimens from day 3 p.i. were fixed 
in formalin, sectioned and stained with H&E (Figure 64, part d).  
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All the infected mice lost weight over the course of the experiment.  There 
was no significant difference in timing or extent of weight loss for any treated group 
from the vehicle only infected animals.  In addition, on days 1, 3 and 5 p.i., there was 
no difference in viral loads in the lungs in any group. On the other hand evidence 
that the course of infection was modified by drug treatment was supported from 
monitoring IFN-α levels in the lungs.  
Importantly, on day three post-infection, the infected untreated mice had a 
significant IFN response, and the RV1088 treatment group had significantly lower 
IFN-α levels than the vehicle/virus group indicating that nebulised RV1088 did reach 
the lungs and that it was able to exert an effect on the innate immune response of 
the mouse.  Surprisingly, the IFN-α levels in lungs of uninfected but vehicle-treated 
mice were very high on day 1. This suggested that the delivery by nebulization to the 
lungs had in itself induced an innate response. How this affected the outcome of 
infection is not clear but overall the levels of IFN in infected animals were not very 
different from the levels seen in previous experiments where virus and drug were 
delivered by the intranasal route suggesting that the effects of virus infection 
overrode the effect of nebulization of vehicle.  
Blinded histological examination of lung tissue sections also indicated that 
RV1088 was modifying the infection outcome. H&E stained sections examined at 
both 10x and 20x revealed that infection with A/England/195/2009 (A(H1N1)pdm09) 
by nebulisation, resulted in distinct histological changes when compared to the 
control uninfected group; specifically, increased polymorphonuclear neutrophil 
(PMN) infiltration and airway plugging can be found (Figure 64, part d). The absence 
of these pathological markers in the RV1088 treatment group suggests that 
nebulised RV1088 did indeed reach the target tissues and that, at this location, it 
exerted an effect on the innate host response, modifying cellular recruitment to the 
site of infection.  
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Figure 64: Effects of RV1088 in the m
ouse m
odel. 
Fem
ale 
BALB/c 
(6-8 
w
eeks) 
w
ere 
exposed 
to 
nebulised drug treatm
ent and nebulized H1N
1 virus 
(A/England/195/2009). Daily w
eights (a) w
ere taken 
at the sam
e tim
e during each trial day. N
o significant 
difference in w
eight loss w
as observed betw
een the 
drug treatm
ent groups and the positive control. O
n 
set days, m
ice from
 each group w
ere culled and viral 
titers (b) and IFN
-α levels (c) in the lungs w
ere 
assessed. Additionally, histology w
ith H&
E staining of 
lung tissue sections w
as perform
ed (d). Results are 
expressed as the m
ean ± standard deviation of five 
sam
ples (student t-test, *p<0.5, **p<0.001). 
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In addition to analysing the lung samples for mouse IFN-α, homogenised lung 
samples from all subjects were analysed on a multiplex plate for further 
cytokine/chemokine expression (Figures 65 & 66). Specifically, IL-1β, IL-12, IL-13, KC, 
VEGF, IP-10, IFN- γ, MIG and IL-6 were examined. Of these, only IL-6 demonstrated 
any significant suppression with the RV1088 demonstrating significant suppression 
on day 5 p.i. when compared to the vehicle+virus group. In contrast, there was a 
marked high level of IL-6 in the lungs of mice infected and treated with Relenza on 
day 1 when compared to all other treatment groups.   
                
Figure 65: Multiplex analysis of homogenised mouse lung. Female BALB/c (6-8 
weeks) were exposed to nebulised drug treatment and nebulised H1N1 virus 
(A/England/195/2009). On set days, mice from each group were culled and the lungs 
harvested. Lungs were subsequently homogenised and a multiplex analysis for 
cytokines/chemokines was conducted. All results were adjusted for lung weight. 
Results are expressed as the mean ± standard deviation of five samples (student t-
test, *p<0.5, **p<0.001).   
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Figure 66: Additional multiplex 
analysis of homogenised mouse 
lung. Female BALB/c (6-8 weeks) 
were exposed to nebulised drug 
treatment and nebulised H1N1 
virus (A/England/195/2009). On 
set days, mice from each group 
were culled and the lungs 
harvested. Lungs were 
subsequently homogenised and a 
multiplex analysis for 
cytokines/chemokines was 
conducted. Results are expressed 
as the mean ± standard deviation 
of five samples (student t-test, 
*p<0.5, **p<0.001). 
Figure continued onto the next 
page. 
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Figure 66: Additional multiplex 
analysis of homogenised mouse 
lung. Female BALB/c (6-8 weeks) 
were exposed to nebulised drug 
treatment and nebulised H1N1 
virus (A/England/195/2009). On 
set days, mice from each group 
were culled and the lungs 
harvested. Lungs were 
subsequently homogenised and a 
multiplex analysis for 
cytokines/chemokines was 
conducted. Results are expressed 
as the mean ± standard deviation 
of five samples (student t-test, 
*p<0.5, **p<0.001). 
Continued from previous page. 
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To further illustrate that the nebuliser system had deliver aerosolised 
pandemic influenza virus to the lung, lung tissue slides were stained using 
fluorescent antibodies specific to viral antigen (Figure 67).  Using this technique, 
areas of infectious foci became visible with all foci of infection being found adjacent 
to an airway space. In addition, all foci observable per tissue section were counted 
and no significant difference in the number of foci with respect to treatment group 
was noted. These results supported the viral lung loads as determined by plaque 
assay employing homogenised lung tissue in which no significant difference in lung 
viral load between treatment groups was found (Figure 67).   
 
 
Figure 67: Immunofluorescence staining of mouse lung tissue slides. a) tissue 
sections were stained with anti-NP (type A) and anti-Actin (alpha). Images of 
infectious foci were then either merged with the anti-Actin or unstained cell images. 
b) A table of the average number of  infectious foci (similar to the one shown in part 
a) per tissue section of lung.   
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6.3 Discussion and Conclusions 
 
In the previous chapter we showed that RV1088 administered alone or in 
combination with Relenza was able to reduce weight loss in mice induced by 
influenza infection. However intranasal instillation of both virus and RV1088 in the 
ferret model failed to result in any significant reduction of weight loss or viral loads. 
It is possible that reducing cytokine/chemokine levels (the proposed primary mode 
of action of RV1088) in the ferret does not prevent them loosing weight. 
Furthermore, in our ferret model, the virus alone group lost very little weight 
secondary to their infections and it is possible that any effect on weight loss of 
RV1088 might not be evident. We hypothesized that a number of factors might 
explain the lack of effect in the ferret including: the quantity of drug in each dose, 
possibly inadequate delivery of the drug to the animal’s respiratory tract and, as of 
yet, unknown differences in their innate response to viral infection when compared 
to mice.  
Within this chapter, we sought to establish a working model for the delivery 
of aerosolised virus and drug compounds to an animal model. The aim of this 
approach was to simulate as closely as possible a “natural” infection by allowing 
aerosolised virus to penetrate deep into the lower airways of the lung, resulting in a 
proportionate stimulation of the innate immune response. As discussed above, 
intranasal instillation can result in skewed infections, wherein pathology can be 
isolated to a single lung lobe and the onset of histopathological changes can be 
delayed (Smith et al., 2011). In contrast, aerosol inoculation has been demonstrated 
to cause a larger degree of lung pathology and enhanced morbidity and mortality 
compared to intranasal inoculation in both animal models and in humans. 
Supporting the hypothesis that aerosol inoculation leads to a more severe clinical 
outcome are human studies conducted by Cowling et al., (2013) which found that 
that aerosol transmission accounted for approximately half of all transmission 
events and carried a higher risk of developing fever (55% compared with 23 and 22% 
risk for droplet and contact routes respectively). In addition, by nebulising a drug 
formulation, particles of the same diameter as those created during the 
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aerosolisation of a virus suspension could theoretically be distributed to multiple 
areas of the lung resulting in a more targeted drug delivery approach.  
The nebulisation of drugs for the treatment and alleviation of numerous human 
conditions (corticosteroids and bronchodilators for asthmatics, for example) is well 
established in the medical world. Normally administered via simple inhalation, 
nebulised Relenza, was employed during the 2009 pandemic under a global 
compassionate use programme in seriously ill, ventilated patients as a second line 
treatment however with inconclusive results (HPA, 2012).  Unfortunately, while data 
was collected and returned to GlaxoSmithKline, this data has not yet been made 
available for public scrutiny and thus, the efficacy of this route of administration has 
not been determined (UKCRN ID 14218).  It has been reported that nebulised 
Relenza blocked ventilation tubing resulting in failed delivery and even the death of 
a patient (Duff, 2009; FDA, 2009). As a result IV zanamivir became the preferred 
second line treatment under compassionate use (Thacker et al., 2009). 
The efficacy of a nebulised kinase inhibitor to control influenza infection in 
the mouse model has been demonstrated in experiments conducted by Droebner 
and colleagues (2011) in which mice were treated with a MEK inhibitor (U0126) via 
the aerosol route. This treatment was shown to reduce progeny virus titers and 
provided protection of influenza-infected mice against a 100X lethal viral challenge 
(intranasal administration) when compared to untreated controls. However, before 
we could test RV1088 in such a manner, we first needed to develop a working 
nebulizer system. 
The initial stages of this project involved the design and validation of a new 
nebuliser system for our laboratory in consultation with EMMS (Hants, UK). The 
system we devised differed from many of those described previously in the literature 
(Masihi et al., 2007; Donovan et al., 2000; Utsunomiya et al., 1997) by several 
important ways. Firstly, our system allows for nose-only exposure thus eliminating 
over exposure through deposition on the subjects fur and eyes. Secondly, the use of 
a “nebulant chamber” allows for the generation of a uniform aerosol cloud before 
subjects are exposed thereby allowing for a greater accuracy in our exposure 
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calculations. Finally, by employing a small miniature pump that we programmed to 
mimic the normal respiratory rate of a standard test subject, we are able to calculate 
the expected inhaled viral dose by a test subject to a great degree of accuracy.    
Additional positive features of our system include the ability to dose and/or 
infect up to 6 test subjects simultaneously while, due to the inherent design of both 
the “nebulant chamber” and “exposure chamber,” that all subjects received a 
uniform and equal level of exposure. In addition, the use of “crush bars” in the 
“exposure tubes” provides a harmless and well-tolerated means of restraining 
subjects and negates the need for anesthetic–based restraint. The latter has been 
previously described (for both parenteral and inhaled anesthesia) to adversely affect 
the respiratory functions of a test subject during the course of sedation resulting in 
different levels of infection severity (Cesarovic et al., 2010; Miller et al., 2012). 
In terms of drawbacks, our system does contain a few that are worth noting. 
Firstly, due to the inherent design, a large quantity of tubing is required to conduct 
air/nebulant cloud throughout the system. The temperature differential, albeit 
minor, is enough to permit the formation of condensation along large sections of this 
tubing. While this was addressed by changing-out tubing between each run, and 
shortening the overall tubing length this remains an area for potential improvement. 
Secondly, the nebulizer unit can experience difficulty in creating a suspended-drug 
aerosol cloud if the substance or compound in question does not dissolve or remains 
poorly suspended in the vehicle solution [a problem previously reported for 
powdered Relenza formations (Duff, 2009; FDA, 2009)]. Finally, the system’s relative 
large size and cost-prohibitive nature may preclude the use of this particular set-up 
in certain situations.  
Before we exposed any animals to our system we first sought to determine 
what quantity of viral input might actually reach a mouse during a set exposure 
period. To achieve this, air sampling was conducted via a midget impinger connected 
to one of the exposure ports that was in turn connected to a miniature pump. The 
miniature pump settings allowed for air to be drawn through the impinge at a 
volume and rate consistent with the normal breathing patterns of the type and sex 
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of mice we planned to employ in further experiments (i.e. female, BALB/c). The 
resultant impinger fluid was then plaqued out on MDCK cells to determine viable 
virus yield (Figure 62). From these results we were able to determine what 
percentage of viral input titer would potentially reach the lungs of a mouse (refer to 
calculations in section 6.2.1).  
The next step in validating the model was to move to the in vivo phase which 
involved exposing groups of mice to different calculated viral inputs to determine 
which specific input resulted in clear quantifiable clinical signs related to an active 
influenza infection (i.e. weight loss). Using this approach, we determined that an 
input titer of 1x108 (equating to approximately 2.6x104 inhaled active virus particles 
as calculated using the same equations detailed above) created a weight loss curve 
similar to that seen with a nasal instillation of 2x105 (Figure 62). Thus, for the drug 
trial study it was this viral input titer that we opted to employ. It is important to 
note, that we have only used one virus [A/England/195/2009 (A(H1N1)pdm09] in 
this system and that different viral inputs might be required if other strains are used.  
These initial viral deposition calculations/results compare well with those of 
Nadithe et al., (2003). They found that when mice were exposed to a nose-only 
aerosolized 99mTc-labeled human serum albumin (HSA), no more than 0.27 ± 0.67% 
of the aerosol delivered to the chamber was deposited in the mice and that only 
0.0216 ± 0.005% reached the lungs. In our system, we calculated (detailed above) 
that, on average, approximately 0.026% (std dev 0.0006%) of the liquid virus 
concentration added to the nebuliser system was inhaled by each mouse. This result 
is very satisfying as it corresponds nicely to the 99mTc-labeled HAS results reported by 
Nadithe and colleagues (2003) while at the same time displaying a remarkably low 
standard deviation – indicating the reproducibility and robustness of our system. 
Supporting this is the observation that for all treatment groups, the nebulised 
delivery of virus±drug compound(s) resulted in markedly less variation in terms of 
group weight loss when compared to its intranasal counterparts (for example, the 
RV1088 treatment groups have an average standard deviation of 3.41 and 2.40 for 
intranasal and nebulised delivery respectively). Unfortunately, we did not assess the 
level of cytokine/chemokine induction in the animals used during these preliminary 
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experiments caused by the different viral input levels. Such data would have been 
useful in comparing the innate immune responses elicited by differing viral input 
levels in both the intranasal and nebulised systems.    
We proceeded to test the effect of treating an influenza infection resulting 
from nebulised virus delivery, with nebulised RV1088, with or without Relenza. 
Results showed that RV1088 reduced weight loss compared with vehicle treated 
group but the difference was not significant. In addition there was no significant 
different in lung viral load in drug treated or vehicle treated groups. However there 
was a significant decrease (p = 3.18x10-5) in lung IL-6 after RV1088 treatment on day 
5 p.i. and in lung IFN-α on day 3. 
These results may suggest that RV1088 might act to suppress IL-6 from a 
particular type of cell that is only present at day 5 as the day 3 levels of this cytokine 
were not affected. In a study conducted by Matheu et al., (2013) immune cell 
recruitment and activity in the lungs of mice in response to H1N1 infection (1x105 
pfu, intratracheal inoculation) was assessed in the mouse model. Overlaying our 
cytokine results onto Matheu and colleagues’s immune cell response timeline, we 
can postulate that RV1088 might be exerting its IL-6 suppressive effect by acting 
against macrophages and/or T cells. However, further investigation is warranted.  In 
contrast, and to our surprise, there was a marked increase in IL-6 levels in the lungs 
of mice infected and treated with Relenza on day 1 that remained elevated on days 3 
and 5 p.i.   
The rather small effect of drug in this study suggests that either the delivery 
of aerosolised virus produced such a severe infection that RV1088 was unable to 
control the immune response elicited by the virus, or that the amount of RV1088 
delivered was simply an insufficient dose. Although we were able to monitor delivery 
of virus in the nebulized system we did not have any assay to quantify drug in lung 
tissue, to confirm sufficient dosing.  It is possible that the drug adhered to the plastic 
tubing in the system- indeed this type of problem has also been noted with Relenza 
given in a hospital setting (Duff, 2009; FDA, 2009). While the experiments differed in 
both length and sampling days, there are some general observations that can be 
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made. The weight loss curves, and cytokine profiles did not differ markedly between 
mice who received virus via nebulizer or intranasal. For example, peak weight loss 
for the RV1088 treatment groups was 91.3 and 95.09 (% of group starting weight) for 
nebuliser and intranasal respectively. In terms of IFN kinetics, levels detected in 
homogenised lung corresponded, and were proportional, to detected viral levels – 
both peaking on day 3 p.i.  However, the RV1088 nebulised group produced almost 
three times the quantity of IFNα when compared to that detected for the intranasal 
group (476.8 compared to 159.4 pg/gram lung tissue for nebulised and intranasal 
respectively) presumable reflecting a difference in the type of cell infected 
(discussed previously above) or higher viral load in the lungs of the former. 
 However, the virus delivered to the lower lung fields via nebulisation did 
replicate to significantly higher levels for all treatment groups when compared to the 
intranasal instillation route. For example, on day +3, the vehicle-alone infected group 
had an average pfu/gram of lung tissue of 4.14x109 after nebulized delivery and only 
5.34x106 after the intranasal delivery.  As such, it is possible that this increased viral 
replication resulted in an overwhelming pathological state against which, the dose of 
RV1088 employed was unable to compensate for.  It is also possible the system input 
dose was correct but that an adequate concentration of this input failed to reach the 
target tissue due to several factors including the build-up of condensation in the 
tube or poor suspension of the drug in the delivery vehicle.   
While RV1088 was not delivered at a dose high enough to significantly affect 
weight loss or lung viral load, enough was deposited to significantly suppress IFN-α & 
IL-6 levels (p = 1.014x10-6 and 3.18x10-5, respectively) and to prevent dramatic 
histological changes related to pathological insult. It is possible that if a higher dose 
of RV1088 were added to the system, even greater effects could be observed, 
providing future avenue of investigation.  
Immunofluorescence staining (Figure 67) of mouse lung tissue sections for 
viral antigen (anti-influenza Type A NP) demonstrated that the delivery of nebulised 
A/England/195/2009 (A(H1N1)pdm09) virus via our system resulted in the 
deposition of  a small number of virions which created finite foci of infection. These 
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foci may correspond to the small, non-extensive foci of acute inflammation in the 
airspaces and interstitium seen on histological examination of lungs taken from fatal 
cases of A(H1N1)pdm09 (Mukhopadhyay et al., 2010). Further supporting this 
observation are results reported by Harms et al., (2010) where, out of eight 
autopsies, small microscopic foci of diffuse alveolar damage-associated necrosis was 
present in 6 cases. Taken together, these reports indicate that a large degree of the 
pathology associated with an A(H1N1)pdm09 virus infection results not from an en 
masse infection of the lung but rather from a small number of distinct foci of 
infection. 
Taken together, the results in this chapter indicate that we can successfully 
infect mice with aerosolized A(H1N1)pdm09 virus, producing observable and 
quantifiable pathological changes. Furthermore, we have shown that RV1088 can be 
delivered to the mouse lung and modulate the cytokine/chemokine response of the 
host; however, further dosing trials are required to determine the optimal dose for 
these effects to reach their maximum potential.   
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Chapter 7. Discussion 
 
Respiratory infections caused by influenza viruses are responsible for 
significant morbidity and mortality world-wide. Seasonal and pandemic influenza 
outbreaks have a huge impact on both the individual and society at large. The 
economic cost of influenza-like illness each year is difficult to directly calculate due 
to the large number of variables involved. Smith and colleagues (2009) constructed a 
general equilibrium-based computer model to estimate the “economy-wide impact” 
of the 2009 H1N1 pandemic in the UK. Using several assumptions based on previous 
influenza pandemics and other respiratory viral outbreaks and economic data from 
2004, they predicted a reduction in the UK GDP of between 0.5-4.3%, translating to 
between £8.4-72.3bn. In a report released by the Health Protection Agency (Pitman 
et al., 2007), that examined the burden of influenza-related disease in the UK 
between 1996 and 2004, it was found that a total of 1,430,121 GP consultations took 
place during this period with an estimated GP consultation cost per episode of 
influenza-like illness of £30 which added up to over £42.9 million. During this same 
period, an average of 18,327 deaths per year have been directly attributed to 
influenza (both Type A and B) infections in the UK alone.  
In recent years, considerable effort and progress have been made in the 
development and application of new and enhanced influenza vaccines. These efforts 
range from multi-national licencing and subsequent role out of quadrivalent vaccines 
(due to premier in the UK in the autumn of 2014), to introduction of live attenuated 
vaccines for children and promising results yielded in the quest for a “universal” 
vaccine (Yewdell, 2013). However, despite all these important and promising 
advances, it is important to note that currently vaccines are only intended for a 
relatively small segment of the population (i.e. those with pre-existing/pre-disposing 
medical conditions, certain child age groups and the elderly). While protecting these 
vulnerable groups should not be underestimated it is important to note that 
vaccinating at risk groups only against influenza offers little-to-no direct benefit to 
the majority of the healthy UK population.  And even if a person does receive the 
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vaccine, strain miss-match can render the vaccine useless or significantly decrease its 
protective value. 
With such potentially significant economic cost, effective treatment regimes 
are an imperative. The currently licenced classes of anti-influenza agents, the 
neuraminidase inhibitors (Oseltamivir and Zanamivir) and the M2 inhibitors 
(Rimantadine and Amantadine), represent the established approach to combating 
viral infections by targeting the virus directly. One of these drug classes the 
adamantanes is limited to the treatment of type A viruses as it is ineffective against 
type B viruses. However, given the virus’ innate ability to mutate at astonishing rates 
[estimated mismatch rate 1:10,000 nucleotides (Lauring & Andino, 2010)] and 
reassort its gene segments with other circulating strains, the emergence of resistant 
strains is an ever-present concern - limiting available treatment options.  
Exemplifying the growing problem of resistance and the significant and rapid 
rise in the frequency of viruses with antiviral-resistant mutations is the story of the 
seasonal HN1 viruses that acquired oseltamivir resistance and spread community 
wide. The H274Y mutation, conferring Oseltamivir resistance, emerged during the 
2007-2008 influenza season and by the following season (2008-2009) almost 100% 
of all tested seasonal A/H1N1 strains in the United States and numerous counties 
worldwide were found to posess this mutation (CDC, 2009; WHO, 2008; Sheu, 2008). 
New treatments targeting both the virus and its corresponding receptor 
targets on host cells have been proposed and investigated but with mixed results 
(Hayden, 2009). A relatively new approach, in the context of an influenza infection, is 
specific targeting of the host’s immune response.  The principle behind this approach 
stems from the current belief that severity of influenza virus pathogenesis is 
influenced by the host’s immune response to virus infection with the most severe 
presentations of influenza-related hospitalizations resulting from an unregulated 
response of pro-inflammatory cytokines and chemokines induced by the TLR and 
RIG-I signalling cascade, creating a so called “cytokine storm” (Chung et al., 2002; 
Osterholm, 2005; Fukuyama & Kawaoka, 2011). 
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Suppression of the over induction of the host’s immune response to 
infectious insult by the influenza virus has been an area of intense research and 
debate.  Studies aimed at suppressing the immunopathology have examined a 
number of potential pharmacological interventions including: COX-2 inhibitors, ant-
TNF agents, Statins and Glucocorticoids but have yielded varying degrees of success 
and clinical potential (Darwish et al., 2011).  This approach has been subject to 
debate as many researchers have questioned the wisdom of suppressing the 
immune response during an active infection.  The contention lies with the possibility 
that if one inhibits the host’s defences during the course of infection, the virus could 
replicate at an increased rate or lead to increase incidences of secondary infections. 
This exact concern has been born out in several studies where the use of steroids 
had been employed (Martin-Loeches et al., 2011). 
Intriguingly, a recent Cochrane meta-analysis and review of the use and 
efficacy of employing neuraminidase inhibitors for preventing and treating influenza 
in healthy adults and children reported evidence that Oseltamivir may indirectly 
exerts its symptom alleviation effect via suppression of the immune system 
(including decreasing IL-6, TNF-α, IFN-γ and other chemokines) and not only through 
suppression of viral replication as previously thought. Furthermore, Oseltamivir’s 
anti-pyretic effect has also been postulated not to be a direct result of decreased 
viral titers but rather via a general depression of the central nervous system (Ono et 
al., 2013). 
The concept of a employing a more targeted approach with respect to 
suppressing the host’s innate immune response to viral assault represents a new and 
exciting avenue for research. Protein kinases, a class of enzyme responsible for 
catalysing the transfer of phosphate to specific substrates, are key regulators in 
numerous cellular processes and are notoriously druggable. In terms of an influenza 
infection, kinases have been shown to play pivotal roles in the generation of the 
innate immune response through their role as members of numerous 
cytokine/chemokine signaling cascades (Jeffrey et al., 2007; Alberts et al., 2002). As 
such, members of this class of enzyme represent tempting targets for 
immunomodulatory interventions.  
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RV1088, a compound developed by RespiVert (London, UK), is a synthesised 
compound specifically designed to target and inhibit certain key kinases (p38 MAPK, 
c-Src and Syk). This compound was originally intended for use in the treatment of 
respiratory disorders linked with a strong inflammatory response (i.e. asthma and 
COPD). However, this PhD project has been concerned with evaluating the potential 
of using this compound to modulate the hyper-activation of the innate immune 
response associated with influenza infection. 
We firstly conducted a series of examinations to demonstrate that in cell 
culture systems RV1088 was non-cytotoxic and that a representative kinase was 
measurably supressed in the presence of this compound. Once having satisfied these 
two points, we progressed to examining how this compound might exert its reported 
ant-inflammatory action. 
By employing a series of plasmids which encode key components of the IFN- 
β signalling pathway, we mapped RV1088’s activity to a level at or below that of 
MAVS with some of its potential effects occurring via TBK-1 resulting in the 
suppression of NFkB activation and IFN induction. Furthermore, we have shown that 
this interference occurs in a dose-dependent manner. These results tie in nicely with 
work previously conducted by several groups where p38 MAPK (one of the targets of 
RV1088) has been implicated in the induction of the IFN response via the NFkB 
signalling pathway (Hui et al., 2009; Saccani et al., 2002; Uddin et al., 1999). Despite 
being a transcription factor associated with the up-regulation of numerous genes in 
responses to viral attack  [including acute phase inflammatory responses, cell 
adhesion, oxidative stress response, apoptosis and generation of the antiviral state 
(Ludwig & Planz, 2008; Pahl, 1999)] the up-regulation of NFkB has been implicated in 
potentiating influenza virus replication  (Wurzer et al., 2004; Nimmerjahn et al., 
2004).  As such, the suppression of NFkB has been suggested as a potential antiviral 
target (Ludwig & Planz, 2008; Pahl, 1999). 
An examination of potential interactions between RV1088 and the viral 
polymerase revealed that this compound was able to supress transcription of the 
vRNA (+) reporter but not the cRNA (-) reporter in a minigenome assay indicating 
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that RV1088 does indeed affect the viral polymerase and inhibit viral replication.  
Further RV1088 also suppressed expression of a viral-like RNA driven directly by 
replicating virus. While the exact mechanism of inhibition of polymerase has yet to 
be determined, other groups in the field have suggested that kinases are involved in 
the process of nuclear release of vRNP complexes during the latter stages of viral 
replication (Ludwig et al., 2009; Pleschka et al., 2008). This could be investigated in 
the future using immunofluorescence to monitor cellular location of the vRNPs 
during infection. In addition, a kinome analysis examining the phosphorylation status 
of viral proteins both in the presence and absence of RV1088 could establish if this 
compound has any direct effect on viral proteins. 
In cultured CALU-3 cells (immortalised lung epithelial cell line) infected at a 
low moi with A/H1N1 RV1088 used alone did not have a significant effect on viral 
titres, but cytokine expression induced by virus infection was supressed at the level 
of transcription (1.58- and 4.76-fold decrease in IFN-β and RANTES respectively). In 
highly differentiated human airway epithelial cells (HAEs) which are maintained at an 
air-liquid interface and faithfully recapitulate the human respiratory tract RV1088 
used alone again did not exert any significant suppression of viral replication But did 
lead to striking suppression of cytokine/chemokines released from the infected 
cultures in apical washings These results were also mirrored in primary peripheral 
blood mononuclear cells (PBMCs). Furthermore, upon microscopic examination of 
the cultures, it was apparent that RV1088 was able to protect infected airway cells 
from the development of virus induced cytopathic effects (CPE) and in all instances, 
the application of drug delayed the appearance of observable CPE by a minimum of 
one day. Importantly, in either culture system, although RV1088 inhibited the innate 
immune response to the virus, we did not observe any increase in viral replication or 
virally-induced, observable pathology.    
This result is especially noteworthy and highlights the potential of employing 
a targeted approach towards immunomodulation during an active influenza 
infection. In contrast to a target approach, the use of corticosteroids in patients 
hospitalized with seasonal A/H1N1 resulted in higher viral titers and prolonged viral 
shedding when compared to non-glucocorticoid-treated patients Lee et al., (2009). 
   Chapter 7 │Discussion 
 
 
233 
One explanation for this could be that RV1088 had a dual action, both inhibiting the 
innate immune response and at the same time inhibiting virus replication such that 
the two effects cancelled each other out in terms of virus titre when RV1088 was 
used alone. 
The use of combination therapy has been employed in the treatment of 
countless diseases (including influenza) as a means of potentiating antiviral activity 
and decreasing the likelihood of resistant strain emergence thereby enhancing 
clinical outcome.  However, to our knowledge, no clinical study has yet been 
undertaken which has examined the potential effects on cytokine/chemokine 
expression and viral replication by a kinase inhibitor used in conjunction with a 
licenced antiviral. To address the question if there existed any additive or synergistic 
effect if RV1088 was used in conjunction with a licenced antiviral, we again 
employed both the CALU-3 and HAE cell culture systems. In our initial experiments, 
RV1088 was used in combination with Relenza, Rimantadine or Oseltamivir (with 
doses chosen being based on the specific drugs’ reported IC50). All three licenced 
drugs suppressed viral replication by several logs as expected. RV1088, when used 
alone, resulted in very little virus suppression, in line with previous results. However, 
when a conventional antiviral and RV1088 were used jointly, a striking and almost 
complete suppression of viral replication and cytokine/chemokine induction was 
noted. 
In order to determine if the inhibitory effect on virus replication observed 
when RV1088 and Relenza was used in combination was additive or synergistic, we 
employed the well-established principles of the combination index (CI) theorem of 
Chou-Talalay (Chou, 2010). By using a specialised software program which employs 
this theorem (CalcuSyn, Biosoft - Cambridge, UK), we were able to determine that 
the relationship produced by RV1088 when used in combination with Relenza is very 
strongly synergistic in nature. 
After obtaining robust in vitro data demonstrating the immune-modulating 
effect of RV1088 and the existence of a strongly synergistic relationship between 
RV1088 and Relenza, we progressed to in vivo models. Intranasal infection and drug 
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dosing with RV1088 administered alone or in combination with Relenza was able to 
reduce weight loss in mice induced by influenza infection. However intranasal 
instillation of both virus and RV1088 in the ferret model failed to result in any 
significant reduction of weight loss or viral loads. It is possible that reducing 
cytokine/chemokine levels (the proposed primary mode of action of RV1088) in the 
ferret does not prevent them loosing weight. Furthermore, in our ferret model, the 
virus alone group lost very little weight secondary to their infections and it is 
possible that any effect on weight loss of RV1088 might not be strictly evident. 
Unfortunately, limitations in reliable and proven ferret cytokine/chemokine reagents 
restricted detailed analysis.  We believed that the lack of a strong response in our 
drug treatment groups resulted from inadequate distribution of the compounds to 
the sites of infection. As such, we sought an alternative route of administration.  
The nebulisation of drugs for the treatment and alleviation of numerous 
human conditions (corticosteroids and bronchodilators for asthmatics, for example) 
is well established in the medical world. During the 2009 pandemic, under a global 
compassionate use programme, Relenza (normally administered via simple 
inhalation) was given to seriously ill/ventilated patients via a nebulised route 
however with inconclusive results due to lack of reporting (HPA, 2012).  To model 
this route of administration for our kinase inhibitor, we worked to establish a model 
for the delivery of aerosolised virus and drug compounds to an animal model. The 
aim of this approach was to simulate as closely as possible a “natural” infection by 
allowing aerosolised virus to penetrate deep into the lower airways of the lung, 
resulting in a proportionate stimulation of the innate immune response. The efficacy 
of a nebulised kinase inhibitor to control influenza infection in the mouse model has 
been demonstrated in experiments conducted by Droebner and colleagues (2011) 
with favorable outcomes reported.  
After numerous “dry runs” and calculations aimed at determining the virus 
concentration in the aerosol cloud produced by the nebulizer unit, the inhaled lung 
deposition concentration and the determining the theoretical percentage of liquid 
virus solution (i.e. nebuliser input) that is deposited into a mouse lung we were 
ready to proceed with the animal model work. Further experiments employing the 
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live animal models were conducted to determine what viral titer input was required 
to initiate an infection with a weight loss curve that would approximate that 
observed in our standard intranasal inoculations. Only after all these parameters had 
been taken into account did we proceed to test the effect of treating an influenza 
infection resulting from nebulised virus delivery, with nebulised RV1088, Relenza or 
a combination of the two. Results showed that RV1088 reduced weight loss 
compared with vehicle treated group but the difference not significant. In addition 
there was no significant different in lung viral load in drug treated or vehicle treated 
groups. However, a significant decrease in IL-6 was observed for the RV1088 
treatment group.  Alarmingly, Relenza did not prove to be greatly protective against 
an influenza infection with A/England/195/2009. Despite this group receiving 4 
doses at 3μg/mouse/dose, little-to-no protective effect was seen in terms of weight 
loss and lung viral titers compared to the vehicle alone treatment group. This lack of 
response ties in with the growing debate on the efficacy and wisdom of employing 
neuraminidase inhibitors in the treatment of influenza infections (highlighted by the 
recent Cochrane Group Review released on April 10th, 2014). Unfortunately, further 
analysis is greatly hindered by that lack of disclosure of vital drug trials by the 
manufacturers of these compounds.  
The rather small effect of drug in this study suggests that either the delivery 
of aerosolised virus produced such a severe infection that RV1088/Relenza was 
unable to control the immune response elicited by the virus, or that the amount of 
RV1088 delivered was simply an insufficient dose. Although we were able to monitor 
delivery of virus in the nebulized system we did not have any assay to quantify drug 
for example in lung tissue, to confirm sufficient dosing. It is also probably that the 
“sticky” nature of the drug formulations (leading the drugs to adhere to the plastic 
tubing in the system) might have impaired adequate delivery to the lung fields. This 
particular problem has been previously noted for Relenza when given previously in a 
hospital setting (Duff, 2009; FDA, 2009). 
We are however, confident that our nebuliser system effectively allowed for 
the delivery of aerosolised virus to our in vivo models. Immunofluorescence staining 
of mouse lung tissue sections for viral antigen (anti-influenza Type A NP) 
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demonstrated that the delivery of nebulised A/England/195/2009 (A(H1N1)pdm09) 
virus resulted in the deposition of  a small number of virions which, in turn, lead to 
the formation of finite foci of infection. This result was particularly exciting as it 
mirrored autopsy findings of necrotic human lung tissue reported during the A/H1N1 
2009 pandemic (Mukhopadhyay et al., 2010; Harms et al., 2010). This result 
indicates that with our nebulizer system, we can closely recapitulate a “natural” 
infection with a pandemic virus resulting in an observable clinical sign (i.e. weight 
loss) and the generation of observable and quantifiable pathology. 
As with any research undertaking, every question addressed and answered 
will invariably result in more questions arising. This project is no exception and 
during our efforts to adequately address the aims of this thesis, a number of 
intriguing areas of potential future investigation have arisen. These new questions 
can roughly be divided into two broad categories: in vitro and in vivo.  
In our synergy examinations, all viruses employed were naturally sensitive to 
the chosen antiviral or possessed an engineered mutation to afford them sensitivity. 
The immunosuppressive and antiviral effects of RV1088 plus an antiviral to which 
the test virus is resistant would be of interest and would help to elucidate if RV1088 
directly augments the antiviral properties of a licenced drug or whether replication 
suppression occurs via some other mechanism.   Furthermore, we believe that the 
nebulised mouse experiment indicates that RV1088 exerts its effect, at least in part, 
on immune cells recruited to sites of infection. To adequately address this 
postulation, we would recommend isolating specific immune cells via Fluorescence 
Assisted Cell Sorting (FACS) making use of cell-specific markers and conducting 
examinations along the same lines that we performed in human PBMCs.  We have 
demonstrated through a series of experiments employing various expression 
plasmids encoding for key members of the IFN pathway that RV1088 exerts its effect 
at the level of MAVS and TBK1 (Chapter 2). However, to further understand the 
mechanism behind RV1088’s activity, we propose employing a series of Western 
blots and specifically probing for the phosphorylation status of TBK-1 in infected and 
treated cells and in cells overexpressing MAVS and treated with RV1088. In addition, 
we suggest analysing virus replication and cytokine induction under condition of 
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siRNA knockdown for the known targets of RV1088.  Finally, we would recommend 
examining if the activity observed when RV1088 is used (either alone or in 
combination with an antiviral) in the context of an influenza infection is conserved 
during other respiratory virus infections. 
There also exists potential for further in vivo experiments. Specifically, for the 
mouse model, it would be of considerable interest to conduct an experiment where 
RV1088±Relenza (or other antiviral) is given as a treatment course after the 
animal(s) develop signs/symptoms of disease (i.e. post infection). While we have 
examined this in HAEs (Chapter 3), such an undertaking was not performed in vivo. 
In addition, with respect to the nebuliser system, it is imperative that the quantity of 
drug deposited in the lungs is established so that an accurate dosing regimen could 
be established. Finally, a further investigation of RV1088s activity in the ferret model 
would be invaluable to understanding how this compound might act in humans. 
Recent advances in cytokine/chemokine detection and understanding of viral 
pathogenesis in this model could make a new examination profitable. Furthermore, 
as we believe that RV1088 acts by modulating the immune response, a detailed 
observation and examination of ferret symptomology would prove interesting. We 
specifically recommend employing both qualitative and quantitative parameters (i.e. 
weight loss, sneezing, activity levels, and core body temperature via implanted 
telemetry devices). While the nebuliser system addresses many of the shortcomings 
of the intranasal instillation route of infection, it still is not fully representative of a 
natural infection. However, by employing a chain of transmission system, where in 
an intranasally infected animal would be used to naturally infect a series of other 
animals via both the direct contact and aerosol routes of transmission, one could 
determine how RV1088 acts in the context of naturally acquired infections. 
With the continued rise of novel reassortment viruses and the emergence 
new subtypes in the human population coupled with the spread of resistance to our 
already limited anti-viral arsenal, the identification of new and innovative drug 
targets and compounds should be of paramount concern. By targeting the host and 
not the virus, kinase inhibitors prove to be an attractive class of compounds for 
potential therapeutic intervention. Already, kinases have been demonstrated to play 
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pivotal roles in potentiating virus replication while at the same time, have also been 
strongly implicated in the generation of hypercytokinemia leading to the dreaded 
“cytokine storm.” Compounds, such as RV1088, which exert their effects by targeting 
a key cluster of kinases, represent a novel paradigm in the treatment of influenza. 
Importantly, this approach indicates that the targeting of these kinases, while 
suppressing the cytokine/chemokine response, did not lead to increased viral 
replication. Furthermore, the significant synergistic effect observed when such a 
compound is used in conjunction with a licensed anti-viral provides exciting new 
avenues for further investigation.   
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Chapter 8. Materials and Methods  
 
 
8.1 Materials 
 
Table 8. Cell lines used during the course of this project. 
Name Cell Type Source 
293-T Human (embryonic) kidney 
cell line 
Glaxo 
Smithkline 
A-549 Human (lungcarcinoma) 
epithelial cells 
ATCC 
 
DF-1 Chicken Fibroblast line ATCC 
Madin Darby Canine Kidney 
(MDCK) 
Dog kidney epithelial cells Glaxo 
Smithkline 
CALU-3 Human (adenocarcinoma) 
epithelial cells 
ATCC 
 
Human Airway Epithelial 
(HAE) 
Biopsy-derived, primary 
airway cultures, ALI 
Epithelix, CH 
Ferret Airway Epithelial 
(FAE) 
Ex vivo-derived, primary 
airway cultures, ALI 
Barclay Lab 
 
 
Table 9. Animal species used in this, together with age and experimental use.  
Species Sex/Age Comment 
BALB/c Mice Female, 6-8 weeks Viral infection 
(intranasal & 
nebulisation) ± 
Treatment 
Ferrets  Female, 16-21 weeks Viral infection 
(intranasal) ± 
Treatment 
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Table 10. Viruses used during the course of this project. 
 
Virus Comments Source 
B/Florida/04/2006 Wild type virus, human 
clinical isolate, 
Yamagata lineage 
Barclay lab stock 
B/Florida/04/2006 - RG Reverse genetics (RG) 
virus  
This project 
B/Malaysia/2506/2004 Wild type virus, human 
clinical isolate, Victoria 
lineage 
Barclay lab stock 
A/England/195/2009 Wild type virus, human 
clinical isolate. 
Prototypic 
A(H1N1)pdm09 virus. 
Barclay lab stock 
A/England/195/2009 - 
RG 
Reverse genetics (RG) 
virus 
Barclay lab stock 
A/Sydney/5/1997  A/H3N2 influenza virus Dr. Maria Zambon, HPA  
A/Turkey/05/05:PR8 
(6:2) 
A/H5N1:PR8, 6:2 
(HA/NA) reassortment 
virus. Biocontainment 
level 3 virus. 
Barclay lab stock 
Newcastle Disease Virus 
(NDV) 
Epizootic avian virus – 
transmissible to 
humans. Potent IFN 
inducer. 
Barclay lab stock 
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Table 11. Plasmid Constructs used during the course of this project*. 
 
Plasmid Constructs Comments Source 
pCMV-England/195-
NS1 
 
Expression plasmid 
encoding for human 
influenza 
England/195/2009 NS1 
protein 
Barclay Lab Stock 
pCMV-Victoria-NS1 
 
Expression plasmid 
encoding for human 
influenza Victoria NS1 
protein 
Barclay Lab Stock 
pCMV5-HA-MAVS Expression plasmid 
encoding for human 
MAVS protein 
Prof. Andrew 
Macdonald (University 
of Leeds) 
pCMV5-HA-IKKb Expression plasmid 
encoding for human 
IKKb protein 
Prof. Andrew 
Macdonald (University 
of Leeds) 
pCMV5-HA-IKKe Expression plasmid 
encoding for human 
IKKe protein 
Prof. Andrew 
Macdonald (University 
of Leeds) 
pCMV5-HA-IRF-3 Expression plasmid 
encoding for human 
IRF-3 protein 
Prof. Andrew 
Macdonald (University 
of Leeds) 
pCMV5-HA-IRF-7 Expression plasmid 
encoding for human 
IRF-7 protein 
Prof. Andrew 
Macdonald (University 
of Leeds) 
pCMV5-HA-TBK-1 Expression plasmid 
encoding for human 
TBK-1 protein 
Prof. Andrew 
Macdonald (University 
of Leeds) 
pCMV5-HA-NFkB Expression plasmid 
encoding for human 
NFkB protein  
Barclay Lab Stock 
* For plasmids used to generate recombinant viruses, refer to Table 18.  
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Table 12. Reporter Constructs used during the course of this project. 
 
 
Plasmid Constructs Comments Source 
IFN-luc (human) Fire fly luciferase 
reporter gene under the 
control of a human IFN- 
promoter 
Prof. Steve Goodbourn, 
St. Georges, London 
IFN-luc (avian) Fire fly luciferase 
reporter gene under the 
control of a avian IFN- 
promoter 
Prof. Steve Goodbourn, 
St. Georges, London 
ISG54-Luc Fire fly luciferase 
reporter gene under the 
control of a human 
ISG54 promoter 
Barclay Lab Stock 
Renilla Luciferase  Transfection control – 
constitutive expression 
of the Renilla Luciferase 
Barclay Lab Stock 
cRNA reporter Firefly luciferase and 
non-coding ends of an 
influenza segment in 
positive orientation 
(cRNA) flanked by a RNA 
polymerase I promoter 
and Pol I terminator 
sequence 
Olivier Moncorge & 
Anna Cauldwell, Barclay 
Lab 
vRNA reporter Firefly luciferase and 
non-coding ends of an 
influenza segment in 
negative orientation 
(vRNA) flanked by a 
RNA polymerase I 
promoter and Pol I 
terminator sequence 
Olivier Moncorge & 
Anna Cauldwell, Barclay 
Lab 
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Table 13. Antibodies used during the course of this project. 
 
Antibody/Stain Comments Source 
Anti-influenza A NP 
monoclonal 
Mouse monoclonal 
antibody raised against 
the influenza A virus NP 
AbD Serotec 
Anti-β tubulin 
monoclonal 
Mouse monoclonal 
antibody raised against 
β-tubulin 
Sigma 
Goat anti-mouse 
IgG:BGAL 
Goat monoclonal 
antibody raised against 
the mouse antibody 
AbD Serotec 
Rabbit anti-Tubulin 
alpha  
Rabbitpolyclonal 
antibody raised against 
tubulin  
Spring Bioscience 
Alexa Fluor 488 Alexa Fluor 488 anti-
mouse IgG 
Invitrogen 
Alexa Fluor 568 Alexa Fluor 568 anti-
mouse IgG 
Invitrogen 
Alexa Fluor 647 Alexa Fluor 647 donkey 
anti-rabbit IgG 
Invitrogen 
Anti-IFNα Mouse IFN-α Verikine 
DAPI Targets the nucleus Invitrogen 
Anti-Cytokeratin Targets cell membrane bdBiosciences 
Anti-Phospho-ATF-2 
(Thr71) 
Rabbit polyclonal - 
detects ATF-2  only 
when phosphorylated at 
Thr71 
Cell Signaling  
Immobilised Phospho-
p38 MAPK 
(Thr180/Tyr182) 
Mouse mAb 
immobilized by 
crosslinking to agarose 
hydrazide beads 
Cell Signaling 
Anti-rabbit IgG HRP-linked antibody Cell Signaling 
Anti-biotin HRP-linked antibody Cell Signaling 
Anti-Vinculin Goat polyclonal 
antibody raised against 
vinculin 
Santa Cruz 
Anti-p38 (total) Detects all isoforms of 
p38 regardless of 
phosphorylation status 
Cell Signaling 
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Table 14. qRT-PCR Primer and Probe Sequences used during the course of this 
project. 
 
Primer Sequence (5’-3’) 
IP-10 (CXCL10) Fw CGATTCTGATTTGCTGCCTTATC 
IP-10 (CXCL10) Rev GCAGGTACAGCGTACGGTTCT 
IP-10 (CXCL10) Probe CTGACTCTAAGTGGCATTCAAGGAGTACCTCTCTC 
IL-6 Fw CCAGGAGCCCAGCTATGAAC 
IL-6 Rev CCCAGGGAGAAGGCAACTG 
IL-6 Probe CCTTCTCCACAAGCGCCTTCGGT 
IFN-β Fw CGCCGCATTGACCATCTA 
IFN-β Rev TTAGCCAGGAGGTTCTCAACAATAGTCTCA 
IFN-β Probe TCAGACAAGATTCATCTAGCACTGGCTGGA 
RANTES (CCL5) Fw GCATCTGCCTCCCCATATTC 
RANTES (CCL5) Rev       CAGTGGGCGGGCAATG 
RANTES (CCL5) Probe TCGGACACCACACCCTGCTGCT 
IL-8 Fw CTGGCCGTGGCTCTCTTG 
IL-8 Rev CCTTGGCAAAACTGCACCTT 
IL-8 Probe CAGCCTTCCTGATTTCTGCAGCTCTGTGT 
18S Fw CGCCGCTAGAGGTGAAATTCT 
18S Rev CATTCTTGGCAAATGCTTTCG 
18S Probe ACCGGCGCAAGACGGACCAGA 
M-gene Fw AAGACAAGACCAATYCTGTCACCTCT 
M-gene Rev TCTACGYTGCAGTCCYCGCT 
M-gene Probe TYACGCTCACCGTGCCCAGTG 
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Table 15. Compounds and Chemicals used during the course of this project. 
 
Compound/Chemical Comments Source 
RV1088 Novel, narrow-
spectrum kinase 
inhibitor 
RespiVert 
Oseltamivir phosphate (Tamiflu) Licenced 
Neuraminidase 
inhibitor 
Santa Cruz 
Biotechnology 
1-(1-Adamantyl)ethylamine 
hydrochloride (Rimantadine)  
Licenced M2 
inhibitor 
Maybridge 
Relenza (Zanamivir) Licenced 
Neuraminidase 
inhibitor 
RespiVert 
Fluticasone Synthetic 
glucocorticoid 
RespiVert 
Dimethyl sulfoxide (DMSO) Polar aprotic solvent Sigma 
SB203580 Specific inhibitor of 
p38α and p38β 
Invitrogen 
Polyinosinic:polycytidylic acid 
(Poly-I:C) 
dsRNA analogue Sigma 
Staurosporine Potent, broad 
spectrum inhibitor 
of protein kinase 
Abcam 
Dasatinib Src family tyrosine 
kinase inhibitor 
RespiVert 
BIRB-796 Inhibitor of all p38 
MAPK isoforms 
RespiVert 
Syk R343 Syk kinase inhibitor RespiVert 
Lipofectamine 2000 Transfection reagent Invitrogen 
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Table 16. Solutions used during the course of this project. 
 
Solution Recipe Use 
Buffers 
RIPA Buffer 100mM NaCl                   
(50mM iodoacetamide)         
1% Nonidet-P40                 
0.1% SDS                            
0.5% Sodium 
deoxycholate 20mM 
Tris-HCl, pH 7.5 
Lysis of cells for western blot 
analysis/SDS-PAGE 
 
SDS loading 
buffer (2x) 
 
45% Glycerol                      
6.5% SDS                            
15% 1M Tris pH 6.8         
dH2O 
Western blot/SDS-PAGE 
sample loading buffer 
 
SDS Running 
buffer 
 
25 mM Tris base                   
250 mM Glycine                   
0.1% SDS pH 8.3 
Buffer for gel 
electrophoresis in western 
blot 
 
Western Blot 
Transfer Buffer 
 
0.037 % (w/v) SDS                
48 mM Tris                            
39 mM Glycine 20% 
(v/v) Ethanol added just 
before use 
Buffer for transfer of 
proteins to PVDF membrane 
in western blot (semi-dry 
system) 
 
Western Blot 
Wash Buffer 
 
PBS                                       
0.1% Tween 20 
Buffer for washing 
membrane during antibody 
staining of proteins in 
western blots analysis 
DNA-Loading 
Buffer (6x) 
 
0.25% Bromophenol 
blue 40% (w/v) sucrose 
in TAE 
Buffer used to load DNA 
samples in gel 
electrophoresis 
TAE Buffer 
 
40mM Tris acetate pH 
8.0 1mM EDTA 
Buffer for making and 
running agarose gel for DNA 
separation 
PBN 
 
PBS                                        
0.5% BSA                            
0.02% Na azide 
Blocking buffer used in 
immunofluorescence 
experiments 
Virus diluent 3% FCS (Bio Sera Resuspension of virus from 
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 International)                     
0.1% Pen/Strep (Gibco)     
PBS 
plaque picks  
 
Poly-L-Lysine 
1:20 dilution poly-L-
Lysine in dH2O 
Attach 293T cell to base of 
dish/slide for virus infection 
/immunofluorescence 
Nebulisation Vehicle 
 
Drug delivery 
vehicle 
 
500mg Tween 20               
100mg Span 20               
4700mg Monosodium 
phosphate dihydrate    
875mg Dibasic sodium  
phosphate anhydrous 
2100mg Sodium 
chloride 500mL dH2O       
Vehicle used to suspend drug 
compounds for nebulized 
delivery 
 
Culture Media 
LB (Luria-Bertani 
Broth) 
 
1% Tryptone                        
0.5% Yeast extract           
0.5% NaCl                          
0.1% Glucose                     
dH2O 
Growth of E.Coli for plasmid 
production 
 
SOC 
 
2% Tryptone                      
0.5% Yeast extract            
10mM NaCl                     
2.5mM KCl                        
10mM MgCl2                                
10mM MgSO4.7H2O               
20mM Glucose 
Growth of E.Coli for plasmid 
selection 
 
Serum-Free 
DMEM 
 
Dulbecco's modified 
Eagle's medium (Life 
Technologies)  
1%glutamine 
(200mM)       2% non-
essential amino acids                                      
1% penicillin- 
streptomycin (5000 
IU/ml;5000μl)         
Sodium Pyruvate 
Cell culture media for virus 
infection/propagation. 
 
 
10% DMEM 
 
Dulbecco's modified 
Eagle's medium (Life 
Cell culture media for MDCK, 
293T, A549 cell growth 
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Technologies)  
1%glutamine 
(200mM)       2% non-
essential amino acids                                      
1% penicillin- 
streptomycin (5000 
IU/ml;5000μl)         
Sodium Pyruvate               
10% Foetal calf serum 
(FCS) 
 
Plaque assay 
overlay media 
 
50ml 10x EMEM                
14ml 7.5% fraction V 
BSA 5ml 100x L-
glutamine        10ml 
7.5% NaHCO3          
5ml 1M HEPES                  
2.5ml 1% dextran              
5ml 10x 
penicillin/streptomycin 
dH2O up to 350ml  
Store in 17.5ml 
aliquots, add 7.5ml 2% 
oxoid agar/aliquot 
Media for MDCK cells for 
titration of viruses by plaque 
assay. 
 
MucilAir culture 
media 
Serum free, contains 
growth factors and 
Phenol Red. 
Cell culture media for HAE cell 
growth. 
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8.2 Methods 
8.2.1 Molecular Biology 
8.2.1.1 Standard polymerase chain reaction conditions 
PCR was performed with K.O.D. Taq polymerase (Novagen) or GoTaq® green 
master mix (Promega). For K.O.D. Taq polymerase PCR a 50μl PCR mix was made 
consisting of 5μl 10X Buffer and 3μl MgSO4 for KOD DNA Polymerase, 0.15μl 
(100pmol/μl) forward and reverse primers, 5μl dNTPs 2 mM, 1μl KOD polymerase 
(2.5U/μl), 10-100ng of DNA template and nuclease free water to 50μl. For Go-Taq 
polymerase PCR of bacterial colony screening, the following was used: 7.5μl 2X 
GoTaq® Green Master Mix, 0.25μM forward and reverse primers, bacteria swab and 
nuclease free water to 15μl. Cycling conditions were performed to the 
manufacturer’s guidelines and varied according to the construct length. 
 
Table 17. Standard PCR thermal cycling conditions. 
 
Step Temperature Time Step 
1 96⁰C 3 min Initial 
denaturation 
2 96⁰C 30 sec Denaturation 
3 55⁰C 30 sec Annealing 
4 72⁰C 1 min/Kb Elongation 
5 Go to step 2, 
repeat 25 times 
  
6 72⁰C 4 min Final extension 
7 4⁰C hold  
8.2.1.2 Agarose gel electrophoresis 
DNA fragments were separated in 0.2% agarose gels diluted with 0.5x TAE 
buffer and supplemented with 1μg/ml Gel Red (Cambridge Bioscience). Gels were 
submerged in TAE buffer (1X). Samples were run simultaneously with a commercially 
available DNA size marker at 80-100V until the bands had separated. DNA was 
visualised using a UV transilluminator.  
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8.2.1.3 DNA product purification 
DNA fragments were excised from the agarose gel, and extracted using the 
SV Gel and PCR Clean-Up system (Promega) following manufacturer’s instructions. 
Similarly, PCR product or digestion products were purified using the same kit. DNA 
fragments were eluted with 35µl of warm (37⁰C) sterile water. 
 
8.2.1.4 Reconstituting plasmids 
Expression plasmids encoding for members of the IFN induction cascade and 
whose transcription was under the control of a pcDNA3 promotor were a kind gift 
from Professor Andrew Macdonald (University of Leeds). Plasmids were shipped 
embedded in filter paper and were reconstituted by soaking plasmid rich areas in 
50µl TE buffer for 5min min at 37⁰C. Stocks were created by transforming competent 
E. coli cells (detailed below).  
 
8.2.1.5 Transformation of competent bacterial cells 
Approximately 50ng of plasmid were transformed into 50μl OneShot®TOP10 
chemically competent E. coli (Invitrogen) and incubated on ice for 30 minutes. Cells 
were heat shocked for 30 seconds at 42°C and returned to ice for 2 minutes. 250μl of 
pre-warmed S.O.C. media (Invitrogen) was added to the mix and incubated for 1 
hour at 37°C in a shaking incubator. After which, a suitable volume was spread on to 
pre- warmed LB agar plates containing 1% Ampicillin (or kanamycin if specified) and 
incubated overnight at 37°C to allow for colony formation. Colonies were screened 
by PCR, and grown overnight in 5ml LB supplemented with appropriate antibiotic 
(100μg/ml). For large-scale bacterial growth, 54ml of LB media containing 
appropriate antibiotic (50Pg/ml final) were inoculated with 1ml of the bacterial 
suspension and incubated over night at 37°C at 225-250 rpm. An aliquot of the 
bacteria suspension (500ul) was mixed with sterile 80% glycerol and stored at -80°C. 
The remaining bacterial culture was centrifuged and the pellet stored at -80°C for 
later plasmid extraction and purification. 
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8.2.1.6 Small scale plasmid purification 
Single bacterial colonies were picked from agar plates containing a selection 
antibiotic (ampicillin or kanamycin) and grown overnight in 5ml Lysogeny Broth (LB) 
containing the same antibiotic at 37°C, with shaking. 250µl of the bacteria 
suspension was mixed with 850µl of sterile glycerol 80% and stored at -80°C as a 
glycerol stock. The remaining bacteria culture was pelleted using a centrifuge at 
3000xg for 5 minutes. The supernatant was discarded. Plasmid DNA was purified 
using the QIAprep spin miniprep kit (QIAGEN) following the manufacturers’ protocol. 
This involves alkaline lysis of bacterial cells followed by neutralisation and binding of 
plasmid DNA to a silica membrane. The membrane was washed and plasmids eluted 
with 50µL of warm (37°C) sterile water in a 1.5ml Eppendorf tube. Plasmids were 
stored at -20°C to prevent DNA degradation.  
 
8.2.1.7 Large scale plasmid purification  
A 100µl sample from a glycerol stock or a single colony was inoculated into 
250ml of LB containing selection antibiotic at the appropriate concentration, and 
grown overnight at 37⁰C with shaking. Plasmids were recovered using the high-
speed plasmid purification maxi kit (QIAGEN) according to the manufacturer’s 
instructions. Briefly, bacterial cells were pelleted by centrifugation at 3000xg for 30 
minutes at 4⁰C. The supernatant was discarded and cells resuspended in 10mls of 
resuspension buffer containing RNaseA. Alkaline lysis buffer containing SDS was 
added to lyse the cells and denature the genomic DNA. The suspension was 
neutralised, precipitating contaminants, centrifugated at 3000xg for 5 minutes and 
the supernatant passed through a resin-containing column that bound plasmid DNA. 
The columns were washed and plasmid DNA eluted. Isopropanol was added to desalt 
and precipitate plasmid DNA, which was then ethanol washed and eluted in 500μl of 
TE (elution) buffer (QIAGEN). Plasmid preparations were stored at -20⁰C. 
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8.2.1.8 DNA concentration determination 
DNA concentrations were determined using a spectrophotometer 
(BioPhotometer, Eppendorf), with optical density measurements at 260nm with the 
assumption that 1 OD260 unit corresponds to 50μg/ml of double stranded (ds) DNA. 
 
8.2.1.9 Sequencing of constructs  
Constructs were sequenced using the MRC sequencing (MRC Clinical Sciences 
Centre, Hammersmith Campus, Du Cane Road, London, W12 0NN). Samples were 
subjected to automated fluorescent DNA sequencing using the ABI3730xl 
instrument. The reaction mixture was dispatched as a 10μl solution containing 
3.2pmol primer, 400 – 600ng DNA and water. 
 
8.2.1.10 Virus gene sequencing 
All virus mutations were verified by sequencing the mutated region of the 
viral gene of successfully generated RG virus. qRT-PCR was carried out on viral RNA 
using QIAgen OneStep qRT-PCR kit (QIAGEN) according to the manufacturer’s 
instructions. The product was isolated using QIAquick Gel extraction kit (Qiagen). 
Chain termination PCR was performed using the BigDye Terminator x3.1 Cycle 
Sequencing Kit (Applied Biosystems). 
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8.2.2. Cell lines and transfection 
8.2.2.1 Cell lines, media and maintenance  
293T, DF-1, CALU-3, A599 and MDCK cells were cultivated in Dulbecco's 
Modified Eagle Medium (DMEM) with pyruvate and L-Glutamine (Invitrogen) 
supplemented with 1% penicillin and streptomycin (Gibco), and 10% (v/v) heat 
inactivated foetal Calf serum (Biosera). Cells were kept at 37°C in a 5% CO2 
atmosphere except DF-1 which were maintained at 39°C in a 5% CO2 atmosphere. 
Cells were trypsinised using a PBS, 2X EDTA and cell trypsin mixture.  
 
8.2.2.2 Freezing and thawing  
Long-term frozen stocks of all immortalised cell lines were kept in liquid 
nitrogen. Frozen stocks were prepared from cells grown to a semi-confluent degree 
in T75 cm2 flasks. Cells were pelleted by centrifugation at 1,200 rpm for 5 minutes. 
Cell pellets were then re-suspended in freezing medium containing 30% foetal calf 
serum plus 20% DMSO in DMEM. Cells were immediately slow cooled at -80°C 
before being transferred to liquid nitrogen the following day. 
Frozen vials of cells were thawed at 37°C for approximately 1 minute before 
being rapidly transferred to a T25 cm2 flask containing 5mls of pre-warmed media 
containing 1% penicillin and streptomycin, and 10% (v/v) heat inactivated foetal Calf 
serum and kept at 37°C in a 5% CO2 atmosphere. 
 
8.2.2.3 Human Airway Epithelium (HAE) Cultures  
Highly differentiated, specific-pathogen free, human airway epithelium (HAE) 
cultures re-constituted from healthy donors are commercially available from 
Epithelix-Sàrl (Switzerland). Upon arrival culture well inserts, containing cells grown 
onto of a permeable mesh, were removed from their gelled shipping media. The 
apical surface of the cultures was washed 3X (100µl) with warmed SFM to remove 
excess culture-produced mucus.  Cultures were maintained at 37°C, 5% CO2 
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subsequently washed with 300µl SFM once a week and maintained with 700μl 
MucilAir (Epithelix) which was refreshed on a bi-weekly basis. The liquid/air interface 
was preserved throughout both the maintenance and experimental phases. 
 
8.2.2.3.1 Treatment of HAE Cultures with drug compounds  
HAE cultures maintained at an ALI (as described above) were treated both 
apically and basally. Treatment was either initiated 3 days prior to infection or only 
on the day of infection (Figure 68). In either case, prior to apical application of the 
compound in question, the surface of the HAEs was washed with SFM (300µl) which 
was left on for 20min at 37°C and then removed. At this time, the well insert 
supporting the HAE culture was transferred to a new 24-well plate containing fresh, 
pre-warmed, MucilAir media (700µl) supplemented with the compound in question 
or vehicle control. If treatment occurred 3 days prior to infection, the basal media 
would be replaced with fresh media and drug on the day of infection (and left in 
place for the remainder of the experiment). SFM (200µl) containing the same 
compound or vehicle control was then added to the apical portion of the HAE culture 
and left in place for 2hrs at 37°C. After such time, the apical media was removed 
returning the culture to an ALI. If treatment of the HAEs commenced 3 days prior to 
infection, this process of apical treatment was repeated each day (including the day 
of infection after which time, apical treatment was stopped). If however, infection 
preceded infection, the apical section was treated with either the compound of 
interest or vehicle control one time, 1hr p.i. for 2hrs before being removed. 
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Figure 68: HAE experimental design. a) Timeline diagram of a typical HAE 
experiment involving pre-infection treatments. Indicated are the timings of apical 
and basal treatments as well as infection and sample harvesting. b) schematic 
representation of an HAE cross-section indicating the location of the apical and basal 
media in relation to the cellular layer. 
 
8.2.2.3.2 Infection of HAE Cultures with influenza virus 
HAE cultures were infected via apical exposure to a virus diluted in SFM. 
Briefly, the apical surface of the culture was washed 1X, 300µl SFM, 20min 
incubation at 37°C in order to remove the mucus overlay. After washing, 200ul of 
diluted virus was added drop-wise to the surface of the culture and incubated at 
37°C for 1hr. After which time, the inoculum was removed and the apical surface 
washed 1X with SFM and returned to 37°C, 5% CO2. Cultures treated with drug 
compound or vehicle controls were either pre- or post-infection treated as described 
above. 
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8.2.2.3.3 Harvesting apical washes from HAE cultures 
At desired time points, cytokines, chemokines and viral progeny were 
harvested from the surface of HAE cultures via apical washings. Briefly, 400µl of SFM 
was added to the apical section of the HAE cultures. After a 5min incubation at 37°C, 
the apical wash was collected, aliquoted and stored promptly at -80°C to await 
further analysis.  
 
8.2.2.4 Isolation of PBMCs 
Whole blood was collected from healthy donors and spun down (2000rpm, 
30min) and washed with HI-FCS wash media. Peripheral-blood leucocytes were 
isolated via Ficoll-Paque density gradient (GE Healthcare). Monocytes were seeded 
onto 96-well round-bottom tissue culture plates (2x105 cells per well). Cultures were 
infected at a moi of 3 unless otherwise indicated. After 1hr of virus adsorption at 
37°C, the virus inoculum was removed, and the cells were incubated in RPMI1640 
supplemented with L-glutamine, HEPES 10ml, Na bicarbonate 5ml, 
penicillin/streptomycin 5ml and 10% foetal bovine serum 50ml). After 1hr of 
incubation, compounds of interest were added to the culture media and left in place 
for the duration of the experiment. At 24hr and 48hr post infection, cultures were 
centrifuged for 3min at 2000rpm, 4°C, overlying media was removed and total RNA 
extracted from the cellular pellet and used for cytokine/chemokine quantification via 
qRT-PCR. 
Wash Medium (HI-FCS) 
Add 0.4ml of Heat Inactivated Foetal Calf Serum (HI-FCS) and 0.2ml of L Glutamine to 
20mls RPMI in a universal. Invert to mix. This mixture will last 7 calendar days if 
stored in the fridge (inclusive of the day it was made). This buffer must be brought to 
room temp before use. 
Media control (for stimulation):  
RPMI1640 with L-glutamine, HEPES 10ml, Na bicarbonate 5ml, 
penicillin/streptomycin 5ml and 10% foetal bovine serum 50ml) 
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8.2.2.5 Transfections  
Transfections were performed either on sub-confluent monolayers of cells 
plated 24 hours beforehand or conducted in suspension. 
 
Monolayer Transfections  
Conducted in 24-well cell culture plate, 1.5μl of Lipofectamine 2000 
transfection reagent (Invitrogen) was mixed with 250μl of Optimem (Invitrogen). 
Separately, plasmid DNA (typically 0.5μg) was mixed with 250μl of Optimem, before 
the two mixtures were combined and incubated at room temperature for 20 
minutes. Renilla (0.04μg/well) acted as a transfection control. The transfection 
mixture was then added drop-wise to the monolayer. Cell culture media was 
replaced 3hrs post transfection. Quantities were increased or decreased as 
appropriate for larger or smaller scale transfections. 
 
Transfection in Suspension 
 An alternative to monolayer transfections is the transfection of cell cultures 
while in suspension. 24-well culture plates were pre-treated for 15min with Poly-L-
Lysine (Sigma) diluted 1:20 in dH2O and then washed with PBS.  During the Poly-L-
Lysine treatment, a confluent T75 flask of 293T cells was trypsinised until all the cells 
had disassociated from the flask. Trypsin was removed from the cells via 
centrifugation at 1000rpm for 5min. The cellular pellet was re-suspended in 25mls 
with 5% DMEM (without the addition of PenStrep). Of this suspension, 3.75ml of 
were set-aside for each treatment group to be run in triplicate wells.  
Expression and/or reporter plasmids (0.375μg each/set of 3-wells) and 
0.125μg of Renilla transfection control were added to 31.25µl Optimem and 
incubated at room temperature for 5min. To a second aliquot of 31.25µl Optimem, 
1.5µl of lipofectamine was added and also incubated at room temperature for 5min. 
Post incubation, the two aliquots containing the plasmids and lipofectamine were 
combined, gently mixed and incubated at room temperature for 15min.   
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Post incubation, the combined transfection mix was added to the 3.75ml cell 
suspension aliquots and any compound(s) of interest could be added to the 
cell/transfection mix at this point. The cell/compound/transfection mix was gently 
vortexed to ensure adequate distribution of all components and aliquoted out 
(0.5ml/well). Cultures were incubated at 37°C, 5% CO2. 
 
8.2.2.6 Minigenome assay   
To assess any effect of the drug compounds on viral polymerase activity, cells 
were transfected in 12-well plates with pCAGGS expression plasmids encoding PB1 
(0.16μg), PB2 (0.16μg), PA (0.04μg) and NP (0.32μg) proteins per well, together with 
0.16μg of the mini-genome firefly reporter plasmid (pHuman-PolI-Firefly or 
pChicken-PolI-Firefly were employed in confluent human 293T or avian DF-1 cells, 
respectively). When DF1 cells were used, twice the normal amount of DNA was 
transfected. Transfected were conducted with the aid of Lipofectamine 3000 
(Invitrogen) and OptiMEM media (Gibco) and cultures were incubated at 37°C for 
three hours. After the initial three hour incubation, overlaying culture media was 
removed and replaced with 1ml 10% DMEM (Gibco) supplemented with either drug 
or vehicle and returned to 37°C. 24hrs post-incubation, media was removed and cells 
lysed with 300µl passive lysis buffer (Promega) per well. Luciferase signal measured 
using a FLUOstar Omega plate reader (BMG Labtech). 
 
8.2.2.7 Firefly luciferase activity assay 
To measure firefly activity, 24 hours after transfection, cells were lysed with 
300μl (12-well) or 200μl (24-well) of passive lysis buffer (Promega), and firefly 
luciferase activity measured using Luciferase Assay System reagent (Promega) on a 
FLUOstar Omega plate reader (BMG Labtech). 
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8.2.2.8 IFN Luciferase assays 
Cells transiently or stably expressing IFN luc reporter construct were infected 
with influenza virus at MOI 2 (unless otherwise stated) in SF DMEM. After 1 hour 
incubation at 34oC or 37oC the media was removed, cells were washed with PBS, and 
the media replaced with 2% DMEM. After 8 hours or appropriate incubation cells 
were lysed in CCLR for 5 minutes, centrifuged 1,000 RPM for 1min, supernatants 
were transferred to clean Eppendorf and stored -20oC. Luciferase was measured 
using a luminometer (BMG Labtech). 
 
8.2.2.9 IFN-β luciferase reporter assay 
To measure the ability of NS1 protein to inhibit IFN-β induction, 0.375μg 
pCAGGS-NS1, 0.25μg human-IFN-β luciferase reporter and 0.04μg/well Renilla 
plasmid DNA was transfected into 293T cells in 12-well format. After 24hours, 
stimulation of IFN induction by influenza virus infection (MOI 3.0), Poly(I:C) or NDV 
was conducted. Cells were incubated at 37°C and harvested after a further 24 hours. 
 
8.2.2.10 BCA Assay for protein content 
The Thermo Scientific Pierce BCA (bicinchoninic acid) Protein Assay was used 
as per manufactures instructions to quantify the protein levels in the cell lysates 
generated with RIPA buffer prior to western blot analysis. The microtitre plate 
methodology was used, briefly the lysates were microfuged; the samples were then 
prepared in PBS (1:50 and 1:100 dilutions) alongside protein standards provided by 
the kit. 1:50 ration of A & B solutions were made up, added to the plate and 
incubated at 37°C for 30 minutes. Then the absorbance was read at 562nm on a 
FLUOstar Omega plate reader (BMG Labtech). 
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8.2.2.11 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Commercially available SDS-PAGE gels were used to separate proteins 
according to size (Ready gel Tris HCl 4-15% linear gradient, BioRad). Samples were 
diluted in 6X gel loading dye (375 mM Tris-HCl pH 6.8, 6% SDS, 30% glycerol, 9% 2-
Mercaptoethanol, and 0.03% bromophenol blue). Before loading, samples were 
heated at 95°C for 10 minutes. Gels were run at 100V for approximately 2 hours in 
running buffer (0.1% SDS, 27.6 mM Tris base, 0.2 M glycine, pH 8.8). Protein sizes 
were determined by comparison to the Novex sharp pre-stained protein standard 
(Invitrogen). 
 
8.2.2.12 Immunoblot analysis 
 
Proteins were electrically transferred onto polyvinylidene difluoride (PVDF, 
GE Healthcare Life Sciences) membranes. Transfers were carried out via the semi-dry 
method (~30min at 15V). Following transfer, membranes were blocked in a 5% milk 
solution (milk powder, 0.1% tween, dissolved in PBS) on a shaker for 1 hour at room 
temperature and then washed with three times for five min each with wash buffer 
(0.1% tween in PBS). Membranes were then incubated with the primary antibody, 
diluted in milk solution, overnight at 4°C. The next day, the antibody solution was 
removed and the membrane was washed with wash buffer twice for 5 minutes each. 
Following the washes, membranes were then incubated for 1 hour at room 
temperature with horseradish peroxidise (HRP) conjugated secondary antibodies for 
detection by enhanced chemiluminescence (ECL). Subsequently, blots were washed 
4 times for 10 minutes in wash buffer, as described above. HRP-conjugated 
antibodies were detected by incubation of the membrane for 1 minute with 
LumiGLO Western Blotting Detection System (Cell Signaling) as manufacturer’s 
instructions. Films (GE Healthcare Life Sciences) were exposed for required times 
and developed on a RGII Fuji x-ray film processor.  
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8.2.3 Toxicity Assays 
8.2.3.1 Cell viability assay 
The MTT [3-(4,5-dimethylthaizol-2-yl)-2,5-diphenyltetrazolium bromide] 
assay is based on an enzymatic reaction of the mitochondrial succinic 
dehydrogenase. In viable and proliferating cells these enzyme cleaves the 
tetrazolium rings of the pale yellow MTT which results in formation of dark blue 
formazan that is largely impermeable to cell membranes and therefore accumulates 
in healthy cells. The amount of formed formazan can be measured in a colorimetric 
assay at OD 562 nm and is directly proportional to the number of viable cells.  
 
8.2.3.2 Measurement of caspase activity  
Activities of caspase 3/7, caspase 8 and caspase 9 were measured using 
commercial available Caspase-Glo kits (Promega), according to the manufacturer’s 
protocol. Influenza A/FPV/ Bratislava/79 (H7N7) infected cells were incubated for 30 
min with reaction buffer (Promega) and luminescence was measured using the 
FLUOstar Omega plate reader (BMG Labtech). For each sample two biological 
replicates were analysed.  
 
8.2.3.3 Trypan blue exclusion test of cell viability 
MDCK or A549 cells were grown on 96 well plates to a confluency of ~80% at 
which point, the drug compound or the vehicle control were added to the overlying 
media and the cultures incubated for a further 24hrs. Following this incubation, the 
media was removed and the cells trypsinised. An aliquot of this cell suspension 
containing 5x105 cells/ml was taken and centrifuged for 5min at 100xg and the 
supernatant discarded. The cellular pellet was resuspended in 1ml SFM. The 
resuspended cells were then mixed 1:1 with a 0.4% trypan blue solution and 
incubated for 3min at room temperature. Cells were counted within 5min of the 
addition of the trypan blue solution with the aid of a haemacytometer.  
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8.2.4 Infectious studies 
8.2.4.1 In vitro 
8.2.4.1.1 Safety & Biosecurity considerations 
All infectious experiments involving A/H5N1:PR8 6:2 reassortment virus were 
performed in Biosafety Level 3 facilities at Imperial College London, St Mary’s 
Campus. All other infectious experiments were conducted at BSL-2.  
 
8.2.4.1.2 Growth of virus stocks 
MDCK cells grown to confluency in 75 cm2 flasks were infected with virus at a 
low multiplicity of infection (MOI) 0.001 in a low volume of serum free media for one 
hour at 37°C. On removal of the initial inoculum, 12mls of serum free DMEM and 
1μg/ml of trypsin (Worthington) were added to the flask which was then incubated 
until virus cytopathic effect (CPE) was observed. The virus was harvested by removal 
and centrifugation of the supernatant at 2500 RPM for 10 minutes to pellet cell 
debris. After confirmation of viral presence by haemagglutination assay and 
assessment of quantity through plaque assay, the virus was stored in aliquots at -
80°C. 
 
8.2.4.1.3 Co-culture virus rescue 
Reassortment or wild-type viruses were “rescued” by means of a reverse 
genetics system. Briefly, 12 plasmids (8 pPol1 plasmids and 4 polymerase protein 
expression plasmids) were transfected into 293T cells (confluency ~70-80%) seeded 
in 12-well plates. 20μl Fugene HD (Roche) was added to 200μl Serum Free (SF) 
DMEM + NEAAs, lacking antibiotics and incubated for 5 minutes at room 
temperature. The DNA mix (Table 18) was then added and incubated with the 
Fugene mix for a further 15 minutes at room temperature, before being added, 
drop-wise, to the 293T monolayer. The transfections were incubated overnight at 
37°C. The next day, a confluent layer of MDCK cells were trypsinised and 
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resuspended in 20ml DMEM + 10% FCS + pyruvate/75cm2 flask. The transfected 
293T cells were washed gently in PBS and detached by forcefully pipetting 1 ml of 
the MDCK cell suspension into the 293T well. After the cells were dislodged 4 
additional mls of the MDCK suspension was added and this mix was transferred to a 
25cm2 flask. These were allowed to adhere for 6 hours at 37°C. Cells were gently 
washed in serum-free DMEM, to remove any FCS, and then 5 ml serum-free DMEM + 
NEAA’s, with 2.5μg/ml porcine trypsin was added. Cultures were incubated at 37°C 
for at least 3-6 days until cytopathic effect was observed, or haemagglutination 
activity was observed by a Haemagglutinination assay. Virus rescues were harvested 
from the supernatant and cell debris was removed by centrifugation at 3000rpm for 
10 minutes. The resulting aliquots were stored at -80°C. 
 
 
 
Table 18. Quantities of plasmids used in 
the rescue of influenza viruses. The 
eight pPolI plasmids correspond to the 
eight vRNA virus segments and the four 
helper plasmids are added to provide the 
polymerase complex to initiate virus 
replication. Using this system, pPol’s with 
genetic modifications could be switched 
in to create a new virus possessing the 
desired characteristic
vRNA Plasmids  pPolI PB1   0.5 μg pPolI PB2   0.5 μg pPolI PA   0.5 μg pPolI HA   0.5 μg pPolI NP   0.5 μg pPolI NA   0.5 μg pPolI M   0.5 μg pPolI NS     0.5 μg 
   
Helper Plasmids  pCMV PB1  0.5 μg pCMV PB2  0.5 μg pCMV PA  <0.05μg  pCMV NP  1 μg 
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8.2.4.1.4 Haemagglutination (HA) assay 
Viruses were diluted in a two-fold serial dilution using PBS in 96 well V-bottomed 
plates to a total volume of 50μl (PBS alone acted as a negative control). Next, an equal 
volume of 0.5% chicken blood cell suspension (diluted in PBS) was added to each well. Plates 
were then incubated on ice for a minimum of 1 hours time. The resulting HA titre was 
defined in this case as the well prior to the first well displaying a blood pellet. 
8.2.4.1.5 Influenza virus titration by plaque assay 
12-well plates were seeded with MDCKs split 1:4 in order to form a confluent 
monolayer to infect the next day. Media was removed, and the cells washed in PBS. Viruses 
were diluted in SF DMEM in a 10-fold dilution series. 200μl of each diluted virus was added 
to each well and the plate incubated for 1 hour at 37°C. After incubation, 1ml of 2% agarose 
plus flu overlay (0.7x EMEM, 0.303 % BSA (fraction V), L-Glutamine, 0.2% NaHC02, 0.7M 
HEPES, 0.7x Pen/Strep (Gibco), 0.007%, dextran DEAE (Sigma), containing 0.4μl/ml of flu 
trypsin, was added to each well and allowed to solidify. After 4-5 days incubation at 37°C, 
the overlay was removed and the cells fixed and stained with Crystal Violet (CV) stain for at 
least 20 minutes. The excess CV stain was then removed and cells washed with water 3X 
before counting the plaques. 
 
 8.2.4.1.6 In vitro growth kinetics 
6-well plates were seeded with cells of interest split 1:4 in order to form a confluent 
monolayer to infect the next day. Media was removed, and the cells washed in PBS. Virus 
was diluted to an moi of 0.001 in 1mL of SFM. The virus/SFM mix was added to the cell 
monolayer and incubated for 1hr at 37°C, 5% CO2. After incubation, the inoculum was 
removed and the cells washed with PBS and then 2mL SFM was added to each well. A 
baseline sample (1mL) was then taken and placed in -80°C. Subsequent time points were 
taken as required and samples stored in -80°C until needed. Titers were determined via 
plaque assay.  
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8.2.4.1.7 In Vitro p38 Kinase Assay 
The effect of RV1088 on the activity of p38 MAP kinase was analysed by a 
commercially available kit (p38 MAP Kinase Assay Kit, New England Biolabs Inc.).The kit 
employs two different antibodies, anti-p38 MAP kinase antibody which is specific for p38 
MAP kinase and dose not cross-react with ERK1/2 or JNK, and antiphosphospecific ATF-2 
antibody to detect p38 MAP kinase-induced phosphorylation of ATF-2. Analysis of activity of 
p38 MAP kinase was performed according to the manufacturer’s instruction. 
Briefly, HAEs that had been previously treated with RV1088 (or DMSO control) and 
infected with influenza virus were washed with ice-cold PBS and lysed with 1X cell lysis 
buffer plus 1 mM phenylmethylsulfonyl fluoride (PMSF) for 5min on ice. The cellular solution 
was then transferred to an eppendorf for further disruption via sonication. After sonication, 
the cell lysate was microcentrifuged for 10min at 4°C. 200μL of cell lysate was incubated 
with anti-p38 MAP kinase antibody (1:100 dilution) to selectively immunoprecipitate p38 
MAP kinase from cell lysates at 4°C overnight with gentle shaking. The resulting 
immunoprecipitate was then mixed with protein A sepharose beads. After 
microcentrifugation, the pellet was washed twice with lysis buffer and then washed twice 
with kinase buffer (25 mmol/L TRIS pH 7.5, 5 mmol/L β-glycerolphosphate, 2 mmol/L DTT, 
0.1 mmol/L Na3VO4, 10 mmol/L MgCl2). The pellet was suspended in 50μL of kinase buffer 
with 100 μmol/L ATP and 2μg of ATF-2 fusion protein, and then incubated for 30 min at 
30°C. The pellet was mixed with the sample buffer consisting of 62.5 mmol/L TRIS base, 10% 
glycerol, 50 mmol/L DTT and 2% SDS to terminate the reaction, and then heated 95°C for 
5min to fully denature the protein prior to Western Immunoblotting.  
 
8.2.4.2 In vivo infection studies  
8.2.4.2.1 Ethics statement 
The animal experiments conducted under the remit of this study were evaluated and 
approved by the Imperial College’s ethics committee for animal studies and was carried out 
in accordance with the UK 1986 Animal Scientific Procedure Act. In all in vivo experiments, 
the animals health and wellbeing were routinely monitored. Any animal falling below pre-
set cut-off points (e.g. falling below our established 20% weight loss cut off point) were 
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killed humanely. 
 
8.2.4.2.2 Experiments Involving Mice 
All in vivo mouse experiments employed BALB/c females aged between 6-8 weeks 
and were certified as specific pathogen free. Subjects were housed in Isocages in groups of 
5. Individuals within each group were distinguished on the basis of ear markings. Treatment 
with a compound of interest of infection with the influenza virus was conducted via either 
intranasal instillation or exposure to an aerosol cloud (for all nebuliser-related protocols, 
please refer to section 8.2.6). 
 
8.2.4.2.2.1 Pre-infection Treatment  
The pre-infection treatment of subjects with either a compound of interest or DMSO 
vehicle control was undertaken three days (inclusive) prior to infection. If conducted via the 
intranasal route of administration, subjects were first anesthetized via inhaled isoflurane. As 
mice are obligate nose breathers, small volumes (adding up to a total volume of 40μl/day) 
of the treatment solution placed on the nares is readily taken up by without any 
complications.     
 
8.2.4.2.2.2 Viral Inoculation 
Intranasal infection was achieved in a manner similar to that described for the 
administration of pre-infection treatments. Briefly, subjects were anesthetized with inhaled 
isoflurane and inoculated by means of drop-wise placement of the viral containing solution 
on the subject’s nares. For the experiments described in this work, virus employed was 
A/England/195/2009 (A/H1N1) at a titer of 2x105 pfu/ml in a total volume of 40μl/subject. 
8.2.4.2.2.3 Health Monitoring  
Subjects were monitored daily for any signs of deterioration in their health status. In 
addition, daily weights were obtained and compared to their individual starting (i.e. pre-
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experimental) weight. If a subject lost 20% or more of their starting weight, they were 
determined to have reached an experimental severity limit and culled via Schedule one on 
the basis of humanitarian grounds. 
 
8.2.4.2.2.4 Necropsy and Tissue Processing   
On set days post-infection, individual subjects from each treatment group were 
culled via Schedule one. Within minutes of death, the subjects lungs were removed and 
either frozen down (-80°C) for cytokine/chemokine and viral quantification or placed in 
formalin for later histopathological analysis.  
 
8.2.4.2.2.5 Lung Homogenisation  
In order to quantify the cytokine/chemokine and viral load found within a subjects 
lungs, whole lungs were weighed, placed in 500μl PBS and homogenised (“Minilys”, Bertin 
Tech). From this homogenate, ELISAs, LUMINEX and plaque assays were conducted. All 
results were subsequently normalised to the subject’s lung weight. 
 
8.2.4.2.2.6 Immunoflouresence & Imaging 
Paraffinised tissue sections mounted on glass slides (processed by ProPath, UK) were 
deparaffinised by immersion in Neoclear for 5 min followed by immersion is 100% ethanol 
for 3 min (X2), 90% ethanol for 3min (X2) and 70% ethanol for 10min. Slides were then 
placed under slow flowing cool tap water for 10 min. Blocking was conducted at room 
temperature in a humidity chamber with 3% BSA in PBS plus 0.05% Tween 20 (PBST) 
overnight. The next day, slides were rinsed in briefly with PBST, followed by the addition of 
the primary antibody (in 1% BSA in PBST) and incubated in the humidity chamber overnight 
at 4°C. Slides were then washed 3X with PBST for 15 min each. The secondary antibody 
antibody (in 1% BSA in PBST) was added and the slides incubated in the humidity chamber 
for 1hr at room temperature. Washing was repeated as before and slides permealised with 
movicol and viewed after allowing time to set. 
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8.2.4.2.3 Experiments involving ferrets 
Weight matched female ferrets aged between 16 and 21 weeks were employed in 
this study and were house in a specially equipped ferret room to ensure adequate comfort 
with environment enrichments. 
 
8.2.4.2.3.1 Pre-infection Treatment  
Treatment with RV1088 began one day before infection and continued daily 
throughout the infection until day 10 p.i. Daily doses of RV1088 (2mg/kg body weight) 
suspended in the vehicle or placebo (vehicle alone) was instilled into the nose under light 
anaesthesia (isofluorane). Total instalation volume was 50μl per day with dosing occuring at 
the same time each day. 
 
8.2.4.2.3.2 Viral Inoculation 
Subjects were inoculated intranasally in duplicate with 4x105 pfu of virus in PBS. 
Inoculations were performed under general anesthesia (ketamine 22 mg/kg/xylazine 0.9 
mg/kg). Post-inoculation, subjects were returned to their cages and placed in the recovery 
position and monitored until full consciousness returned.  
 
8.2.4.2.3.3 Health Monitoring  
Subjects were monitored daily for any adverse signs or symptoms resulting from 
either treatment or infection. In addition, daily weights were recorded and any animal 
which lost 20% or more of its pre-experimental weight was culled via a Schedule one 
method on humanitarian grounds.  
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8.2.4.2.3.4 Nasal Washing  
Daily nasal washes (1ml PBS in total divided equally between nares) was performed 
on non-anesthetised subjects. The recovered PBS (~800μl) was kept on ice and tested daily 
for vial proteins using a BD directigenTM xA&B kits (BD Diagnostic systems) and subjected to 
a plaque assay to assess viral titre.  
 
8.2.5 Cytokine and chemokine quantification 
8.2.5.1 Cytokine Assay/Luminex System  
Culture supernatants or lung homogenate, collected at a designated time points, 
were assayed for an array of cytokines/chemokines by using a Luminex xMAP multiplexing 
technology employing a magnetic bead panel according to the manufacturer's instructions 
(Milliplex Map Kit - Millipore). The assay plate was analyzed with the MAGPIX instrument 
and the results complied using xPONENT software (both by Luminex Corporation).  
 
8.2.5.2 ELISA 
Samples of viral culture supernatant or lung homogenate were irradiated with 
ultraviolet light (CL-100 Ultra Violet Cross linker) for 15min to inactivate any infectious virus 
before the ELISA assays were performed. The assays themselves, were conducted with R&D 
System’s “Quantikine” kit and conducted following manufacturer’s instructions.   
 
8.2.5.3 RNA extraction and qRT-PCR 
Total cellular RNA from cell cultures or lung homogenate was extracted using TRIzol 
(Invitrogen) or via RNeasy Mini kit (Qiagen) according to their respective manufacturers 
instructions. In terms of the TRIzol method, cells were washed with PBS, lysed in 1 ml TRIzol, 
transferred to an RNase free Eppendorf. Following addition of 200μl of chloroform, the 
protocol is the same as for TRIzol LS RNA extraction. The pellet was air dried for 10 minutes 
and dissolved in 50-100μl nuclease free water. RNA was quantified by spectrophotometry 
by measurement of absorbance at 260nm. Concentration (μg/ml) = A260 X e where for RNA 
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e= 44.19. mRNA was combined with poly(dT) primers and Superscript II reverse 
transcriptase (Life Technologies) in order to synthesis cDNA. The process was quantified by 
real-time PCR analysis with a LightCycler (Roche). The mRNA for various 
cytokines/chemokines, viral M-gene and 18s were quantitated using real-time RT-PCR.  
 
8.2.6 Nebuliser 
8.2.6.1 System overview 
Our nebuliser system is a closed system which operates based on a push/pull 
technique where in the aerosol could is simultaneously pushed through the system by a 
current of air (10L/min) and drawn out by a separate pump (Bias Flow Generator, Info Disp) 
at the same flow rate. The aerosol cloud (whether viral or pharmacological) is produced by 
the Aroneb nebuliser (Aerogen). The nubulant is first introduced in to the nebuliser chamber 
where the cloud is allowed to form a uniform density before flowing via tubing into the 
exposure chamber. All tubing was replaced between each aerosolisation event to reduce 
incidences of condensation. Designed by EMMS (Haunts, UK), the exposure chamber is 
composed of an inner chamber that ensures an equal flow and distribution of the cloud to 
an outer chamber. This outer chamber contains a series of six equally spaced ports to which 
sampling equipment (discussed further below) can be attached or to which animal exposure 
tubes (EMMS) can be affixed. Leading out of the exposure chamber was tubing which 
conducted any non-inhaled nebulant cloud through a series of Virkon disinfectant traps and 
filters before finally passing through a series of large capacity indicating silica drying 
columns (EMMS) columns to dry the air prior to entering the “pulling” pump.  
 
8.2.6.2 Nebulisation of virus and drug compounds  
Viral stocks were diluted to the required concentration in PBS, vortexed for 2min on 
medium speed and added directly to the nebuliser unit.  On the day that nebulisation was 
due to occur, powdered drug suspensions were freshly prepared. Compounds were 
diluted/suspended by vortexing (4min, max speed) in a specialised vehicle (Table 16) to 
enable efficient nebulisation and distribution throughout the system. After each 
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nebulisation event, the nebuliser unit was thoroughly washed three times with PBS in 
accordance with manufacturer’s specifications.  
 
8.2.6.3 Sampling of the nebulant cloud 
Employing the equation discussed in Chapter 6, we calculated the number of active 
viral particles (PFU) suspended in the aerosol cloud with the aid of a midget impinger 
(Sigma). The impinger contained 10mls of PBS and was connected directly to the nebulisers 
exposure chamber (i.e. where an animal subject would be exposed to the aerosol cloud). 
Downstream of the impinger was a small programmable pump (model 210-1002MTX, SKC, 
Dorset) that was set to mimic the normal respiratory rate of an average female BALB/c 
mouse (volumetric flow set to = 0.6L/min) drawing the aerosol cloud through the PBS for 
10min thus trapping any aerosolised virus in the PBS. The trapped virus was later titered via 
plaque assay. 
 
8.2.6.4 Subject exposure to nebulant cloud 
Each individual exposure tube is capable of holding and securing a single mouse in a 
nose-first orientation via a lockable crush-bar. This design ensures that only the test 
subject’s nose is directly exposed to the nebulant cloud; thus avoiding unwanted secondary 
exposure to the subjects eyes and fur. Animals were placed in the tubes easily without the 
use of anaesthetics and were exposed to a specific nebulant cloud for a period of 10min. 
After which time, subjects were returned to their cages with no apparent ill effects. 
 
 8.2.6.5 Biohazard & Safety considerations 
Prior to employing any infectious agents, the systems seals were tested at maximum 
pressure and flow with PBS. In all experiments, any part of the system considered to be 
potentially “dirty” was kept in a biological safety cabinet to minimise the risk of accidental 
exposure or leakage. All air flowing from “dirty” to “clean” components was first passed 
through a series of Vikon traps and filters. Once experiments were complete and while still 
in the hood, the system was disassembled and soaked in Virkon for 45min prior to removal. 
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The virus employed in these experiments was susceptible to Oseltamivir treatment and was 
covered by that year’s seasonal vaccine (user was vaccinated). 
 
8.2.7 Bioinformatics analysis 
8.2.7.1 Sequence analysis 
AlI influenza sequences were downloaded from the NCBI Influenza Virus Resource 
and aligned using the using Clustal Omega EBI resource. Sequence alignments were 
analysed using Geneious R6 software. 
 
8.2.7.2 Synergistic analysis 
The presence or absence of synergy was determined by means of the combination 
index (CI) theorem of Chou-Talalay. This test used the quantitative definitions of antagonism 
(CI >1), additive effect  (CI=1), and synergistic effect (CI < 1) in drug combination. 
Calculations were made with the aid of the CalcuSyn software program (Biosoft - 
Cambridge, UK) which employs the Chou-Talalay theorem equations. 
 
8.2.7.3 Statistical analysis 
All statistical analyses were performed using Prism 6 software (GraphPad). Statistical 
calculations included: two-tailed paired t-test, two-way ANOVA with Bonferroni’s post-test, 
one-way ANOVA and Area Under the Curve (AUC) analysis. P-values less than 0.05 were 
considered significant.  
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